US20030024537A1 - Device and method for forming a lesion - Google Patents
Device and method for forming a lesion Download PDFInfo
- Publication number
- US20030024537A1 US20030024537A1 US10/171,390 US17139002A US2003024537A1 US 20030024537 A1 US20030024537 A1 US 20030024537A1 US 17139002 A US17139002 A US 17139002A US 2003024537 A1 US2003024537 A1 US 2003024537A1
- Authority
- US
- United States
- Prior art keywords
- heart
- ablating
- probe
- penetration
- elongated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/00234—Surgical instruments, devices or methods, e.g. tourniquets for minimally invasive surgery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/0057—Implements for plugging an opening in the wall of a hollow or tubular organ, e.g. for sealing a vessel puncture or closing a cardiac septal defect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/02—Surgical instruments, devices or methods, e.g. tourniquets for holding wounds open; Tractors
- A61B17/0218—Surgical instruments, devices or methods, e.g. tourniquets for holding wounds open; Tractors for minimally invasive surgery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/04—Surgical instruments, devices or methods, e.g. tourniquets for suturing wounds; Holders or packages for needles or suture materials
- A61B17/0469—Suturing instruments for use in minimally invasive surgery, e.g. endoscopic surgery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/04—Surgical instruments, devices or methods, e.g. tourniquets for suturing wounds; Holders or packages for needles or suture materials
- A61B17/06—Needles ; Sutures; Needle-suture combinations; Holders or packages for needles or suture materials
- A61B17/06061—Holders for needles or sutures, e.g. racks, stands
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/32—Surgical cutting instruments
- A61B17/320016—Endoscopic cutting instruments, e.g. arthroscopes, resectoscopes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/34—Trocars; Puncturing needles
- A61B17/3468—Trocars; Puncturing needles for implanting or removing devices, e.g. prostheses, implants, seeds, wires
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/02—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by cooling, e.g. cryogenic techniques
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/04—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating
- A61B18/12—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating by passing a current through the tissue to be heated, e.g. high-frequency current
- A61B18/14—Probes or electrodes therefor
- A61B18/1482—Probes or electrodes therefor having a long rigid shaft for accessing the inner body transcutaneously in minimal invasive surgery, e.g. laparoscopy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/04—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating
- A61B18/12—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating by passing a current through the tissue to be heated, e.g. high-frequency current
- A61B18/14—Probes or electrodes therefor
- A61B18/1492—Probes or electrodes therefor having a flexible, catheter-like structure, e.g. for heart ablation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B90/00—Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups A61B1/00 - A61B50/00, e.g. for luxation treatment or for protecting wound edges
- A61B90/50—Supports for surgical instruments, e.g. articulated arms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/24—Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body
- A61F2/2427—Devices for manipulating or deploying heart valves during implantation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M39/00—Tubes, tube connectors, tube couplings, valves, access sites or the like, specially adapted for medical use
- A61M39/02—Access sites
- A61M39/0247—Semi-permanent or permanent transcutaneous or percutaneous access sites to the inside of the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B1/00—Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor
- A61B1/04—Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor combined with photographic or television appliances
- A61B1/042—Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor combined with photographic or television appliances characterised by a proximal camera, e.g. a CCD camera
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/04—Surgical instruments, devices or methods, e.g. tourniquets for suturing wounds; Holders or packages for needles or suture materials
- A61B17/0467—Instruments for cutting sutures
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/28—Surgical forceps
- A61B17/29—Forceps for use in minimally invasive surgery
- A61B17/2909—Handles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/32—Surgical cutting instruments
- A61B17/3209—Incision instruments
- A61B17/3211—Surgical scalpels, knives; Accessories therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/04—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating
- A61B18/12—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating by passing a current through the tissue to be heated, e.g. high-frequency current
- A61B18/14—Probes or electrodes therefor
- A61B18/1442—Probes having pivoting end effectors, e.g. forceps
- A61B18/1445—Probes having pivoting end effectors, e.g. forceps at the distal end of a shaft, e.g. forceps or scissors at the end of a rigid rod
- A61B18/1447—Probes having pivoting end effectors, e.g. forceps at the distal end of a shaft, e.g. forceps or scissors at the end of a rigid rod wherein sliding surfaces cause opening/closing of the end effectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/18—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/18—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves
- A61B18/20—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using laser
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/00234—Surgical instruments, devices or methods, e.g. tourniquets for minimally invasive surgery
- A61B2017/00238—Type of minimally invasive operation
- A61B2017/00243—Type of minimally invasive operation cardiac
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/00234—Surgical instruments, devices or methods, e.g. tourniquets for minimally invasive surgery
- A61B2017/00238—Type of minimally invasive operation
- A61B2017/00243—Type of minimally invasive operation cardiac
- A61B2017/00247—Making holes in the wall of the heart, e.g. laser Myocardial revascularization
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/0057—Implements for plugging an opening in the wall of a hollow or tubular organ, e.g. for sealing a vessel puncture or closing a cardiac septal defect
- A61B2017/00575—Implements for plugging an opening in the wall of a hollow or tubular organ, e.g. for sealing a vessel puncture or closing a cardiac septal defect for closure at remote site, e.g. closing atrial septum defects
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B2017/00831—Material properties
- A61B2017/00946—Material properties malleable
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/02—Surgical instruments, devices or methods, e.g. tourniquets for holding wounds open; Tractors
- A61B2017/0237—Surgical instruments, devices or methods, e.g. tourniquets for holding wounds open; Tractors for heart surgery
- A61B2017/0243—Surgical instruments, devices or methods, e.g. tourniquets for holding wounds open; Tractors for heart surgery for immobilizing local areas of the heart, e.g. while it beats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/04—Surgical instruments, devices or methods, e.g. tourniquets for suturing wounds; Holders or packages for needles or suture materials
- A61B17/0469—Suturing instruments for use in minimally invasive surgery, e.g. endoscopic surgery
- A61B2017/047—Suturing instruments for use in minimally invasive surgery, e.g. endoscopic surgery having at least one proximally pointing needle located at the distal end of the instrument, e.g. for suturing trocar puncture wounds starting from inside the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/04—Surgical instruments, devices or methods, e.g. tourniquets for suturing wounds; Holders or packages for needles or suture materials
- A61B17/0469—Suturing instruments for use in minimally invasive surgery, e.g. endoscopic surgery
- A61B2017/0472—Multiple-needled, e.g. double-needled, instruments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/04—Surgical instruments, devices or methods, e.g. tourniquets for suturing wounds; Holders or packages for needles or suture materials
- A61B17/0469—Suturing instruments for use in minimally invasive surgery, e.g. endoscopic surgery
- A61B2017/0474—Knot pushers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/04—Surgical instruments, devices or methods, e.g. tourniquets for suturing wounds; Holders or packages for needles or suture materials
- A61B17/0469—Suturing instruments for use in minimally invasive surgery, e.g. endoscopic surgery
- A61B2017/0475—Suturing instruments for use in minimally invasive surgery, e.g. endoscopic surgery using sutures having a slip knot
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/28—Surgical forceps
- A61B17/29—Forceps for use in minimally invasive surgery
- A61B2017/2926—Details of heads or jaws
- A61B2017/2931—Details of heads or jaws with releasable head
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/28—Surgical forceps
- A61B17/29—Forceps for use in minimally invasive surgery
- A61B2017/2926—Details of heads or jaws
- A61B2017/2932—Transmission of forces to jaw members
- A61B2017/2943—Toothed members, e.g. rack and pinion
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/28—Surgical forceps
- A61B17/29—Forceps for use in minimally invasive surgery
- A61B2017/2926—Details of heads or jaws
- A61B2017/2945—Curved jaws
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/30—Surgical pincettes without pivotal connections
- A61B2017/306—Surgical pincettes without pivotal connections holding by means of suction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/34—Trocars; Puncturing needles
- A61B17/3403—Needle locating or guiding means
- A61B2017/3405—Needle locating or guiding means using mechanical guide means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/34—Trocars; Puncturing needles
- A61B17/3417—Details of tips or shafts, e.g. grooves, expandable, bendable; Multiple coaxial sliding cannulas, e.g. for dilating
- A61B2017/3419—Sealing means between cannula and body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/34—Trocars; Puncturing needles
- A61B2017/348—Means for supporting the trocar against the body or retaining the trocar inside the body
- A61B2017/3482—Means for supporting the trocar against the body or retaining the trocar inside the body inside
- A61B2017/3484—Anchoring means, e.g. spreading-out umbrella-like structure
- A61B2017/3486—Balloon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/34—Trocars; Puncturing needles
- A61B2017/348—Means for supporting the trocar against the body or retaining the trocar inside the body
- A61B2017/3492—Means for supporting the trocar against the body or retaining the trocar inside the body against the outside of the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2018/00053—Mechanical features of the instrument of device
- A61B2018/00214—Expandable means emitting energy, e.g. by elements carried thereon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2018/00053—Mechanical features of the instrument of device
- A61B2018/00214—Expandable means emitting energy, e.g. by elements carried thereon
- A61B2018/0022—Balloons
- A61B2018/00232—Balloons having an irregular shape
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2018/00053—Mechanical features of the instrument of device
- A61B2018/00214—Expandable means emitting energy, e.g. by elements carried thereon
- A61B2018/0022—Balloons
- A61B2018/0025—Multiple balloons
- A61B2018/00261—Multiple balloons arranged in a line
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2018/00053—Mechanical features of the instrument of device
- A61B2018/00273—Anchoring means for temporary attachment of a device to tissue
- A61B2018/00291—Anchoring means for temporary attachment of a device to tissue using suction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2018/00315—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body for treatment of particular body parts
- A61B2018/00345—Vascular system
- A61B2018/00351—Heart
- A61B2018/00363—Epicardium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2018/00315—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body for treatment of particular body parts
- A61B2018/00345—Vascular system
- A61B2018/00351—Heart
- A61B2018/00392—Transmyocardial revascularisation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2018/00571—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body for achieving a particular surgical effect
- A61B2018/00577—Ablation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/02—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by cooling, e.g. cryogenic techniques
- A61B2018/0212—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by cooling, e.g. cryogenic techniques using an instrument inserted into a body lumen, e.g. catheter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/02—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by cooling, e.g. cryogenic techniques
- A61B2018/0225—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by cooling, e.g. cryogenic techniques using an instrument for clamping tissue, e.g. forceps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/02—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by cooling, e.g. cryogenic techniques
- A61B2018/0231—Characteristics of handpieces or probes
- A61B2018/0262—Characteristics of handpieces or probes using a circulating cryogenic fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/04—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating
- A61B18/12—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating by passing a current through the tissue to be heated, e.g. high-frequency current
- A61B18/14—Probes or electrodes therefor
- A61B2018/1405—Electrodes having a specific shape
- A61B2018/1425—Needle
- A61B2018/1432—Needle curved
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/04—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating
- A61B18/12—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating by passing a current through the tissue to be heated, e.g. high-frequency current
- A61B18/14—Probes or electrodes therefor
- A61B18/1442—Probes having pivoting end effectors, e.g. forceps
- A61B2018/145—Probes having pivoting end effectors, e.g. forceps wherein the effectors remain parallel during closing and opening
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/04—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating
- A61B18/12—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating by passing a current through the tissue to be heated, e.g. high-frequency current
- A61B18/14—Probes or electrodes therefor
- A61B2018/1465—Deformable electrodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B8/00—Diagnosis using ultrasonic, sonic or infrasonic waves
- A61B8/12—Diagnosis using ultrasonic, sonic or infrasonic waves in body cavities or body tracts, e.g. by using catheters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B90/00—Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups A61B1/00 - A61B50/00, e.g. for luxation treatment or for protecting wound edges
- A61B90/36—Image-producing devices or illumination devices not otherwise provided for
- A61B90/37—Surgical systems with images on a monitor during operation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/01—Introducing, guiding, advancing, emplacing or holding catheters
- A61M25/02—Holding devices, e.g. on the body
- A61M2025/028—Holding devices, e.g. on the body having a mainly rigid support structure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M39/00—Tubes, tube connectors, tube couplings, valves, access sites or the like, specially adapted for medical use
- A61M39/02—Access sites
- A61M39/0247—Semi-permanent or permanent transcutaneous or percutaneous access sites to the inside of the body
- A61M2039/0252—Semi-permanent or permanent transcutaneous or percutaneous access sites to the inside of the body for access to the lungs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M39/00—Tubes, tube connectors, tube couplings, valves, access sites or the like, specially adapted for medical use
- A61M39/02—Access sites
- A61M39/0247—Semi-permanent or permanent transcutaneous or percutaneous access sites to the inside of the body
- A61M2039/0276—Semi-permanent or permanent transcutaneous or percutaneous access sites to the inside of the body for introducing or removing fluids into or out of the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M39/00—Tubes, tube connectors, tube couplings, valves, access sites or the like, specially adapted for medical use
- A61M39/02—Access sites
- A61M39/0247—Semi-permanent or permanent transcutaneous or percutaneous access sites to the inside of the body
- A61M2039/0279—Semi-permanent or permanent transcutaneous or percutaneous access sites to the inside of the body for introducing medical instruments into the body, e.g. endoscope, surgical tools
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/33—Controlling, regulating or measuring
- A61M2205/3331—Pressure; Flow
- A61M2205/3344—Measuring or controlling pressure at the body treatment site
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/33—Controlling, regulating or measuring
- A61M2205/3331—Pressure; Flow
- A61M2205/3355—Controlling downstream pump pressure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/36—General characteristics of the apparatus related to heating or cooling
- A61M2205/366—General characteristics of the apparatus related to heating or cooling by liquid heat exchangers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
- A61M25/1011—Multiple balloon catheters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N7/00—Ultrasound therapy
- A61N7/02—Localised ultrasound hyperthermia
Definitions
- Atrial fibrillation may occur alone, this arrhythmia often associates with numerous cardiovascular conditions, including congestive heart failure, hypertensive cardiovascular disease, myocardial infarcation, rheumatic heart disease and stroke.
- three separate detrimental sequelae result: (1) a change in the ventricular response, including the onset of an irregular ventricular rhythm and an increase in ventricular rate; (2) detrimental hemodynamic consequences resulting from loss of atroventricular synchrony, decreased ventricular filling time, and possible atrioventricular valve regurgitation; and (3) an increased likelihood of sustaining a thromboembolic event because of loss of effective contraction and atrial stasis of blood in the left atrium.
- Atrial arrythmia may be treated using several methods.
- Pharmacological treatment of atrial fibrillation is initially the preferred approach, first to maintain normal sinus rhythm, or secondly to decrease the ventricular response rate. While these medications may reduce the risk of thrombus collecting in the atrial appendages if the atrial fibrillation can be converted to sinus rhythm, this form of treatment is not always effective. Patients with continued atrial fibrillation and only ventricular rate control continue to suffer from irregular heartbeats and from the effects of impaired hemodynamics due to the lack of normal sequential atrioventricular contractions, as well as continue to face a significant risk of thromboembolism.
- this procedure includes the excision of both atrial appendages, and the electrical isolation of the pulmonary veins. Further, strategically placed atrial incisions not only interrupt the conduction routes of the most common reentrant circuits, but they also direct the sinus impulse from the sinoatrial node to the atrioventricular node along a specified route. In essence, the entire atrial myocardium, with the exception of the atrial appendages and the pulmonary veins, is electrically activated by providing for multiple blind alleys off the main conduction route between the sinoatrial node to the atrioventricular node.
- Atrial transport function is thus preserved postoperatively, as generally set forth in the series of articles: Cox, Schuessler, Boineau, Canavan, Cain, Lindsay, Stone, Smith, Corr, Chang, and D'Agostino, Jr., The Surgical Treatment of Atrial Fibrillation (pts. 1-4), 101 Thorac Cardiovasc Surg., 402-426, 569-592 (1991).
- Such a large opening further enables manipulation of surgical instruments and/or removal of excised heart tissue since the surgeon can position his or her hands within the thoracic cavity in close proximity to the exterior of the heart.
- the patient is then placed on cardiopulmonary bypass to maintain peripheral circulation of oxygenated blood.
- Yet another object of the present invention is to provide a surgical procedure and surgical devices which are capable of strategically ablating heart tissue from the interior chambers or external cardiac surfaces thereof without substantially disturbing the structural integrity of the atria.
- Still another object of the present invention is to enable surgeons to ablate medically refractory atrial fibrillation while the heart is still beating.
- the present invention provides surgical systems and methods for ablating heart tissue within the interior and/or exterior of the heart.
- This procedure is particularly suitable for surgeries such as the MAZE III procedure developed to treat medically refractory atrial fibrillation since the need for substantial, elongated, transmural incisions of the heart walls are eliminated.
- this technique is preferably performed without having to open the chest cavity via a median sternotomy or major thoracotomy.
- the system is configured for being introduced through a small intercostal, percutaneous penetration into a body cavity and engaging the heart wall through purse-string incisions. As a result, the procedure of the present invention reduces potential postoperative complications, recovery time and hospital stays.
- a system for transmurally ablating heart tissue including an ablating probe having an elongated shaft positionable through the chest wall and into a transmural penetration extending through a muscular wall of the heart and into a chamber thereof.
- the shaft includes an elongated ablating surface for ablating heart tissue.
- the system of the present invention further includes a sealing device fixable to the heart tissue around the transmural penetration for forming a hemostatic seal around the probe to inhibit blood loss therethrough.
- a preferred method and device for ablating the heart tissue is with a cryosurgical ablation device.
- cryosurgical ablation is a preferred method, a number of other ablation methods could be used instead of cryoablation.
- tissue ablation means are Radio Frequency (RF), ultrasound, microwave, laser, heat, localized delivery of chemical or biological agents and light-activated agents to name a few.
- the system of the present invention enables the formation of a series of strategically positioned and shaped elongated, transmural lesions which cooperate with one another to reconstruct a main electrical conduction route between the sinoatrial node to the atrioventricular node. Atrial transport function is thus preserved postoperatively for the treatment of atrial fibrillation.
- the system includes a plurality of surgical probes each having an elongated shaft.
- Each shaft includes an elongated ablating surface of a predetermined shape for contact with at least one specific surface of the heart and specifically the interior walls of atria chamber. Such contact with the ablating surface for a sufficient period of time causes transmural ablation of the wall.
- a series of strategically positioned and shaped elongated, transmural lesions are formed which cooperate with one another to treat atrial fibrillation.
- Each transmural penetration includes a purse-string suture formed in the heart tissue around the respective transmural penetration in a manner forming a hemostatic seal between the respective probe and the respective transmural penetration to inhibit blood loss therethrough.
- the probe When using a cryosurgical probe, the probe includes a shaft having a delivery passageway for delivery of pressurized cryogen therethrough and an exhaust passageway for exhaust of expended cryogen.
- the pressurized cryogen is expanded in a boiler chamber thereby cooling the elongated ablating surface for cryogenic cooling of the elongated ablating surface.
- the elongated shaft is configured to pass through the chest wall and through a penetration in the patient's heart for ablative contact with a selected portion of the heart.
- a surgical method for ablating heart tissue from the interior and/or exterior walls of the heart including the steps of forming a penetration through a muscular wall of the heart into an interior chamber thereof and positioning an elongated ablating device having an elongated ablating surface through the penetration.
- the method further includes the steps of forming a hemostatic seal between the device and the heart wall penetration to inhibit blood loss through the penetration and contacting the elongated ablating surface of the ablating device with a first selected portion of an interior and/or exterior surface of the muscular wall for ablation thereof.
- a method for ablating medically refractory atrial fibrillation of the heart comprising the steps of forming a penetration through the heart and into a chamber thereof positioning an elongated ablating devices having an elongated ablating surface through the penetration and forming a hemostatic seal between the ablating device and the penetration to inhibit blood loss therethrough.
- the present invention method further includes the steps of strategically contacting the elongated ablating surface of the ablating device with a portion of the muscular wall for transmural ablation thereof to form at least one elongated transmural lesion and repeating these steps for each remaining lesion.
- Each transmural lesion is formed through contact with the ablating surface of one of the plurality of ablating device and the strategically positioned elongated transmural lesions cooperate to guide the electrical pulse pathway along a predetermined path for the surgical treatment of atrial fibrillation.
- the entire procedure is preferably performed through a series of only five purse-strings sutures strategically located in the right and left atria, and pulmonary vein portions.
- multiple lesions can be formed through a single purse-string either through the use of assorted uniquely shaped ablating devices or through the manipulation of a single ablating device.
- FIG. 1 is an upper left, posterior perspective view of a human heart incorporating the system and procedure for treatment of medically refractory atrial fibrillation constructed in accordance with the principles of the present invention.
- FIG. 2 is a right, antero-lateral perspective view of the human heart incorporating the present invention system and procedure thereof.
- FIGS. 3A and 3B are schematic diagrams of the atria portion of the heart illustrating the pattern of transmural cryolesions to create a predetermined conduction path in the atrium using the system and procedure of the present invention.
- FIG. 4 is a top plan view of a set of cryoprobe devices constructed in accordance with the present invention, and utilized in the system and procedure of the present invention.
- FIG. 5 is a top perspective view of a patient showing use of the system and procedure on the patient.
- FIG. 6 is an enlarged, fragmentary, top plan view, in cross-section, of one of the cryoprobes in the set of cryoprobes of FIG. 4, illustrating the expansion chamber thereof.
- FIGS. 6 A- 6 D illustrate use of a slidable insulative tube for insulating portions of the probe.
- FIG. 7 is a front elevation view, in cross-section, of the ablating end of a cryoprobe, taken substantially along the plane of the line 7 - 7 in FIG. 6.
- FIG. 8 is a front elevation view, in cross-section, of an alternative embodiment of the ablating end of FIG. 7.
- FIG. 9 is a transverse cross-sectional view of the system and patient, taken through the patient's thorax generally along the plane of the line 9 - 9 in FIG. 11A, showing the relative positioning of the right and left intercostal percutaneous penetrations.
- FIG. 10 is a front schematic view of a patient's cardiovascular system illustrating the positioning of a cardiopulmonary bypass system for arresting the heart and establishing cardiopulmonary bypass in accordance with the principles of the present invention.
- FIGS. 11 A- 11 D is a series of top plan views of the patient undergoing a pericardiotomy as well as the installation of a purse-string suture and a stay suture to assist in suspending the pericardium.
- FIGS. 12 A- 12 C is a series of enlarged, fragmentary side elevation views looking into the patient's thoracic cavity at the right atrium through a soft tissue retractor (not shown) in the system of FIG. 5, and illustrating the introduction of cryoprobes constructed in accordance with the present invention through purse-strings for the formation of a posterior longitudinal right atrial cryolesion and a tricuspid valve annulus cryolesion.
- FIG. 13 is an enlarged, fragmentary, transverse cross-sectional view, partially broken away, of the system and patient's heart of FIG. 5, and illustrating the introduction of a tricuspid valve cryoprobe through a purse-string suture in the right atrial freewall to form the elongated, transmural, tricuspid valve annulus cryolesion.
- FIG. 14 is a side elevation view peering at the right atrial appendage through the soft tissue retractor passageway (not shown) in the system of FIG. 5, showing the formation of a perpendicular right atrial cryolesion.
- FIG. 15 is a fragmentary, transverse cross-sectional view of the system and patient's heart, illustrating the formation of a right atrial anteromedial counter cryolesion.
- FIG. 16 is an upper left, posterior perspective view the human heart of FIG. 1, illustrating the location of the purse-string sutures in the right and left atrial walls, to access opposite sides of the atrial septum wall for the introduction of an atrial septum clamping cryoprobe.
- FIG. 17 is a fragmentary, transverse cross-sectional view, partially broken away, of the system and patient's heart, showing the atrial septum clamping cryoprobe engaged with the atrial septum wall for the formation of an anterior limbus of the fossa ovalis cryolesion.
- FIGS. 18A and 18B is a sequence of enlarged, fragmentary, transverse cross-sectional views, partially broken away, of the system and patient's heart, illustrating the technique employed to enable insertion of the distal ends of the atrial septum clamping cryoprobe through the adjacent purse-string sutures.
- FIGS. 19 A- 19 D is a series of fragmentary, transverse cross-sectional views, partially broken away, of the system and patient's heart, showing the formation of an endocardial pulmonary vein isolation cryolesion using a four-step process.
- FIGS. 20A and 20B is a sequence of fragmentary, transverse cross-sectional views, partially broken away, of the system and patient's heart, showing the formation of the pulmonary vein isolation cryolesion through an alternative two-step process.
- FIG. 21 is an upper left, posterior perspective view of the human heart illustrating the formation of an additional epicardial pulmonary vein isolation cryolesion.
- FIG. 22 is a fragmentary, transverse cross-sectional view of the system and patient's heart, showing the formation of a left atrial anteromedial cryolesion.
- FIG. 23 is a fragmentary, transverse cross-sectional view of the system and patient's heart, illustrating the formation of a posterior vertical left atrial cryolesion.
- FIG. 24 is a top plan view of the right angle cryoprobe of FIGS. 12A and 12B.
- FIG. 25 is a top plan view of the tricuspid valve annulus cryoprobe of FIG. 13.
- FIG. 26 is a top plan view of an alternative embodiment of the tricuspid valve annulus cryoprobe of FIG. 25.
- FIG. 27 is a top plan view of the right atrium counter lesion cryoprobe of FIG. 15.
- FIG. 28 is a top plan view of the atrial septum clamping cryoprobe of FIGS. 17 and 18.
- FIG. 29 is an enlarged front elevation view, in cross-section, of a coupling device of the septum clamping cryoprobe, taken substantially along the plane of the line 29 - 29 in FIG. 28.
- FIG. 30 is an enlarged rear elevation view, in cross-section, of an aligning device of the septum clamping cryoprobe, taken substantially along the plane of the line 30 - 30 in FIG. 28.
- FIG. 31 is an enlarged, fragmentary, top plan view of an alternative embodiment to the atrial septum clamping cryoprobe of FIG. 28.
- FIG. 32 is a top plan view of an all-purpose cryoprobe of FIGS. 19A and 19B.
- FIG. 33 is a top plan view of the pulmonary vein loop cryoprobe of FIGS. 20 and 21.
- FIG. 34 is a top plan view of the left atrial anteromedical cryoprobe of FIG. 22.
- FIG. 35 is a top plan view of an alternative embodiment of the all-purpose cryoprobe of FIG. 23.
- FIG. 36 is an enlarged, fragmentary, top plan view of an alternative embodiment to the cryoprobes formed for contact of the ablation surface with the epicardial surface of the heart.
- FIG. 37 is an exploded view of a cryogen delivery tube.
- FIG. 38 is a partial cross-sectional view of the probe having the delivery tube of FIG. 37.
- FIG. 39 is an exploded view of the outer tube of the probe of FIG. 38.
- FIG. 40 is an end view of the ablating surface of the probe of FIG. 39.
- FIG. 41 shows a probe having a delivery tube with adjustable holes wherein an outer tube is slidably movable relative to an inner tube.
- FIG. 42 shows the probe of FIG. 41 with the outer tube moved distally relative to the inner tube.
- FIG. 43 shows a probe having vacuum ports for adhering the probe to the tissue to be ablated.
- FIG. 44 is a cross-sectional view of the probe of FIG. 43 along line I-I.
- FIG. 45 shows a probe having a malleable shaft.
- FIG. 46 shows the tip of the probe of FIG. 45.
- FIG. 47 is a cross-sectional view of the probe of FIG. 45 along line II-II.
- FIGS. 1 - 3 where a human heart H is illustrated incorporating a series of strategically positioned transmural lesions throughout the right atrium RA and the left atrium LA formed with the heart treatment procedure and system of the present invention.
- FIG. 1 represents the desired pattern of lesions created on the right atrium RA, including the posterior longitudinal right atrial lesion 50 , the tricuspid valve annulus lesion valve annulus lesion 51 , the pulmonary vein isolation lesion vein isolation lesion 52 and the perpendicular lesion 53 ; while FIG. 2 represents a right, anterior perspective view of the heart H illustrating right atrium RA including a right atrial anteromedial counter lesion 55 .
- the cumulative pattern of lesions reconstruct a main electrical conduction route between the sinoatrial node to the atrioventricular node to postoperatively preserve atrial transport function.
- the system and procedure of the present invention employ a closed-heart technique which eliminates the need for gross multiple elongated incisions of the atria to ablate heart tissue in the manner sufficient to preclude electrical conduction of reentrant pathways in the atria.
- a set of uniquely-shaped, elongated tip ablation probes 57 (FIG. 4, to be discussed in detail below) are employed which are formed and dimensioned for insertion through at least one of a plurality of heart wall penetrations, preferably sealed by means of purse-string sutures 58 , 60 , 61 , 62 and 63 , strategically positioned about the atria of the heart H.
- purse-string sutures 58 , 60 , 61 , 62 and 63 strategically positioned about the atria of the heart H.
- FIG. 4 represents a collection or set of probes 57 constructed in accordance with the present invention which are employed to preclude electrical conduction of reentrant pathways in the atria using closed-heart surgical techniques.
- the probes enable the surgical formation of a series of lesions which are illustrated in FIGS. 3A and 3B.
- Each probe (FIGS. 24 - 28 and 32 - 35 ) includes an elongated shaft 66 formed to extend through an access port or passageway 67 in a retractor 68 (FIG. 5) which is mounted in a percutaneous intercostal penetration.
- percutaneous intercostal penetration and “intercostal penetration” as used herein refer to a penetration, in the form or a cut, incision, hole, retractor, cannula, trocar sleeve, or the like, through the chest wall between two adjacent ribs wherein the patient's rib cage and sternum remain generally intact. These terms are intended to distinguish a gross thoracotomy, such as a median sternotomy, wherein the sternum and/or one or more ribs are cut or removed from the rib cage. It should be understood that one or more ribs may be retracted to widen the intercostal space between adjacent ribs without departing from the scope of the invention.
- each probe Proximate the distal end of each probe is an elongated ablating end 70 having an ablating surface 65 formed to transmurally ablate heart tissue.
- Access to the selected portions of the atria of the heart H are provided by the specially shaped shafts 66 and ablating ends 70 which are configured to position the elongated ablating surface 65 through the chest wall of patient P and through a strategically positioned penetration in the muscular wall of the patient's heart H for ablative contact with a selected portion of an interior surface of the muscular wall. Subsequent contact of the ablating surface 65 with specific selected wall portions of the atria enable selected, localized transmural ablation thereof.
- the probes 57 form the lesions by freezing the heart tissue.
- freezing is a preferred method of ablating tissue
- the probe 57 may use any other method such as RF ablation, ultrasound, microwave, laser, localized delivery of chemical or biological agents, light-activated agents, laser ablation or resistance heating ablation.
- the device may include an injection device capable of injecting the chemical or biological agent onto or into the desired tissue for localized ablation thereof.
- the source of the chemical or biological agent may be stored in a reservoir contained in the probe or be stored in an external reservoir coupled to the injecting end of the probe.
- an opposite end of the probe has a fitting 71 formed for releasable coupling to an end of a delivery hose which in turn is coupled to a source (both of which are not shown) of cryogenic media.
- a threaded portion 72 of the fitting is formed for removable mounting to the delivery hose and further provides communication with the cryogenic media for both delivery to and exhaust from the probe.
- each probe includes an elongated shaft 66 sufficiently dimensioned and shaped to enable manual manipulation of the ablating end 70 into contact with the desired heart tissue from outside the thoracic cavity.
- the shaft 66 is preferably tubular-shaped and defines a communication passageway 73 extending therethrough which provides both delivery and exhaust of the cryogen to and from the ablating end 70 .
- Communication passageway 73 extends fully from the fitting 71 (FIG. 4) to a closed-end boiler chamber 75 where the cryogen exits the ablating end 70 .
- the tubular shaft 66 includes an outer diameter in the range of about 2.0 mm to about 5.0 mm, and most preferably about 4.0 mm; while the inner diameter is in the range of about 1.5 mm to about 4.5 mm, and most preferably about 3.0 mm.
- each probe Concentrically positioned in the communication passageway 73 of each probe is a delivery tube 76 (FIG. 6) which extends from the fitting 71 to proximate the boiler chamber 75 for communication therebetween enabling delivery and dispersion of the cryogen to the boiler chamber.
- the proximal end of delivery tube 76 is coupled to the cryogen liquid source through a conventional fitting for delivery of the cryogen through a delivery passageway 77 .
- the outer diameter of delivery tube 76 is dimensioned such that an annular exhaust passageway 78 is formed between the outer diameter of the delivery tube 76 and the inner diameter of the tubular shaft 66 .
- This exhaust passageway 78 provides a port through which the expended cryogen exiting the boiler chamber can be exhausted.
- the delivery tube 76 includes an outer diameter in the range of about 1.4 mm to about 3.0 mm, and most preferably about 2.0 mm; while the inner diameter is in the range of about 1.15 mm to about 2.75 mm, and most preferably about 1.50 mm.
- each probe 56 is specifically formed and shaped to facilitate performance of one or more of the particular procedures to be described in greater detail below.
- each probe may not always accommodate a particular patient for the designated procedure.
- the shaft must be capable of bending and reshaping without kinking or collapsing. Such properties are especially imperative for the devices employed in the pulmonary vein isolation lesion formation which are particularly difficult to access.
- This malleable material may be provided by certain stainless steels, NiTi or a shape memory alloy in its superelastic state such as a superelastic alloy.
- the shaft portion with the exception of the ablating surface, may be composed of a polymer material such as plastic which of course exhibits favorable thermoplastic deformation characteristics.
- the exhaust and delivery shafts 66 and 76 are composed of bright annealed 304 stainless steel.
- the delivery tube 76 may also be composed of NiTi or other superelastic alloy.
- the delivery tube 76 may be isolated and separated from contact with the inner walls of the exhaust shaft 66 by placing spacers around the delivery tube. These spacers may be provided by plastic or other polymer material. Alternatively, the delivery tube may be brazed or welded to one side of the inner wall of the exhaust shaft 66 along the longitudinal length thereof to resist vibrational contact, as illustrated in FIG. 8.
- the lesions formed by this system and procedure are generally elongated in nature.
- the ablating end 70 is thus provided by an elongated ablating surface 65 which extends rearwardly from the distal end a distance of at least about seven (7) times to about thirty (30) times the outer diameter of the ablating end, which incidentally is about the same as the outer diameter of the shaft 66 .
- the length of the ablating surface is at least three (3) cm long, more preferably at least four (4) cm long, and most preferably at least five (5) cm long.
- the ablating surface 65 has a length of between about three (3) cm to about eight (8) cm.
- FIG. 6 represents a typical cross-sectional view of an ablating end 70 of one of the probe devices of the present invention in which the ablating surface 65 is formed to contact the heart tissue for localized, transmural ablation thereof.
- Ablating end 70 therefore is preferably provided by a material exhibiting high thermal conductivity properties suitable for efficient heat transfer during cryogenic cooling of the tip. Such materials preferably include silver, gold and oxygen free copper or the like.
- the ablating end 70 is preferably provided by a closed-end, elongated tube having an interior wall 80 which defines the boiler chamber 75 , and is about 1.0 mm to about 1.5 mm thick, and most preferably about 1.25 mm thick. This portion is specifically shaped for use in one or more ablation procedures and is formed for penetration through the muscular walls of the heart.
- the distal end of exhaust shaft 66 is preferably inserted through an opening 81 into the boiler chamber 75 such that the exterior surface 82 at the tip of the exhaust shaft 66 seatably abuts against the interior wall 80 of the ablating end 70 for mounting engagement therebetween
- silver solder or the like may be applied to fixably mount the ablating end to the end of the exhaust shaft.
- proximal end of ablating end 70 can be mounted directly to the distal end of exhaust shaft 66 (i.e., in an end-to-end manner) using electron-beam welding techniques. In either mounting technique, a hermetic seal must be formed to eliminate cryogen leakage.
- a delivery portion 83 Proximate the distal end of delivery tube 76 is a delivery portion 83 which extends through the opening 81 and into boiler chamber 75 of the ablating end 70 .
- This closed-end delivery portion includes a plurality of relatively small diameter apertures 85 which extend through the delivery portion 83 into delivery passageway 77 to communicate the pressurized cryogen between the delivery passageway and the boiler chamber 75 .
- the cryogen flows through the delivery passageway in the direction of arrow 86 and into the delivery portion 83 where the cryogen expands through the apertures from about 600-900 psi to about 50-200 psi in the boiler chamber.
- the cryogen As the cryogen expands, it impinges upon the interior wall 80 of the ablating end cooling the ablating surface 65 . Subsequently, the expended cryogen flows in the direction of arrow 87 passing through the exhaust passageway 78 and out through the delivery hose.
- the number of apertures required to uniformly cool the ablating end is primarily dependent upon the length of the boiler chamber 75 , the diameter of the apertures, the type of cryogen employed and the pressure of the cryogen.
- these delivery apertures 85 are equally spaced-apart at about 5 mm to about 12 mm intervals, and extend from the proximal end of the boiler chamber to the distal end thereof.
- the preferred diameters of the apertures 85 range from about 0.004 inch to about 0.010 inch. These diameters may vary of course.
- apertures or sets of apertures spaced-apart longitudinally along delivery end portion are sufficient. Only one aperture 85 may be required at each longitudinal spaced location along the delivery portion 83 (FIG. 8). This one aperture may be strategically positioned radially about the delivery portion to direct the stream of cryogen onto the portion of the interior wall 80 directly beneath or near the predetermined portion of the ablating surface 65 which is to contact the heart wall tissue for a particular procedure. Hence, the spaced-apart apertures may be strategically positioned to collectively direct the cryogen onto particular surfaces of the ablating end to assure maximum cooling of those portions. In some instances, however (as shown in FIG.
- more than one aperture 85 may be radially positioned about the delivery portion 83 at any one longitudinal spaced location, proximate a plane extending transversely therethrough, for additional cryogenic cooling of the ablating surface. This may be especially important where the probe is to be employed in more than one procedure.
- the ablating surface 65 Due to the elongated and curved nature of the ablating surface 65 , it is difficult to maintain a generally uniform temperature gradient along the desired portions of the ablating surface during cryogenic cooling. This may be due in part to the pressure decrease in the delivery passageway 77 of the delivery portion 83 as the cryogen passes therethrough. To compensate for this pressure loss as the cryogen passes through the delivery portion, the diameters of the apertures 85 , 85 ′, 85 ′′ etc., may be slightly increased from the proximal end of the delivery portion 83 to the distal end thereof. Thus, as the cryogen travels through the delivery portion 83 of the delivery tube, a more uniform volume of cryogen may be distributed throughout the boiler chamber 75 even though the cryogenic pressure incrementally decreases from the proximal end of the delivery portion 83 .
- the delivery volume of the cyrogenic cooling also may be controlled by varying the number of apertures at particular portions of the ablating end i.e., increasing or decreasing the number of apertures at a particular location.
- This directed cooling will have a localized cooling effect, and is exemplified in the ablating end 70 of FIG. 4.
- the increased number of apertures along the inner bight portion 88 of delivery portion 83 delivers a more direct and greater volume of cryogen against the inner bight portion 88 , as compared to the outer bight portion 90 .
- An insulative coating or tubing 89 is preferably included extending circumferentially around portions of the cryoprobe shaft 66 near the ablation end 70 .
- This insulative tubing provides an insulatory barrier around shaft 66 to prevent inadvertent direct contact between the shaft, which will be cooled by the expended cryogen flowing through the exhaust passageway 75 , and any organs or tissue of the percutaneous penetration.
- the insulative tubing is preferably spaced from the shaft 66 to define an air gap between the inner surface of the tubing and the outer surface of the shaft.
- the insulative tubing 89 preferably extends around the elongated shaft 66 from the base of the ablation end 70 to the fitting 71 . In some instances, however, the tubing may only need to extend from the base of the ablation end to a midportion of the elongated shaft.
- the insulative tubing 89 is preferably provided by heat shrink polyolefin tubing, silicone, TEFLON@, or the like.
- the transverse, cross-sectional dimension of the ablating end 70 is circular-shaped having a substantially uniform thickness.
- the ablating surface 65 may include a generally flat contact surface 91 formed for increased area contact with the heart tissue without requiring a substantial increase in the diameter of the ablating surface.
- contact surface 91 may be generally flat or have a much larger radius than that of the ablating end.
- the spaced-apart apertures 85 are preferably oriented and formed to deliver the cryogen into direct impingement with the underside of the contact surface 91 of ablating end 70 .
- the delivery portion 83 of the delivery tube 76 may be mounted to one side of the interior wall 80 , as set forth above.
- the contact surface can be provided by a blunted edge or the like to create a relatively narrow lesion.
- the transverse cross-sectional dimension of this embodiment would appear teardrop-shaped.
- FIGS. 6 A- 6 D illustrate an embodiment of the probe 57 in which an insulative jacket or sleeve 304 is disposed on the probe so as to be movable relative thereto.
- the sleeve 304 has a window or cut-out portion 305 which exposes a selected area of the probe 57 .
- FIG. 6A shows the sleeve 304 located around the probe shaft
- FIG. 6B shows the sleeve after it has been slid over part of the probe ablating surface 65
- FIG. 6C shows the sleeve 304 after it has been slid completely over the ablating surface 65 to a position where the window 305 exposes one area of the surface 65 for ablating tissue.
- FIG. 6A shows the sleeve 304 located around the probe shaft
- FIG. 6B shows the sleeve after it has been slid over part of the probe ablating surface 65
- FIG. 6C shows the sleeve 304 after it has
- FIG. 6D shows the sleeve 304 rotated to a different position where the window 305 exposes a different area of the surface 65 for ablating tissue.
- the sleeve 304 may be slidable and rotatable relative to the probe as show in FIGS. 6 A- 6 D.
- the sleeve 304 may be fixed axially with respect to the probe 57 but rotatable relative thereto so that the window is able to expose different areas of the ablating surface.
- the sleeve 304 may be fixed on the probe 57 such that only a selected area of ablation surface 65 is exposed through window 305 .
- the sleeve 304 may be formed of any suitable material, for example, a flexible polymer having low thermal conductivity.
- the preferred cryogen employed in the devices of the present invention is nitrous oxide (N 2 O) which is normally stored in a compressed gas cylinder (not shown).
- Other cryogenic fluids may be employed which include liquid nitrogen or liquified air stored in a Dewar vessel (not shown), freon 13, freon 14, freon 22, and normally gaseous hydrocarbons.
- cryogen is selectively delivered through the delivery passageway 77 of delivery tube 76 into the delivery conduit thereof.
- the gas expands into the boiler chamber 75 , cooling the ablating surface using the well known Joule-Thompson effect.
- the elongated ablating surface 65 is then immediately cooled to a temperature of preferably between about ⁇ 50° C. to about ⁇ 80° C., when nitrous oxide is employed.
- Direct conductive contact of the cooled, elongated ablating surface 65 with the selected heart tissue causes cryogenic ablation thereof.
- a localized, elongated, transmural lesion is formed at a controlled location which sufficiently prevents or is resistant to electrical conduction therethrough.
- the lesions must be transmural in nature.
- the minimum length of time for conductive contact of the ablating surface with the selected heart tissue necessary to cause localized, transmural ablation thereof is to a large degree a function of the thickness of the heart wall tissue, the heat transfer loss due do the convective and conductive properties of the blood in fluid contact with the ablating surface, as well as the type of cryogen employed and the rate of flow thereof.
- tissue contact is preferably in the range of about 2-4 minutes.
- FIGS. 5 and 9 illustrate system 56 for closed-chest, closed-heart surgery positioned in a patient P on an operating table T.
- the patient is prepared for cardiac surgery in the conventional manner, and general anesthesia is induced.
- the patient is positioned on the patient's left side so that the right lateral side of the chest is disposed upward.
- a wedge or block W having a top surface angled at approximately 20° to 45° is positioned under the right side of the patient's body so that the right side of the patient's body is somewhat higher than the left side.
- a similar wedge or block W is positioned under the left side of patient P (not shown) when performing the surgical procedure on the left atrium In either position, the patient's right arm A or left arm (not shown) is allowed to rotate downward to rest on table T, exposing either the right lateral side or the left lateral side of the patient's chest.
- a thoracoscopic access device 68 e.g. a retractor, trocar sleeve or cannulae
- This access device 68 has an outer diameter preferably less than 14 mm and an axial passage of a length less than about 12 mm.
- thoracoscopic trocars or the like may be positioned within intercostal spaces in the right lateral chest inferior and superior to the retractor 68 , as well as in the right anterior (or ventral) portion of the chest if necessary.
- instruments may be introduced directly through small, percutaneous intercostal incisions in the chest.
- retractor 68 such as that described in detail in commonly assigned U.S. patent application Ser. No. 08/610,619 filed Mar. 4, 1996, surgical access to the body cavity of patient P through the first intercostal percutaneous penetration 92 in the tissue 93 .
- retractor 68 includes an anchoring frame 95 having a passageway 67 therethrough which defines a longitudinal retractor axis.
- the anchoring frame 95 is positionable through the intercostal percutaneous penetration 92 into the body cavity.
- a flexible tensioning member 96 is attached to anchoring frame 95 and extendible from the anchoring frame out of the body through intercostal penetration 92 to deform into a non-circular shape when introduced between two ribs.
- the tensioning member 96 is selectively tensionable to spread the tissue radially outward from the longitudinal axis. Hence, it is the tension imposed on the flexible tensioning member 96 which effects retraction of the tissue, rather than relying on the structural integrity of a tubular structure such as a trocar sheath.
- An endoscope 97 (FIG. 5) of conventional construction is positioned through a percutaneous intercostal penetration into the patient's chest, usually through the port of the soft tissue retractor 68 .
- a video camera 98 is mounted to the proximal end of endoscope 97 , and is connected to a video monitor 100 for viewing the interior of the thoracic cavity.
- Endoscope 97 is manipulated so as to provide a view of the right side of the heart, and particularly, a right side view of the right atrium.
- an endoscope of the type having an articulated distal end such as the Distalcam 360, available from Welch-Allyn of Skameateles Falls, N.Y., or a endoscope having a distal end disposed at an angle between 30 i and 90 i will be used, which is commercially available from, for example, Olympus Corp., Medical Instruments Division, Lake Success, N.Y.
- a light source (not shown) is also provided on endoscope 97 to illuminate the thoracic cavity.
- the surgeon may simply view the chest cavity directly through the access port 67 of the retractor 68 .
- a transesophageal echocardiography may be used, wherein an ultrasonic probe is placed in the patient's esophagus or stomach to ultrasonically image the interior of the heart.
- a thoracoscopic ultrasonic probe may also be placed through access device 68 into the chest cavity and adjacent the exterior of the heart for ultrasonically imaging the interior of the heart.
- An endoscope may also be employed having an optically transparent bulb such as an inflatable balloon or transparent plastic lens over its distal end which is then introduced into the heart.
- an optically transparent bulb such as an inflatable balloon or transparent plastic lens over its distal end which is then introduced into the heart.
- the balloon may be inflated with a transparent inflation fluid such as saline to displace blood away from distal end and may be positioned against a site such a lesion, allowing the location, shape, and size of cryolesion to be visualized.
- an endoscope may be utilized which employs a specialized light filter, so that only those wavelengths of light not absorbed by blood are transmitted into the heart.
- the endoscope utilizes a CCD chip designed to receive and react to such light wavelengths and transmit the image received to a video monitor.
- the endoscope can be positioned in the heart through access port 67 and used to see through blood to observe a region of the heart.
- a visualization system based on such principles is described in U.S. Pat. No. 4,786,155, which is incorporated herein by reference.
- the heart treatment procedure and system of the present invention may be performed while the heart remains beating. Hence, the trauma and risks associated with cardiopulmonary bypass (CPB) and cardioplegic arrest can be avoided. In other instances, however, arresting the heart may be advantageous. Should it be desirable to place the patient on cardiopulmonary bypass, the patient's right lung is collapsed and the patient's heart is arrested. Suitable techniques for arresting cardiac function and establishing CPB without a thoracotomy are described in commonly-assigned, co-pending U.S. patent application Ser. No. 08/282,192, filed Jul. 28, 1994 and U.S. patent application Ser. No. 08/372,741, filed Jan. 17, 1995, all of which are incorporated herein by reference. Although it is preferred to use the endovascular systems described above, any system for arresting a patient's heart and placing the patient on CPB may be employed.
- CPB is established by introducing a venous cannula 101 into a femoral vein 102 in patient P to withdraw deoxygenated blood therefrom.
- Venous cannula 101 is connected to a cardiopulmonary bypass system 104 which receives the withdrawn blood, oxygenates the blood, and returns the oxygenated blood to an arterial return cannula 105 positioned in a femoral artery 106 .
- a pulmonary venting catheter 107 may also be utilized to withdraw blood from the pulmonary trunk 108 .
- Pulmonary venting catheter 107 may be introduced from the neck through the interior jugular vein 110 and superior vena cava 111 , or from the groin through femoral vein 102 and inferior vena cava 103 .
- An alternative method of venting blood from pulmonary trunk 108 is described in U.S. Pat. No. 4,889,137, which is incorporated herein by reference.
- an endovascular device is positioned from the interior jugular vein in the neck through the right atrium, right ventricle, and pulmonary valve into the pulmonary artery so as to hold open the tricuspid and pulmonary valves.
- an aortic occlusion catheter 113 is positioned in a femoral artery 106 by a percutaneous technique such as the Seldinger technique, or through a surgical cut-down.
- the aortic occlusion catheter 113 is advanced, usually over a guidewire (not shown), until an occlusion balloon 115 at its distal end is disposed in the ascending aorta 116 between the coronary ostia and the brachiocephalic artery.
- Blood may be vented from ascending aorta 116 through a port 120 at the distal end of the aortic occlusion catheter 113 in communication with an inner lumen in aortic occlusion catheter 113 , through which blood may flow to the proximal end of the catheter.
- the blood may then be directed to a blood filter/recovery system 121 to remove emboli, and then returned to the patient's arterial system via CPB system 104 .
- occlusion balloon 115 When it is desired to arrest cardiac function, occlusion balloon 115 is inflated until it completely occludes ascending aorta 116 , blocking blood flow therethrough.
- a cardioplegic fluid such as potassium chloride (KCl) is preferably mixed with oxygenated blood from the CPB system and then delivered to the myocardium in one or both of two ways. Cardioplegic fluid may be delivered in an anterograde manner, retrograde manner, or a combination thereof.
- KCl potassium chloride
- the cardioplegic fluid is delivered from a cardioplegia pump 122 through an inner lumen in aortic occlusion catheter 113 and the port 120 distal to occlusion balloon 115 into the ascending aorta upstream of occlusion balloon 115 .
- the cardioplegic fluid may be delivered through a retroperfusion catheter 123 positioned in the coronary sinus from a peripheral vein such as an internal jugular vein in the neck.
- the procedure is conducted while the heart is still beating. Accordingly, it is necessary to form a hemostatic seal between the ablation device and the penetration.
- purse-string sutures 58 , 60 , 61 , 62 and 63 are placed in the heart walls at strategic or predetermined locations to enable introduction of the ablating probes into the heart while maintaining a hemostatic seal between the probe and the penetration.
- a pericardiotomy is performed using thoracoscopic instruments introduced through retractor access port 67 .
- Instruments suitable for use in this procedure including thoracoscopic angled scissors 130 and thoracoscopic grasping forceps 131 , are described in commonly assigned U.S. Pat. No. 5,501,698, issued Mar. 26, 1996, which is incorporated herein by reference.
- a curved suture needle 137 attached to one end of a suture thread 138 is introduced into the chest cavity through passageway 67 with of a thoracoscopic needle driver 140 (FIG. 11B).
- a suture snare device 141 This is accomplished by positioning a hooked end 142 of suture snare device 141 through at least one additional percutaneous intercostal penetration 143 positioned about the chest to enable penetration into the thoracic cavity.
- a trocar needle (not shown) is employed which not only forms the penetration, but also provides access into the thoracic cavity without snaring tissue during removal of the snare device.
- both sides of the suture thread 138 are snared and pulled through the chest wall for manipulation of the stay suture from outside of the body cavity.
- the ends of the stay suture 136 are coupled to a surgical clamp (not shown) for angled manipulation and tension adjusting. While only two stay sutures are illustrated, it will be appreciated that more stay sutures may be employed as needed to further manipulate the pericardial opening.
- a first 4-0 purse-string suture 58 is placed in the heart wall proximate the site at which it is desired to initiate the first heart wall penetration 146 (FIG. 11D). Again, this is accomplished by using a thoracoscopic needle driver to drive the suture needle through the heart wall to form a running stitch in a circular pattern approximately 1.0-3.0 mm in diameter.
- a double-armed suture may also be used, wherein the suture thread 145 (about 3 mm to about 10 mm in diameter) has needles (not shown) at both ends, allowing each needle to be used to form one semi-circular portion of the purse-string.
- Suture thread 138 is long enough to allow both ends of the suture to be drawn outside of the chest cavity once purse-string suture 58 has been placed. The suture needle is then cut from thread 145 using thoracoscopic scissors.
- cinching instrument 147 comprises a shaft 148 with a slidable hook 150 at its distal end thereof for this purpose. Hook 150 may be retracted proximally to frictionally retain suture thread 145 against the distal end of shaft 148 .
- the cinching instrument may be clamped in position to maintain tension on suture thread 145 .
- a slidable tensioning sleeve 151 (FIG. 11D), commonly referred to as a snugger, may be provided in which the suture threads are positioned through a bore extending therethrough. The snugger is then slid along the suture thread until it abuts against the epicardial surface 152 of the heart wall. The cinching instrument is then pulled proximally relative to tensioning sleeve 151 to obtain the desired degree of tension on suture thread 145 .
- Tensioning sleeve 151 is configured to frictionally couple to suture thread 145 to maintain tension on the suture.
- An incision device 153 is introduced through access device 68 into the chest cavity for piercing the heart H.
- a blade 155 positioned on the distal end of a manipulating shaft 156 is advanced to pierce the heart wall within the bounds of purse-string suture 58 .
- the blade 155 is preferably about 5.0 mm in length and about 3.0 mm wide terminating at the tip thereof.
- FIG. 11D illustrates that as the incision device 153 is manually moved further into contact with the epicardial surface 152 of the heart wall, blade 155 will be caused to pierce therethrough to form a penetration of about 1.0-2.0 mm across.
- the blade 155 is rigidly mounted to shaft 156 for direct one-to-one manipulation of the blade.
- the incision device may employ a spring loaded mechanism or the like which advances the blade forwardly from a retracted position, retracted in a protective sleeve of the shaft, to an extended position, extending the blade outside of the sleeve and into piercing contact with the tissue.
- a button or the like may be provided near the proximal end of the shaft for operation of the blade between the retracted and extended positions.
- a thoracoscopic grasping instrument (not shown) may be employed to grasp the heart wall near purse-string suture 58 to counter the insertion force of blade 155 and incision device 153 .
- incision device 153 is advanced to extend transmurally into the heart through the penetration 146 formed in heart wall.
- the entire procedure is preferably performed through a series of only five purse-strings sutures 58 , 60 , 61 , 62 and 63 , and the corresponding cardiac penetrations 146 , 157 , 158 , 160 and 161 of which two penetrations 158 , 160 are strategically positioned in the right atrium RA; one penetration 161 is positioned in the left atrium LA; and two penetrations 158 , 160 are positioned near the pulmonary vein trunk 108 .
- Such small incisions are significantly less traumatic on the heart tissue muscle than the elongated transmural incisions of the prior MAZE techniques.
- the first series of lesions is formed on the right atrium RA to form a posterior longitudinal right atrial lesion 50 and a tricuspid valve annulus lesion 51 .
- the transmural lesions can be formed in any order without departing from the true spirit and nature of the present invention.
- first purse-string suture 58 By strategically placing the first heart wall penetration 146 of first purse-string suture 58 at the base of the right atrial appendage RAA where the anticipated intersection between the longitudinal right atrial lesion 50 and the tricuspid valve annulus lesion 51 are to occur (FIG. 12C), these two lesions can be formed through a series of three independent ablations.
- the upper section segment 162 half of the longitudinal right atrial lesion 50
- the first elbow portion has an arc length of about 85° to about 95° and a radius of curvature of about 3.2 mm to about 6.4 mm.
- the ablating end 70 is preferably about 2.0 mm to about 4.0 mm in diameter, and about 2.0 cm to about 6.0 cm in length. In this configuration, the ablating surface 65 extends, circumferentially, from a distal end 165 thereof to just past an elbow portion 166 of the right angle probe 163 .
- the probe ablating end 70 and the shaft 66 of probe 163 is introduced into the thoracic cavity through the retractor 68 by manipulating a handle (not shown) releasably coupled to fitting 71 .
- the distal end 165 is guided along the shaft 156 of incision device 153 (FIG. 11D) until positioned proximate the first penetration 146 .
- the blade 155 of incision device is withdrawn from the first penetration whereby the distal end of the probe is immediately inserted through the first penetration. Not only does this technique facilitate insertion of the probe but also minimizes loss of blood through the penetration.
- the first purse-string suture may require adjustment to ensure the formation of a proper hemostatic seal between the penetration and the shaft of the probe. If the loss of blood should occur, the purse-string suture can be easily tightened through either a Rumel tourniquet or tensioning sleeve 151 .
- FIG. 12A best illustrates that the right angle probe 163 is preferably inserted through the penetration 146 until an elbow portion 166 thereof just passes through the penetration.
- the angular manipulation of the end of the right angle probe is limited due to the access provided by the retractor, the insertion should be easily accommodated since the heart wall tissue of the right atrium is substantially resilient and flexible.
- a thoracoscopic grasping instrument (not shown) may be employed to grasp the heart wall near the first purse-string suture 58 to counter the insertion force of right angle probe 163 through the first penetration 146 .
- the elongated ablating end 70 is oriented to position a longitudinal axis thereof generally parallel to the right atrioventricular groove.
- This upper section segment 162 of the longitudinal right atrial lesion 50 extends generally from the first penetration 146 to the orifice of the superior vena cava 111 .
- the probe may use any method to ablate the heart tissue.
- the cryogen stored in a Dewar vessel or pressurized cylinder is selectively released where it passes into the boiler chamber 75 of the device 163 , thereby cooling the probe ablating surface for localized ablation of heart tissue.
- continuous contact of the ablating surface therewith should occur for about 2-4 minutes.
- transmural cryosurgical ablation of the tissue is generally represented by a localized lightening or discoloration of the epicardial surface 168 of the ablated heart tissue which can be directly viewed through the access port 67 of access device 68 .
- This method of determining cryoablation of the tissue can be used in combination with the timed probe contact therewith. As a result, the upper section segment 162 of the longitudinal right atrial lesion 50 will be formed.
- the ablating surface 65 probe can be separated from the contacted endocardial surface of the heart tissue. Due to the extremely low temperatures of the ablating surface (i.e., about ⁇ 50° to about ⁇ 80°) and the moistness of the heart tissue, cryoadhesion can occur. Accordingly, the probe tip must be properly thawed or defrosted to enable safe separation after the tissue has been properly ablated.
- thawing is commenced by halting the flow of cryogen through the probe and maintaining continuous contact between the probe ablating surface and the cryoablated tissue.
- the conductive and convective heat transfer or heat sink effect from the surrounding tissue and blood is sufficient to reverse the cryoadhesion.
- the system may also be provided with a defrost mode which serves to warm the tissue to room temperature. This may be accomplished by raising the pressure of the cryogen adjacent the ablating surface such that its temperature increases, for example, by restricting the exhaust gas flow.
- a room temperature or slightly heated liquid may be wetted or impinged upon the exterior surface of the ablated area.
- such liquid may include saline or other non-toxic liquid introduced into the thoracic cavity through the retractor passageway 67 .
- multiple lesions can be formed through a single purse-string suture either through the use of assorted uniquely shaped ablating devices or through the manipulation of a single ablating device.
- the respective ablating device can be manipulated through the respective penetration to strategically contact the corresponding elongated ablating surface with another selected portion of the interior surface of the muscular wall for transmural ablation thereof.
- the ablating surface 65 is rotated approximately 180° about the longitudinal axis to re-position the distal end generally in a direction toward the orifice of the inferior vena cava 103 . As shown in FIG.
- the right angle probe 163 is retracted rearwardly, generally in the direction of arrow 167 , causing the ablating surface 65 of the probe to sufficiently contact the endocardium of the right atrium. After the cryogen has continuously cooled the elongated ablating surface 65 of the probe for about 2-4 minutes, the remaining lower section segment of the longitudinal right atrial lesion 50 will be formed. Thereafter, the probe is defrosted to reverse the effects of cryoadhesion. It will be understood that while it is beneficial to employ the same right angle probe to perform both the upper and lower section segments of the longitudinal right atrial lesion, a second right angle probe having an ablating surface shorter in length than that of the first right angle probe could easily be employed.
- the tricuspid valve annulus lesion 51 can be formed employing one of at least two probes.
- the right angle probe 163 may again be used by rotating the elongated ablating surface 65 about the probe shaft longitudinal axis to reposition the distal end trans-pericardially, generally in a direction across the lower atrial free wall and toward the tricuspid valve 171 (FIGS. 12C and 13).
- the distal end of the probe ablating surface 65 must extend all the way to the tricuspid valve annulus 172 .
- the formation of the tricuspid valve annulus lesion 51 with the right angle probe may be difficult to perform.
- a special shaped tricuspid valve annulus probe 173 (FIGS. 13 and 25) is employed which is formed and dimensioned to enable contact of the probe ablating surface 65 with appropriate portion of the right atrium interior wall all the way from the first penetration 146 to the tricuspid valve annulus 172 to form the tricuspid valve annulus lesion 51 .
- the ablating end 70 and the shaft 66 of this probe cooperate to form one of the straighter probes 57 of the set shown in FIG. 4.
- FIG. 25 best illustrates the tricuspid valve annulus probe 173 which includes an elongated shaft 66 having a first elbow portion 166 positioned between a generally straight first portion 175 and a generally straight second portion 176 having a length of about 2.0 cm to about 6.0 cm.
- the first elbow portion has an arc length of about 20° to about 40° and a radius of curvature of about 13.0 cm to about 18.0 cm.
- a second elbow portion 177 is positioned between the second portion 176 and a third portion 178 of the shaft, angling the third portion back toward the longitudinal axis of the first portion 175 of the elongated shaft 66 .
- the third portion 178 includes a length of about 2.0 cm to about 6.0 cm, while the second elbow portion has an arc length of about 5° to about 20° and a radius of curvature of about 15.0 cm to about 20.0 cm.
- the ablating end 70 is relatively straight and is coupled to the distal end of the third portion 178 of the elongated shaft 66 in a manner angling the ablating end back away from the longitudinal axis and having an arc length of about 5° to about 20° and a radius of curvature of about 13.0 cm to about 18.0 cm.
- the ablating end 70 is formed to extend from the first penetration and to the rim 172 of the tricuspid valve 171 from outside of the body cavity.
- the ablating surface 65 is preferably about 2.0 cm to about 6.0 cm in length. It will be understood that while the illustrations and descriptions of the probes are generally two dimensional, the configurations of the shaft and ablating end combinations could be three dimensional in nature.
- the cryogen is selectively released into the boiler chamber to subject the desired tissue to localized cryothermia. Due to the nature of the transmural ablation near the tricuspid valve annulus, the need for dividing all atrial myocardial fibers traversing the ablated portion is effectively eliminated. Thus, the application of the nerve hook utilized in the prior MAZE procedures is no longer necessary.
- the distal end of the probe must extend to the base of the tricuspid valve annulus 172 .
- This lesion is difficult to create since the right atrial free-wall in this region lies beneath the atrioventricular groove fat pad (not shown).
- an alternative tricuspid valve clamping probe 180 (FIG. 26) may be employed rather than or in addition to the tricuspid valve annulus probe 173 .
- This probe includes a primary shaft 66 and ablating end 70 which are cooperatively shaped and dimensioned substantially similar to the tricuspid valve annulus probe 173 .
- a clamping device 181 of clamping probe 180 includes a mounting member 179 providing an engagement slot 182 formed for sliding receipt of a pin member 184 coupled to primary shaft 66 .
- This arrangement pivotally couples the clamping device 181 to the primary shaft 66 for selective cooperating movement of a clamping jaw portion 183 of the clamping device 181 and the ablating end 70 between a released position, separating the clamping jaw portion from the ablating end 70 (phantom lines of FIG. 26), and a clamped position, urging the clamping jaw portion against the ablating end 70 (solid lines of FIG. 26).
- the clamping jaw portion 183 is shaped and dimensioned substantially similar to the corresponding ablating end 70 to enable clamping of the heart tissue therebetween when the tricuspid valve clamping probe 180 is moved to the clamped position.
- a handle portion 185 is positioned at the opposite end of the clamping jaw portion 183 for manipulation of the jaw portion between the released and clamped positions in a pliers-type motion.
- the clamping jaw is moved toward the released position to enable the distal end of the ablating end to be negotiated through the first penetration 146 .
- the ablating end is moved into contact with the predetermined portion of the right atrium interior wall all the way from the first penetration 146 to the tricuspid valve annulus 172 .
- the clamping jaw portion is moved to the clamped position, via handle portion 185 , to contact the epicardial surface 168 of the heart wall opposite the tissue ablated by the probe. This arrangement increases the force against the ablating surface 65 to facilitate contact and heat transfer.
- Cryogen is then provided to the boiler chamber to cool the ablating surface 65 thereby forming the tricuspid valve annulus lesion 51 .
- the first purse-string suture 58 is further tightened to prevent blood loss.
- the engagement slot 182 of mounting member 179 is formed to permit release of the pin member 184 therefrom.
- the clamping device 181 can be released from primary shaft 66 of the clamping probe 180 .
- This arrangement is beneficial during operative use providing the surgeon the option to introduce the clamping probe 180 into the thoracic cavity as an assembled unit, or to first introduce the ablation end 70 and primary shaft 66 , and then introduce of the clamping device 181 for assembly within the thoracic cavity.
- a second 4-0 purse-string suture 59 is placed in the right atrial appendage RAA proximate a lateral midpoint thereof in the same manner as above-discussed.
- This portion of the heart is again accessible from the right side of the thoracic cavity through the first access device 68 .
- a second penetration 157 is formed central to the second purse-string suture wherein blood loss from the second penetration is prevented through a second tensioning sleeve 186 .
- the distal end of a right angle probe or a right atrium counter lesion probe 187 (FIGS. 15 and 27)
- Second purse-string suture 59 may then be adjusted through second tensioning sleeve 186 , as necessary to maintain a hemostatic seal between the penetration and the probe.
- the right atrium counter lesion probe 187 includes an elongated shaft 66 having a first elbow portion 166 positioned between a relatively straight first portion 175 and a generally straight second portion 176 , whereby the first elbow portion has an arc length of about 85° to about 95° and a radius of curvature of about 1.9 cm to about 3.2 cm.
- the second portion is preferably about 2.0 cm to about 6.0 cm in length.
- a second elbow portion 177 is positioned between the second portion 176 and a generally straight third portion 178 of the shaft which is about 2.0 cm to about 6.0 cm in length.
- the second elbow portion has an arc length of about 40° to about 70° and a radius of curvature of about 3.2 cm to about 5.7 cm, angling the third portion 178 back toward the longitudinal axis of the first portion 175 of the elongated shaft 66 .
- the ablating end 70 is coupled to the distal end of the third portion 178 of the elongated shaft 66 , and includes an arc length of about 85° to about 95° and a radius of curvature of about 6.0 mm to about 19.0 mm to curve the distal end thereof back toward the longitudinal axis of the first portion 175 of the shaft 66 .
- this equates to an ablating surface length of preferably about 4.0 cm to about 8.0 cm in length.
- FIGS. 14 and 15 best illustrate that the position of this second penetration 157 is higher up than the first penetration, relative the heart, when accessed from the predetermined intercostal penetration 92 .
- the handle (not shown) of the probe 187 is manipulated and oriented from outside the thoracic cavity to position the distal end of the ablating surface 65 in a direction generally toward the first purse-string suture 58 .
- the probe is retracted rearwardly out of the retractor passageway, generally in the direction of arrow 167 in FIG. 14, to urge the ablating surface 65 of the probe into contact with the endocardial surface of the interior wall of the right atrial appendage RAA.
- the perpendicular lesion 53 of the right atrial appendage is transmurally formed.
- the next lesion to be created is the anteromedial counter lesion 55 which is to be formed through the second penetration 157 .
- This lesion is positioned just anterior to the apex of the triangle of Koch and the membranous portion of the interatrial septum.
- the elongated ablating surface 65 is urged further inwardly through the second penetration 157 toward the rear atrial endocardium of the right atrial appendage RAA (FIG. 15).
- the probe 187 is slightly rotated upwardly in the direction of arrows 191 in FIG. 15 to exert a slight force against the rear endocardial surface.
- the next step in the procedure is an atrial septotomy to from an anterior limbus of the fossa ovalis lesion 192 .
- the formation of this lesion will likely be performed without direct or laparoscopic visual assistance since the ablation occurs along internal regions of the interatrial septum wall 193 .
- two side-by-side purse-string sutures 61 and 62 are surgically affixed to an epicardial surface 168 proximate the pulmonary trunk 108 using the same techniques utilized for the first and second purse-string sutures.
- the third purse-string suture 61 is positioned on one side of the septum wall 193 for access to the right atrium chamber, while the fourth purse-string suture 62 is positioned on the opposite side of the septum wall for access to the left atrium chamber.
- FIG. 17 further illustrates that the introduction of thoracoscopic instruments and access to the third and fourth purse-strings are preferably provided through the retractor 68 .
- an incision device (not shown) is introduced into the thoracic cavity to incise the penetrations central to the respective purse-string sutures. Due to the angle of the upper heart tissue surface relative the retractor 68 , the incision device may incorporate an angled end or blade for oblique entry through the heart wall tissue in the direction of arrow 197 to form the third and fourth penetrations 158 , 160 (FIG. 18).
- the incision device may include a blade end which is capable of selective articulation for pivotal movement of the blade end relative the elongated shaft.
- a thoracoscopic grasping instrument facilitates grasping of the epicardium near the pulmonary trunk 108 to counter the insertion force of the angled blade during formation of the respective penetrations 158 , 160 .
- a special atrial septum clamping probe 198 (FIGS. 17 and 28) is provided having opposed right angled jaw portions 200 , 201 formed and dimensioned for insertion through the corresponding third and fourth penetrations 158 , 160 for clamping engagement of the anterior limbus of the fossa ovalis therebetween. As illustrated in FIG.
- the atrial septum clamping probe 198 includes a primary clamping member 202 having a generally straight, elongated clamping shaft 66 with a first elbow portion 166 positioned between the clamping shaft 66 and a generally straight outer jaw portion 200 (ablating end 70 ), whereby the first elbow portion has an arc length of about 85° to about 95° and a radius of curvature of about 3.2 mm to about 6.4 mm.
- the ablating surface extends just beyond elbow portion 166 and is of a length of preferably about 2.0 cm to about 6.0 cm.
- an attachment device 203 is coupled to the clamping shaft 205 which includes an inner jaw portion 201 formed and dimensioned to cooperate with the outer jaw portion 200 (i.e., the elongated ablating surface 65 ) of clamping member 202 for clamping engagement of the interatrial septum wall 193 therebetween (FIG. 17).
- the inner jaw portion and the outer jaw portion move relative to one another between a clamped condition (FIG. 17 and in phantom lines in FIG. 28) and an unclamped condition (FIG. 14A and in solid lines in FIG. 28).
- the inner jaw portion 201 of the attachment device 203 is positioned away from the outer jaw portion 200 to permit initial insertion of the distal end 165 of the outer jaw portion 200 of the clamping probe 198 into the fourth penetration 160 , as will be discussed.
- the attachment device 203 is preferably provided by a generally straight, elongated attachment shaft 206 having a first elbow portion 207 positioned between the attachment shaft 206 and a generally straight inner jaw portion 201 .
- FIG. 28 best illustrates that the first elbow portion of inner jaw portion 201 has an arc length and radius of curvature substantially similar to that of the outer jaw portion 200 . Further, the length of the inner jaw portion is preferably about 2.0 mm to about 6.0 mm.
- the attachment shaft 206 is slidably coupled to the clamping shaft 66 through a slidable coupling device 208 enabling sliding movement of the inner jaw portion 201 between the clamped and unclamped conditions.
- a plurality of coupling devices 208 are provided spaced-apart along the attachment shaft 206 .
- Each coupling device includes a groove 210 (FIG. 29) formed for a sliding, snap-fit receipt of the clamping shaft 66 therein for sliding movement of the attachment device in a direction along the longitudinal axis thereof.
- the coupling devices are preferably composed of TEFLON®, plastic, polyurethane or the like, which is sufficiently resilient and bendable to enable the snap-fit engagement. Further, such materials include sufficient lubricating properties to provide slidable bearing support as the clamping shaft 66 is slidably received in groove 210 to move inner jaw portion 201 between the clamped and unclamped conditions. Moreover, the coupling device configuration may permit rotational motion of the inner jaw portion 201 about the attachment shaft longitudinal axis, when moved in the unclamped condition. This ability further aids manipulation of the clamping probe 198 when introduced through the access device 68 and insertion through the corresponding fourth penetration 160 .
- FIG. 30 best illustrates that alignment device 211 is provided by a set of spaced-apart rail members 212 , 212 ′ each extending from the outer jaw portion 200 to the clamping shaft 66 of the clamping member 202 .
- the rail members 212 , 212 ′ cooperate to define a slot 213 therebetween which is dimensioned for sliding receipt of an elbow portion 207 of the inner jaw portion 201 .
- the elbow portion 207 of the inner jaw portion 201 may include a rectangular cross-section dimensioned for squared receipt in the slot 213 formed between the rail members 212 , 212 ′.
- alignment may be provided by the inclusion of a locking device positioned at the handle of the probe, or by indexing detents included on the clamping shaft.
- the septum clamping probe 198 includes staggered length jaw portions which position the distal end 165 of the outer jaw portion 200 slightly beyond the distal end 215 of the inner jaw portion 201 to facilitate alignment and insertion through the penetrations 158 , 160 .
- the right angled clamping member 202 is initially introduced through access device 68 for positioning of the distal end proximate the fourth purse-string suture 62 .
- the clamping member 202 is manipulated in the direction of arrow 197 for insertion of the outer jaw portion partially into the left atrium chamber.
- the initial insertion depth of the tip is to be by an amount sufficient to retain the outer jaw portion 200 in the fourth penetration, while permitting the shorter length inner jaw portion 201 of the attachment device to move from the unclamped condition toward the clamped condition (FIGS. 18A and 18B).
- the slidable attachment device 203 will either be unattached to the right angle probe or will be prepositioned in the unclamped condition. In the former event, the slidable attachment device 203 will be introduced through the access device 68 and slidably coupled or snap fit to the clamping shaft 66 of the clamping member 202 via coupling devices 208 . As the inner jaw portion 201 is advanced in the direction of arrow 216 toward the clamped condition, the attachment shaft 206 is rotated about its longitudinal axis, if necessary, until the elbow portion 207 is aligned for receipt in the slot 213 formed between the spaced-apart rails members 212 , 212 ′. In this arrangement, the inner jaw portion 201 will be aligned co-planar with the outer jaw portion 200 of the clamping member 202 .
- the length of the inner jaw portion 201 is preferably shorter than the length of the outer jaw portion 200 of clamping member 202 (preferably by about 5 mm). With the distal end 165 of the outer jaw portion 200 partially penetrating the fourth penetration 160 and the distal end 215 of the inner jaw portion 201 aligned with the third penetration 158 (FIG. 18B), the jaw portions are moved in the direction of arrow 197 to position the jaws through the penetrations, on opposite sides of the septum wall 193 , and into the atrial chambers.
- the jaw portions 200 , 201 are inserted to a desired depth whereby the clamping probe can be aligned to pass through the anterior limbus of the fossa ovalis.
- the jaw portions can be moved fully to the clamped position exerting an inwardly directed force (arrows 216 , 216 ′) toward opposed sides of the interatrial septum wall 193 .
- the cryogen is released into the boiler chamber of the outer jaw portion of the clamping member thereby cooling the ablating surface 65 and subjecting the septal wall to cryothermia.
- the length of the outer jaw portion is preferably between about 3 cm to about 5 cm, while the length of the inner jaw portion is generally about 5 mm less than the length of the outer jaw portion. Further, the diameter of the inner and outer jaw portions is preferably between about 2-4 mm. The determination of the diameter and/or length of the particular jaw portions and combinations thereof to be utilized will depend upon the particular applications and heart dimensions.
- the clamping arrangement of this probe enables a substantial clamping force urged between the two opposed jaw portions for more efficient heat conduction.
- This configuration more effectively ablates the relatively thicker septum wall since greater leverage can be attained.
- only the outer jaw portion 200 (i.e., the ablating surface 65 ) of the clamping member 202 needs to be cooled to be effective.
- the attachment device 203 may include the boiler chamber to cool the inner jaw portion as well for ablation of both sides of the septum wall 193 .
- the outer and inner jaw portions 200 , 201 may cooperate to provide a gap 217 at and between the outer elbow portion 166 and the inner elbow portion 207 .
- This gap 217 is formed to accommodate the typically thicker tissue juncture 218 where the septum wall 193 intersects the outer atrial wall 220 .
- the clamping probe 198 is moved to the clamped condition, the gap 217 is formed to receive this tissue juncture 218 so that a more constant compression force may be applied across the septum wall between the opposing jaws. This may be especially problematic when the tissue juncture is significantly thicker than the septum wall which, due to the disparity in thickness, may not enable the distal ends of the respective jaw portions to effectively contact the septum wall for transmural ablation thereof.
- FIG. 31 illustrates that the gap 217 is primarily formed through the offset curvature at the elbow portion 207 of inner jaw portion 201 , it will be understood that the outer jaw portion 200 alone or a combination thereof may be employed to form the gap 217 . Further, in some instances, the clamping probe 198 may be derived from the right angle probe set forth above.
- the right atrial appendage RAA may be excised along the direction of solid line 221 in FIG. 3 and broken line 222 in FIG. 19, to be described below. This excision is optional depending upon the particular circumstance since the risk of a fatal clot or thromboembolism is not as great as compared to left atrial appendage LAA. Should this excision be performed, the right atrial appendage RAA will, preferably, first be sutured closed along broken line 222 using conventional thoracoscopic instruments. This closure must be hemostatic to prevent blood loss when the right atrial appendage is excised. Once a hemostatic seal is attained, the appendage is excised using thoracoscopic scissors or an incision device.
- the right atrial appendage may first be surgically closed along broken line 222 using staples.
- a thoracoscopic stapling device would be inserted into the thoracic cavity through the retractor passageway 67 for access to the appendage.
- the right atrial appendage may be conductively isolated by applying a specially designed cryoprobe clamping device (not shown) formed to be placed across the base of the appendage to engage the exterior surface thereof. This lesion will extend completely around the base along the line 221 , 222 in FIGS. 3 and 19 which corresponds to the right atrial appendage excision in the prior surgical procedures.
- a second access device 223 preferably the retractor 68 , placed between the ribs on the left side of the patient P, usually in the third or fourth intercostal space, and most preferably the third intercostal space as shown in FIG. 11A.
- this percutaneous penetration is positioned so that thoracoscopic instruments introduced through it may be directed toward the left atrium LA of the heart H.
- the intercostal space between the ribs may be through spreading of the adjacent ribs, or portions of the ribs can be easily removed to widen the percutaneous penetration.
- the right lung will be re-inflated for use, while the left lung will be deflated to promote access while surgery is being performed.
- Other lung ventilation techniques may be employed such as high frequency ventilation without departing from the true spirit and nature of the present invention.
- a pericardiotomy is performed to gain access to the left side of the heart H utilizing thoracoscopic instruments introduced through the retractor 68 .
- a fifth 4-0 purse-string suture 63 is then formed in the atrial epicardium of left atrial appendage LAA proximate a lateral midpoint thereof.
- the orifices of the pulmonary veins can be accessed to procure conductive isolation from the remainder of the left atrium LA.
- the pulmonary vein isolation lesion 52 is formed using a two or more step process to completely encircle and electrically isolate the four pulmonary veins.
- a four-step technique is employed initially commencing with the use of a C-shaped, probe 225 .
- the probe includes an elongated shaft 66 and a C-shaped ablating end 70 mounted to the distal end of the shaft 66 .
- the C-shaped ablating end 70 is shaped and dimensioned such that a distal end of the ablating end curves around and terminates in a region proximate the longitudinal axis extending through the shaft.
- the ablating end preferably includes an arc length of about 120° to about 180°, and a radius of the arc between about 6.0 mm to about 25.0 mm. This equates to an ablating surface length of preferably about 3.0 cm to about 6.0 cm.
- probe 225 With the aid of a thoracoscopic grasping instrument (not shown in FIG. 19A), the distal end of probe 225 is inserted through fifth penetration 161 to a position past the semi-circular ablating surface 65 .
- a fifth tensioning sleeve 226 may be cinched tighter in the event to prevent blood loss therefrom.
- the distal end of the all-purpose probe is preferably positioned to contact the pulmonary endocardial surface 228 of the left atrium LA about 3-10 mm superior to the right superior pulmonary vein orifice 230 .
- a bight portion 232 of the ablating surface 65 is positioned about 3-10 mm outside of and partially encircling the right superior and left superior pulmonary vein orifices 230 , 231 .
- the ablating surface 65 of the probe is urged into ablative contact with the desired pulmonary endocardial surface 228 to form about ⁇ fraction (1/3) ⁇ of the pulmonary vein isolation lesion 52 (i.e., the first segment 227 ).
- FIG. 19B best illustrates that the bight portion 232 of the probe is positioned on the other side of pulmonary trunk to contact the pulmonary endocardium about 3-10 mm just outside of and partially encircling the right inferior and left inferior pulmonary vein orifices 235 , 236 .
- the distal end of the probe is positioned to overlap the distal of the first segment 227 by at least about 5 mm.
- the ablating surface 65 thereof is urged into ablative contact with the desired pulmonary endocardium to form the second segment 233 of the pulmonary vein isolation lesion 52 .
- the probe is retracted rearwardly from the fifth penetration 161 and removed from the second retractor 68 .
- An articulating probe (not shown) may also be employed for this procedure which includes an ablating end capable of selected articulation of the ablating surface to vary the curvature thereof.
- the articulation of the end may be manually or automatically controlled through control devices located at the handle portion of the probe. This probe may be particularly suitable for use in the formation of the pulmonary vein isolation lesion due to the anatomical access difficulties.
- a right angle probe is to be inserted through the fifth penetration 161 of the left atrial appendage LAA, in the manner above discussed, to create a third segment 237 of the pulmonary vein isolation lesion 52 .
- the formation of this segment may require a different right angle probe, having a shorter length ablating surface 65 (about 2.0 cm to about 6.0 cm) than that of the first right angle probe 163 utilized in the previous ablative procedures.
- the ablating surface 65 is oriented just outside the left superior pulmonary vein orifice 231 by at least about 5 mm.
- cryothermia is induced for the designated period to transmurally ablate the third segment 237 of the pulmonary vein isolation lesion 52
- the right angle probe ablating surface 65 is properly defrosted to reverse cryoadhesion and enable separation from the tissue.
- the probe is rotated approximately 180° about the longitudinal axis of the probe shaft to position the ablating surface 65 just outside the left inferior pulmonary vein orifice 236 by at least about 5 mm (FIG. 19D).
- the probe is rotated approximately 180° about the longitudinal axis of the probe shaft to position the ablating surface 65 just outside the left inferior pulmonary vein orifice 236 by at least about 5 mm (FIG. 19D).
- Fiberoptic visualization or the like is employed to facilitate proper continuity between the segments and placement of the probe.
- cryothermia is induced for the designated period to ablate the fourth segment of the pulmonary vein isolation lesion 52 .
- the probe is retracted rearwardly from the fifth penetration 161 and removed from the second retractor 68 .
- an alternative two-step endocardial procedure may be performed to isolate the pulmonary veins.
- an S-shaped end probe 240 is provided having a uniquely shaped, opened-looped ablating surface 65 formed to substantially extend around or encircle the pulmonary vein orifices.
- the S-shaped probe 240 includes an elongated shaft 66 having a substantially straight first portion 175 and a C-shaped second portion 176 mounted to the distal end of the first portion and terminating at a position proximate the longitudinal axis of the first portion 175 of shaft 66 .
- a C-shaped ablating end 70 which curves back in the opposite direction such that the two C-shaped sections cooperate to form an S-shaped end.
- This unique shape enables the ablating surface 65 of ablating end 70 to have an arc length of between about 290° to about 310°, with a radius of curvature of about 1.2 cm to about 3.0 cm.
- FIG. 33 illustrates that the C-shaped ablating end 70 is shaped and dimensioned such that a distal end of the ablating end curves around and terminates in a region proximate the longitudinal axis extending through the shaft. Consequently, the ablating end 70 , having a radius of about 12.0 mm to about 25.0 mm, can then extend substantially around the endocardial surface of the pulmonary vein trunk. This is accomplished by providing the C-shaped second portion 176 having a radius of curvature of at least bout 5 mm to about 7 mm which enables the unimpeded flow of cryogen through the delivery tube of the shaft 66 . The elimination or substantial reduction of this C-shaped second portion 176 positioned just before the C-shaped ablating end 70 would create such an acute angle that the flow of cryogen about that angle may be impeded.
- the looped ablating surface 65 is aligned and positioned to substantially encircle the pulmonary vein orifices.
- the probe ablating surface 65 is urged into contact with the pulmonary endocardial surface 228 about 3-10 mm just outside of the pulmonary vein orifices.
- a first segment 241 of this technique is formed (FIG. 20B) which preferably constitutes at least about ⁇ fraction (3/4) ⁇ of the pulmonary vein isolation lesion.
- the loop probe is removed from the fifth penetration and withdrawn through the retractor.
- FIG. 20B illustrates that both the distal end and the elbow portion of the probe ablating surface 65 are aligned to overlap the corresponding ends of the first segment 241 during the formation of a second segment 242 of the pulmonary vein isolation lesion 52 . This ensures continuity between the two connecting segments.
- an epicardial pulmonary vein loop probe 240 substantially similar to the probe employed in the procedure of FIG. 20A, is provided for introduction through the passageway of the retractor.
- This probe instrument includes an open-looped ablating surface 65 defining an opening 245 (FIG. 33) formed for passage of the pulmonary trunk 108 therethrough.
- the probe 240 is situated under the pulmonary veins wherein the pulmonary trunk 108 is urged through the opening 245 in the looped ablating surface.
- cryogenic liquid is introduced into the boiler chamber of the loop probe 240 for cryogenic cooling of the ablating surface 65 .
- the loop probe is separated from the pulmonary trunk and retracted rearwardly out of the retractor 68 .
- this pulmonary epicardial surface isolation may be performed from the right side of the thoracic cavity through the first access device 68 (not shown).
- the open-looped ablating surface 65 of the loop probe 240 is positioned behind the superior vena cava 111 , across the anterior surface of the right pulmonary veins, and underneath the inferior vena cava 103 . Once properly positioned, the epicardial surface 168 of the pulmonary trunk 108 can be ablated.
- This lesion 246 is relatively short extending only about 5-7 mm from the anteromedial portion of the left atrial appendage LAA to the pulmonary vein isolation lesion 52 proximate a central portion between the left superior and inferior pulmonary vein orifices 231 , 236 . Due to the position of this lesion and the flexible nature of the appendage tissue, any one of a number of probes already mentioned, such as the probes illustrated in FIG. 32, the right angle probe (FIG. 24) or the pulmonary vein to mitral valve probe (FIG. 34), can be employed for this task. Typically, the probe device 247 of FIG.
- the ablating end 70 preferably includes the second elbow portion 177 , having an arc length of about 80° to about 100°, and a radius of curvature of about 6.0 mm to about 1.9 mm. This translates to an ablating surface of about 2.0 cm to about 6.0 cm in length.
- One of the above-mentioned probes will be introduced through the second retractor 68 where the distal end of the probe will be inserted through the same fifth penetration 161 central to the fifth purse-string suture 63 .
- the ablating surface 65 is urged into contact with the atrial endocardial surface of the left atrial appendage LAA for localized ablation. Subsequently, the left atrial anteromedial lesion 246 will be formed.
- the last lesion to be performed through the fifth penetration 161 is the posterior vertical left atrial lesion 248 , also known as the coronary sinus lesion (FIG. 23), extending from the pulmonary vein isolation lesion 52 to the annulus 250 of the mitral valve MV.
- This lesion may be critical since improper ablation may enable atrial conduction to continue in either direction beneath the pulmonary veins. This may result in a long macro-reentrant circuit that propagates around the posterior-inferior left atrium, the atrial septum, the anterior-superior left atrium, the lateral wall of the left atrium beneath the excised left atrial appendage, and back to the posterior inferior left atrium.
- a modified probe 251 (FIG. 35) is employed to ablate this critical coronary sinus lesion 248 .
- This probe 251 includes an elongated shaft 66 having a first elbow portion 166 positioned between a generally straight first portion 175 and a generally straight second portion 176 .
- the first elbow portion has an arc length of about 30° to about 50° and a radius of curvature of about 1.2 cm to about 3.0 cm.
- Mounted at the distal end of the second portion 176 is the ablating end which is substantially similar in shape to the ablating end of the probe of FIG. 32.
- the ablating end 70 curves back toward the longitudinal axis of the first portion 175 of the elongated shaft 66 .
- this interior region of the heart H is accessed through the fifth penetration 161 , via the second access device 223 .
- the distal end of the probe 251 is positioned through the penetration in the same manner as previous ablations.
- the unique curvature of this probe 251 enables manipulation of the ablating surface 65 from outside the thoracic cavity into proper alignment.
- FIG. 23 best illustrates that ablating surface 65 is moved into contact with the endocardial surface of the left atrial wall atrium for localized ablation extending from the pulmonary vein isolation lesion 52 to the mitral valve annulus 250 .
- Particular care, as mentioned above, is taken to assure that this lesion extends through the coronary sinus for circumferential electrical isolation thereof.
- the ablating surface 65 of the probe is properly defrosting and the probe 251 is retracted rearwardly from the fifth penetration 161 for removal from the retractor. Subsequently, the fifth penetration 161 is further cinched to prevent blood lose through the fifth purse-string suture 63 .
- an epicardial ablation may be performed on a portion of the outside heart wall opposite the endocardial ablation of the coronary sinus.
- this additional lesion (not shown) must be in the same plane as the coronary sinus lesion 248 (i.e., to the mitral valve annulus lesion) to assure circumferential ablation of the coronary sinus. This is performed by introducing a standard probe through the retractor 68 , and strategically contacting the epicardial surface at the desired location opposite the coronary sinus lesion.
- the left atrial appendage LAA is excised along the direction of broken line 252 in FIG. 23, similar to that of the prior procedures. This excision is considered more imperative than the excision of the right atrial appendage RAA since the threat of thromboembolism or clotting would more likely be fatal, induce strokes or cause other permanent damage. In the preferred form, this excision is performed in the same manner as the excision of the right atrial appendage (i.e., through suturing or stapling. After hemostatic closure is attained, the left atrial appendage LAA is excised using thoracoscopic scissors or an incision device. This left appendagectomy will extend completely around the base of the left atrial appendage along the solid line 252 in FIG. 3 or the broken line 253 in FIG. 23, which corresponds to the left atrial appendage excision in prior procedures.
- the probes may be formed and dimensioned for contact with the epicardial surface 168 of the heart H.
- no purse-string suture may be necessary for elongated transmural ablation.
- a right-angle clamp type probe 255 is provided having an outer clamping portion 256 coupled to and formed to cooperate with a right angle probe or inner clamping portion 257 for transmural ablation of the heart wall through contact with epicardial surface 168 of the heart H.
- an outer jaw portion 258 of outer clamping portion 256 is relatively thin (about 0.5 mm to about 2.0 mm in diameter) and preferably needle shaped to facilitate piercing of the heart wall at puncture 260 .
- a pointed end 261 which enables piercing of the heart wall without requiring an initial incision and subsequent purse-string suture to prevent blood loss through the puncture 260 .
- FIG. 36 illustrates that inner jaw portion 262 includes ablation end 70 having ablation surface 65 which contacts epicardial surface 168 for ablation.
- an alignment device 263 is provided which cooperates between the outer and inner clamping portions 256 , 257 for operating alignment between the outer jaw portion 258 and the inner jaw portion 262 .
- This alignment device may be provided by any conventional alignment mechanism such as those alignment devices employed in the clamping probe 198 .
- the needle-shaped outer jaw portion 258 may incorporate a temperature sensor 265 (FIG. 36) embedded in or positioned on the outer jaw portion to measure the temperature of the endocardial surface. Measurement of the proper surface temperature will better ensure transmural ablation.
- a temperature sensor 265 FIG. 36
- These temperature sensors may be provided by a variety of conventional temperature sensors.
- a cryogen delivery tube 282 is positioned within an outer tube 284 .
- a tip 286 seals an end of the outer tube 284 .
- the delivery tube 282 is coupled to the source of cryogen (not shown) for delivering the cryogen to a boiler chamber 288 .
- the cryogen is exhausted from the boiler chamber 288 through the annular area between the delivery tube 282 and outer tube 284 .
- the delivery tube 282 has an end cap 290 which receives first and second tubes 292 , 294 for delivery of cryogen to the boiler chamber 288 from the delivery tube 282 .
- the first tube 292 has an exhaust port 296 which extends further into the boiler chamber 288 than an exhaust port 298 of the second tube 294 so that the cryogen is distributed throughout the boiler chamber 288 .
- FIG. 38 depicts only the first and second outlet tubes 292 , 294 , any number of tubes may be provided.
- Ablating surface 300 of the outer tube 284 is preferably made of a highly thermally conductive material such as copper.
- the ablating surface 300 preferably has a ribbed inner surface 302 for enhanced thermal conduction between the boiler chamber 288 and the ablating surface 300 .
- the probe 280 may take any of the configurations described herein.
- FIGS. 41 and 42 another probe 306 is shown which has a device for adjusting the delivery rate of cryogen.
- the delivery tube 308 includes an inner tube 310 and an outer tube 312 .
- the inner and outer tubes 310 , 312 have holes 314 , 316 therein through which the cryogen is delivered to boiler chamber 318 .
- the outer tube 312 is slidable relative to the inner tube 310 and can be locked relative to the inner tube 310 at a number of discrete positions where the holes 314 in the inner tube 310 are aligned with the holes 316 in the outer tube 312 .
- the holes 314 in the inner tube 310 are larger than holes 316 in the outer tube 312 so that when the outer tube 312 is in the position of FIG.
- the delivery tube 308 may be used in the manner described above with any of the probe configurations described herein.
- FIGS. 43 and 44 still another probe 318 is shown which includes suction ports 320 for ensuring intimate contact between the ablating surface 322 and the tissue.
- the suction ports 320 are coupled to a longitudinal channel 324 which is coupled to a vacuum source for applying suction.
- a cryogen delivery tube 326 delivers cryogen to boiler chamber 328 in the manner described herein.
- a probe 330 having a malleable shaft 332 is shown.
- a malleable metal rod 334 is coextruded with a polymer 336 to form the shaft 332 .
- a tip 338 having a boiler chamber 340 is attached to the shaft 332 .
- the rod 334 permits the user to shape the shaft 332 as necessary so that the tip 338 can reach the tissue to be ablated.
- the tip 338 has fittings 342 which are received in a cryogen exhaust path 344 and a cryogen delivery path 346 in the shaft 332 .
- the rod 334 is preferably made of stainless steel and the polymer 336 is preferably polyurethane.
- the tip 338 may be made of a suitable thermally conductive material such as copper. Cryogen is delivered through ports 348 in a delivery tube 350 and is expanded in the boiler chamber 340 . The cryogen is then withdrawn through the exhaust path 344 .
- access devices may be placed in the heart walls to enable the passage of the probes through the wells of the access devices.
- the present invention has been primarily directed toward ablation from the endocardial surfaces of the atria, it will be understood that many lesions or portions of the lesions may be created through ablation of the endocardial surfaces of the atria employing the present probes. While the specific embodiments of the invention described herein will refer to a closed-chest surgical procedure and system for the treatment of medically refractory atrial fibrillation, it is understood that the invention will be useful in ablation of other tissue structures, including surgical treatment of Wolfe-Parkinson-White (WPW) Syndrome, ventricular fibrillation, congestive heart failure and other procedures in which interventional devices are introduced into the interior of the heart, coronary arteries, or great vessels.
- WPW Wolfe-Parkinson-White
- the present invention facilitates the performance of such procedures through percutaneous penetrations within intercostal spaces, eliminating the need for a median sternotomy or other form of gross thoracotomy.
- the system and procedure of the present invention could be performed in an open-chest surgical procedure as well.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Surgery (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Otolaryngology (AREA)
- Pathology (AREA)
- Plasma & Fusion (AREA)
- Physics & Mathematics (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
- Pulmonology (AREA)
- Anesthesiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Surgical Instruments (AREA)
- Ultra Sonic Daignosis Equipment (AREA)
Abstract
The invention provides surgical systems and methods for ablating heart tissue within the interior and/or exterior of the heart. A plurality of probes is provided with each probe configured for introduction into the chest for engaging the heart. Each probe includes an elongated shaft having an elongated ablating surface of a predetermined shape. The elongated shaft and the elongated ablating surface of each probe are configured to ablate a portion of the heart. A sealing device affixed to the heart tissue forms a hemostatic seal between the probe and the penetration in the heart to inhibit blood loss therethrough.
Description
- This application is a continuation of co-pending application Ser. No. 08/943,683, which is a continuation-in-part of commonly-assigned, co-pending application Ser. No. 08/735,036 filed Oct. 22, 1996; which is a continuation-in-part of application Ser. No. 08/425,179, filed Apr. 20, 1995; which is a continuation-in-part of U.S. Pat. No. 5,571,215, issued Nov. 5, 1996; which is a continuation-in-part of U.S. Pat. No. 5,452,733, issued Sep. 26, 1995. The complete disclosures of these applications are hereby incorporated by reference.
- It is well documented that atrial fibrillation, either alone or as a consequence of other cardiac disease, continues to persist as the most common cardiac arrhythmia. According to recent estimates, more than one million people in the U.S. suffer from this common arrhythmia, roughly 0.15% to 1.0% of the population. Moreover, the prevalence of this cardiac disease increases with age, affecting nearly 8% to 17% of those over 60 years of age.
- Although atrial fibrillation may occur alone, this arrhythmia often associates with numerous cardiovascular conditions, including congestive heart failure, hypertensive cardiovascular disease, myocardial infarcation, rheumatic heart disease and stroke. Regardless, three separate detrimental sequelae result: (1) a change in the ventricular response, including the onset of an irregular ventricular rhythm and an increase in ventricular rate; (2) detrimental hemodynamic consequences resulting from loss of atroventricular synchrony, decreased ventricular filling time, and possible atrioventricular valve regurgitation; and (3) an increased likelihood of sustaining a thromboembolic event because of loss of effective contraction and atrial stasis of blood in the left atrium.
- Atrial arrythmia may be treated using several methods. Pharmacological treatment of atrial fibrillation, for example, is initially the preferred approach, first to maintain normal sinus rhythm, or secondly to decrease the ventricular response rate. While these medications may reduce the risk of thrombus collecting in the atrial appendages if the atrial fibrillation can be converted to sinus rhythm, this form of treatment is not always effective. Patients with continued atrial fibrillation and only ventricular rate control continue to suffer from irregular heartbeats and from the effects of impaired hemodynamics due to the lack of normal sequential atrioventricular contractions, as well as continue to face a significant risk of thromboembolism.
- Other forms of treatment include chemical cardioversion to normal sinus rhythm, electrical cardioversion, and RF catheter ablation of selected areas determined by mapping. In the more recent past, other surgical procedures have been developed for atrial fibrillation, including left atrial isolation, transvenous catheter or cryosurgical ablation of His bundle, and the Corridor procedure, which have effectively eliminated irregular ventricular rhythm. However, these procedures have for the most part failed to restore normal cardiac hemodynamics, or alleviate the patient's vulnerability to thromboembolism because the atria are allowed to continue to fibrillate. Accordingly, a more effective surgical treatment was required to cure medically refractory atrial fibrillation of the heart.
- On the basis of electrophysiologic mapping of the atria and identification of macroreentrant circuits, a surgical approach was developed which effectively creates an electrical maze in the atrium (i.e., the MAZE procedure) and precludes the ability of the atria to fibrillate. Briefly, in the procedure commonly referred to as the MAZE III procedure, strategic atrial incisions are performed to prevent atrial reentry and allow sinus impulses to activate the entire atrial myocardium, thereby preserving atrial transport function postoperatively. Since atrial fibrillation is characterized by the presence of multiple macroreentrant circuits that are fleeting in nature and can occur anywhere in the atria, it is prudent to interrupt all of the potential pathways for atrial macroreentrant circuits. These circuits, incidentally, have been identified by intraoperative mapping both experimentally and clinically in patients.
- Generally, this procedure includes the excision of both atrial appendages, and the electrical isolation of the pulmonary veins. Further, strategically placed atrial incisions not only interrupt the conduction routes of the most common reentrant circuits, but they also direct the sinus impulse from the sinoatrial node to the atrioventricular node along a specified route. In essence, the entire atrial myocardium, with the exception of the atrial appendages and the pulmonary veins, is electrically activated by providing for multiple blind alleys off the main conduction route between the sinoatrial node to the atrioventricular node. Atrial transport function is thus preserved postoperatively, as generally set forth in the series of articles: Cox, Schuessler, Boineau, Canavan, Cain, Lindsay, Stone, Smith, Corr, Chang, and D'Agostino, Jr.,The Surgical Treatment of Atrial Fibrillation (pts. 1-4), 101
Thorac Cardiovasc Surg., 402-426, 569-592 (1991). - While this MAZE III procedure has proven effective in ablating medically refractory atrial fibrillation and associated detrimental sequelae, this operational procedure is traumatic to the patient since substantial incisions are introduced into the interior chambers of the heart. Moreover, using current techniques, many of these procedures require a gross thoracotomy, usually in the form of a median stemotomy, to gain access into the patient's thoracic cavity. A saw or other cutting instrument is used to cut the sternum longitudinally, allowing two opposing halves of the anterior or ventral portion of the rib cage to be spread apart. A large opening into the thoracic cavity is thus created, through which the surgical team may directly visualize and operate upon the heart for the MAZE III procedure. Such a large opening further enables manipulation of surgical instruments and/or removal of excised heart tissue since the surgeon can position his or her hands within the thoracic cavity in close proximity to the exterior of the heart. The patient is then placed on cardiopulmonary bypass to maintain peripheral circulation of oxygenated blood.
- Not only is the MAZE m procedure itself traumatic to the patient, but the postoperative pain and extensive recovery time due to the conventional thoracotomy substantially increase trauma and further extend hospital stays. Moreover, such invasive, open-chest procedures significantly increase the risk of complications and the pain associated with sternal incisions. While heart surgery produces beneficial results for many patients, numerous others who might benefit from such surgery are unable or unwilling to undergo the trauma and risks of current techniques.
- Accordingly, it is an object of the present invention to provide a surgical procedure and system for closed-chest, closed heart ablation of heart tissue.
- It is another object of the present invention to provide a surgical procedure and system for ablating medically refractory atrial fibrillation.
- Yet another object of the present invention is to provide a surgical procedure and surgical devices which are capable of strategically ablating heart tissue from the interior chambers or external cardiac surfaces thereof without substantially disturbing the structural integrity of the atria.
- Still another object of the present invention is to enable surgeons to ablate medically refractory atrial fibrillation while the heart is still beating.
- In accordance with the foregoing objects of the invention, the present invention provides surgical systems and methods for ablating heart tissue within the interior and/or exterior of the heart. This procedure is particularly suitable for surgeries such as the MAZE III procedure developed to treat medically refractory atrial fibrillation since the need for substantial, elongated, transmural incisions of the heart walls are eliminated. Moreover, this technique is preferably performed without having to open the chest cavity via a median sternotomy or major thoracotomy. The system is configured for being introduced through a small intercostal, percutaneous penetration into a body cavity and engaging the heart wall through purse-string incisions. As a result, the procedure of the present invention reduces potential postoperative complications, recovery time and hospital stays.
- A system for transmurally ablating heart tissue is provided including an ablating probe having an elongated shaft positionable through the chest wall and into a transmural penetration extending through a muscular wall of the heart and into a chamber thereof. The shaft includes an elongated ablating surface for ablating heart tissue. The system of the present invention further includes a sealing device fixable to the heart tissue around the transmural penetration for forming a hemostatic seal around the probe to inhibit blood loss therethrough.
- A preferred method and device for ablating the heart tissue is with a cryosurgical ablation device. Although cryosurgical ablation is a preferred method, a number of other ablation methods could be used instead of cryoablation. Among these tissue ablation means are Radio Frequency (RF), ultrasound, microwave, laser, heat, localized delivery of chemical or biological agents and light-activated agents to name a few.
- More specifically, the system of the present invention enables the formation of a series of strategically positioned and shaped elongated, transmural lesions which cooperate with one another to reconstruct a main electrical conduction route between the sinoatrial node to the atrioventricular node. Atrial transport function is thus preserved postoperatively for the treatment of atrial fibrillation.
- The system includes a plurality of surgical probes each having an elongated shaft. Each shaft includes an elongated ablating surface of a predetermined shape for contact with at least one specific surface of the heart and specifically the interior walls of atria chamber. Such contact with the ablating surface for a sufficient period of time causes transmural ablation of the wall. Collectively, a series of strategically positioned and shaped elongated, transmural lesions are formed which cooperate with one another to treat atrial fibrillation. Each transmural penetration includes a purse-string suture formed in the heart tissue around the respective transmural penetration in a manner forming a hemostatic seal between the respective probe and the respective transmural penetration to inhibit blood loss therethrough.
- When using a cryosurgical probe, the probe includes a shaft having a delivery passageway for delivery of pressurized cryogen therethrough and an exhaust passageway for exhaust of expended cryogen. The pressurized cryogen is expanded in a boiler chamber thereby cooling the elongated ablating surface for cryogenic cooling of the elongated ablating surface. The elongated shaft is configured to pass through the chest wall and through a penetration in the patient's heart for ablative contact with a selected portion of the heart.
- In another aspect of the present invention, a surgical method for ablating heart tissue from the interior and/or exterior walls of the heart is provided including the steps of forming a penetration through a muscular wall of the heart into an interior chamber thereof and positioning an elongated ablating device having an elongated ablating surface through the penetration. The method further includes the steps of forming a hemostatic seal between the device and the heart wall penetration to inhibit blood loss through the penetration and contacting the elongated ablating surface of the ablating device with a first selected portion of an interior and/or exterior surface of the muscular wall for ablation thereof.
- More preferably, a method for ablating medically refractory atrial fibrillation of the heart is provided comprising the steps of forming a penetration through the heart and into a chamber thereof positioning an elongated ablating devices having an elongated ablating surface through the penetration and forming a hemostatic seal between the ablating device and the penetration to inhibit blood loss therethrough. The present invention method further includes the steps of strategically contacting the elongated ablating surface of the ablating device with a portion of the muscular wall for transmural ablation thereof to form at least one elongated transmural lesion and repeating these steps for each remaining lesion. Each transmural lesion is formed through contact with the ablating surface of one of the plurality of ablating device and the strategically positioned elongated transmural lesions cooperate to guide the electrical pulse pathway along a predetermined path for the surgical treatment of atrial fibrillation.
- The entire procedure is preferably performed through a series of only five purse-strings sutures strategically located in the right and left atria, and pulmonary vein portions. Generally, multiple lesions can be formed through a single purse-string either through the use of assorted uniquely shaped ablating devices or through the manipulation of a single ablating device.
- It should be understood that while the invention is described in the context of thoracoscopic surgery on the heart, the systems and methods disclosed herein are equally useful to ablate other types of tissue structures and in other types of surgery such as laparoscopy and pelviscopy.
- The procedure and system of the present invention have other objects of advantages which will be readily apparent from the following description of the preferred embodiments.
- FIG. 1 is an upper left, posterior perspective view of a human heart incorporating the system and procedure for treatment of medically refractory atrial fibrillation constructed in accordance with the principles of the present invention.
- FIG. 2 is a right, antero-lateral perspective view of the human heart incorporating the present invention system and procedure thereof.
- FIGS. 3A and 3B are schematic diagrams of the atria portion of the heart illustrating the pattern of transmural cryolesions to create a predetermined conduction path in the atrium using the system and procedure of the present invention.
- FIG. 4 is a top plan view of a set of cryoprobe devices constructed in accordance with the present invention, and utilized in the system and procedure of the present invention.
- FIG. 5 is a top perspective view of a patient showing use of the system and procedure on the patient.
- FIG. 6 is an enlarged, fragmentary, top plan view, in cross-section, of one of the cryoprobes in the set of cryoprobes of FIG. 4, illustrating the expansion chamber thereof.
- FIGS.6A-6D illustrate use of a slidable insulative tube for insulating portions of the probe.
- FIG. 7 is a front elevation view, in cross-section, of the ablating end of a cryoprobe, taken substantially along the plane of the line7-7 in FIG. 6.
- FIG. 8 is a front elevation view, in cross-section, of an alternative embodiment of the ablating end of FIG. 7.
- FIG. 9 is a transverse cross-sectional view of the system and patient, taken through the patient's thorax generally along the plane of the line9-9 in FIG. 11A, showing the relative positioning of the right and left intercostal percutaneous penetrations.
- FIG. 10 is a front schematic view of a patient's cardiovascular system illustrating the positioning of a cardiopulmonary bypass system for arresting the heart and establishing cardiopulmonary bypass in accordance with the principles of the present invention.
- FIGS.11A-11D is a series of top plan views of the patient undergoing a pericardiotomy as well as the installation of a purse-string suture and a stay suture to assist in suspending the pericardium.
- FIGS.12A-12C is a series of enlarged, fragmentary side elevation views looking into the patient's thoracic cavity at the right atrium through a soft tissue retractor (not shown) in the system of FIG. 5, and illustrating the introduction of cryoprobes constructed in accordance with the present invention through purse-strings for the formation of a posterior longitudinal right atrial cryolesion and a tricuspid valve annulus cryolesion.
- FIG. 13 is an enlarged, fragmentary, transverse cross-sectional view, partially broken away, of the system and patient's heart of FIG. 5, and illustrating the introduction of a tricuspid valve cryoprobe through a purse-string suture in the right atrial freewall to form the elongated, transmural, tricuspid valve annulus cryolesion.
- FIG. 14 is a side elevation view peering at the right atrial appendage through the soft tissue retractor passageway (not shown) in the system of FIG. 5, showing the formation of a perpendicular right atrial cryolesion.
- FIG. 15 is a fragmentary, transverse cross-sectional view of the system and patient's heart, illustrating the formation of a right atrial anteromedial counter cryolesion.
- FIG. 16 is an upper left, posterior perspective view the human heart of FIG. 1, illustrating the location of the purse-string sutures in the right and left atrial walls, to access opposite sides of the atrial septum wall for the introduction of an atrial septum clamping cryoprobe.
- FIG. 17 is a fragmentary, transverse cross-sectional view, partially broken away, of the system and patient's heart, showing the atrial septum clamping cryoprobe engaged with the atrial septum wall for the formation of an anterior limbus of the fossa ovalis cryolesion.
- FIGS. 18A and 18B is a sequence of enlarged, fragmentary, transverse cross-sectional views, partially broken away, of the system and patient's heart, illustrating the technique employed to enable insertion of the distal ends of the atrial septum clamping cryoprobe through the adjacent purse-string sutures.
- FIGS.19A-19D is a series of fragmentary, transverse cross-sectional views, partially broken away, of the system and patient's heart, showing the formation of an endocardial pulmonary vein isolation cryolesion using a four-step process.
- FIGS. 20A and 20B is a sequence of fragmentary, transverse cross-sectional views, partially broken away, of the system and patient's heart, showing the formation of the pulmonary vein isolation cryolesion through an alternative two-step process.
- FIG. 21 is an upper left, posterior perspective view of the human heart illustrating the formation of an additional epicardial pulmonary vein isolation cryolesion.
- FIG. 22 is a fragmentary, transverse cross-sectional view of the system and patient's heart, showing the formation of a left atrial anteromedial cryolesion.
- FIG. 23 is a fragmentary, transverse cross-sectional view of the system and patient's heart, illustrating the formation of a posterior vertical left atrial cryolesion.
- FIG. 24 is a top plan view of the right angle cryoprobe of FIGS. 12A and 12B.
- FIG. 25 is a top plan view of the tricuspid valve annulus cryoprobe of FIG. 13.
- FIG. 26 is a top plan view of an alternative embodiment of the tricuspid valve annulus cryoprobe of FIG. 25.
- FIG. 27 is a top plan view of the right atrium counter lesion cryoprobe of FIG. 15.
- FIG. 28 is a top plan view of the atrial septum clamping cryoprobe of FIGS. 17 and 18.
- FIG. 29 is an enlarged front elevation view, in cross-section, of a coupling device of the septum clamping cryoprobe, taken substantially along the plane of the line29-29 in FIG. 28.
- FIG. 30 is an enlarged rear elevation view, in cross-section, of an aligning device of the septum clamping cryoprobe, taken substantially along the plane of the line30-30 in FIG. 28.
- FIG. 31 is an enlarged, fragmentary, top plan view of an alternative embodiment to the atrial septum clamping cryoprobe of FIG. 28.
- FIG. 32 is a top plan view of an all-purpose cryoprobe of FIGS. 19A and 19B.
- FIG. 33 is a top plan view of the pulmonary vein loop cryoprobe of FIGS. 20 and 21.
- FIG. 34 is a top plan view of the left atrial anteromedical cryoprobe of FIG. 22.
- FIG. 35 is a top plan view of an alternative embodiment of the all-purpose cryoprobe of FIG. 23.
- FIG. 36 is an enlarged, fragmentary, top plan view of an alternative embodiment to the cryoprobes formed for contact of the ablation surface with the epicardial surface of the heart.
- FIG. 37 is an exploded view of a cryogen delivery tube.
- FIG. 38 is a partial cross-sectional view of the probe having the delivery tube of FIG. 37.
- FIG. 39 is an exploded view of the outer tube of the probe of FIG. 38.
- FIG. 40 is an end view of the ablating surface of the probe of FIG. 39.
- FIG. 41 shows a probe having a delivery tube with adjustable holes wherein an outer tube is slidably movable relative to an inner tube.
- FIG. 42 shows the probe of FIG. 41 with the outer tube moved distally relative to the inner tube.
- FIG. 43 shows a probe having vacuum ports for adhering the probe to the tissue to be ablated.
- FIG. 44 is a cross-sectional view of the probe of FIG. 43 along line I-I.
- FIG. 45 shows a probe having a malleable shaft.
- FIG. 46 shows the tip of the probe of FIG. 45.
- FIG. 47 is a cross-sectional view of the probe of FIG. 45 along line II-II.
- Attention is now directed to FIGS.1-3 where a human heart H is illustrated incorporating a series of strategically positioned transmural lesions throughout the right atrium RA and the left atrium LA formed with the heart treatment procedure and system of the present invention. FIG. 1 represents the desired pattern of lesions created on the right atrium RA, including the posterior longitudinal right
atrial lesion 50, the tricuspid valve annulus lesionvalve annulus lesion 51, the pulmonary vein isolation lesionvein isolation lesion 52 and theperpendicular lesion 53; while FIG. 2 represents a right, anterior perspective view of the heart H illustrating right atrium RA including a right atrialanteromedial counter lesion 55. The cumulative pattern of lesions reconstruct a main electrical conduction route between the sinoatrial node to the atrioventricular node to postoperatively preserve atrial transport function. Unlike prior surgical treatments, the system and procedure of the present invention, generally designated 56 in FIGS. 4 and 5, employ a closed-heart technique which eliminates the need for gross multiple elongated incisions of the atria to ablate heart tissue in the manner sufficient to preclude electrical conduction of reentrant pathways in the atria. - In accordance with the heart treatment procedure and system of the present invention, a set of uniquely-shaped, elongated tip ablation probes57 (FIG. 4, to be discussed in detail below) are employed which are formed and dimensioned for insertion through at least one of a plurality of heart wall penetrations, preferably sealed by means of purse-
string sutures elongated ablating surface 65 thereof is maneuvered into contact with the selected endocardial surface of an interior wall of the atria to create an elongated, transmural lesion. As shown in FIGS. 3A and 3B, these individual lesions collectively form a pattern of transmurally ablated heart tissue to surgically treat medically refractory atrial fibrillation. - Briefly, FIG. 4 represents a collection or set of
probes 57 constructed in accordance with the present invention which are employed to preclude electrical conduction of reentrant pathways in the atria using closed-heart surgical techniques. Collectively, as will be apparent, the probes enable the surgical formation of a series of lesions which are illustrated in FIGS. 3A and 3B. Each probe (FIGS. 24-28 and 32-35) includes anelongated shaft 66 formed to extend through an access port orpassageway 67 in a retractor 68 (FIG. 5) which is mounted in a percutaneous intercostal penetration. The terms “percutaneous intercostal penetration” and “intercostal penetration” as used herein refer to a penetration, in the form or a cut, incision, hole, retractor, cannula, trocar sleeve, or the like, through the chest wall between two adjacent ribs wherein the patient's rib cage and sternum remain generally intact. These terms are intended to distinguish a gross thoracotomy, such as a median sternotomy, wherein the sternum and/or one or more ribs are cut or removed from the rib cage. It should be understood that one or more ribs may be retracted to widen the intercostal space between adjacent ribs without departing from the scope of the invention. - Proximate the distal end of each probe is an
elongated ablating end 70 having an ablatingsurface 65 formed to transmurally ablate heart tissue. Access to the selected portions of the atria of the heart H are provided by the specially shapedshafts 66 and ablating ends 70 which are configured to position theelongated ablating surface 65 through the chest wall of patient P and through a strategically positioned penetration in the muscular wall of the patient's heart H for ablative contact with a selected portion of an interior surface of the muscular wall. Subsequent contact of the ablatingsurface 65 with specific selected wall portions of the atria enable selected, localized transmural ablation thereof. - In a preferred embodiment the
probes 57 form the lesions by freezing the heart tissue. Although freezing is a preferred method of ablating tissue, theprobe 57 may use any other method such as RF ablation, ultrasound, microwave, laser, localized delivery of chemical or biological agents, light-activated agents, laser ablation or resistance heating ablation. Regarding the localized delivery of chemical or biological agents, the device may include an injection device capable of injecting the chemical or biological agent onto or into the desired tissue for localized ablation thereof. The source of the chemical or biological agent may be stored in a reservoir contained in the probe or be stored in an external reservoir coupled to the injecting end of the probe. - When the probe freezes tissue during ablation, an opposite end of the probe has a fitting71 formed for releasable coupling to an end of a delivery hose which in turn is coupled to a source (both of which are not shown) of cryogenic media. A threaded portion 72 of the fitting is formed for removable mounting to the delivery hose and further provides communication with the cryogenic media for both delivery to and exhaust from the probe.
- As shown in FIG. 6, each probe includes an
elongated shaft 66 sufficiently dimensioned and shaped to enable manual manipulation of theablating end 70 into contact with the desired heart tissue from outside the thoracic cavity. Theshaft 66 is preferably tubular-shaped and defines acommunication passageway 73 extending therethrough which provides both delivery and exhaust of the cryogen to and from the ablatingend 70.Communication passageway 73 extends fully from the fitting 71 (FIG. 4) to a closed-end boiler chamber 75 where the cryogen exits theablating end 70. Preferably, thetubular shaft 66 includes an outer diameter in the range of about 2.0 mm to about 5.0 mm, and most preferably about 4.0 mm; while the inner diameter is in the range of about 1.5 mm to about 4.5 mm, and most preferably about 3.0 mm. - Concentrically positioned in the
communication passageway 73 of each probe is a delivery tube 76 (FIG. 6) which extends from the fitting 71 to proximate theboiler chamber 75 for communication therebetween enabling delivery and dispersion of the cryogen to the boiler chamber. The proximal end ofdelivery tube 76 is coupled to the cryogen liquid source through a conventional fitting for delivery of the cryogen through adelivery passageway 77. The outer diameter ofdelivery tube 76 is dimensioned such that anannular exhaust passageway 78 is formed between the outer diameter of thedelivery tube 76 and the inner diameter of thetubular shaft 66. Thisexhaust passageway 78 provides a port through which the expended cryogen exiting the boiler chamber can be exhausted. Preferably, thedelivery tube 76 includes an outer diameter in the range of about 1.4 mm to about 3.0 mm, and most preferably about 2.0 mm; while the inner diameter is in the range of about 1.15 mm to about 2.75 mm, and most preferably about 1.50 mm. - The shaft of each
probe 56 is specifically formed and shaped to facilitate performance of one or more of the particular procedures to be described in greater detail below. However, due to the nature of the procedure and the slight anatomical differences between patients, each probe may not always accommodate a particular patient for the designated procedure. Accordingly, it is highly advantageous and desirable to provide anexhaust shaft 66 anddelivery tube 76 combination which is malleable. This material property permits reshaping and bending of the exhaust shaft and delivery tube as a unit to reposition the ablating surface for greater ablation precision. Moreover, the shaft must be capable of bending and reshaping without kinking or collapsing. Such properties are especially imperative for the devices employed in the pulmonary vein isolation lesion formation which are particularly difficult to access. - This malleable material, for example, may be provided by certain stainless steels, NiTi or a shape memory alloy in its superelastic state such as a superelastic alloy. Moreover, the shaft portion, with the exception of the ablating surface, may be composed of a polymer material such as plastic which of course exhibits favorable thermoplastic deformation characteristics. Preferably, however, the exhaust and
delivery shafts delivery tube 76 may also be composed of NiTi or other superelastic alloy. - To prevent or substantially reduce contact between the concentric tubes during operation, due to resonance or the like, the
delivery tube 76 may be isolated and separated from contact with the inner walls of theexhaust shaft 66 by placing spacers around the delivery tube. These spacers may be provided by plastic or other polymer material. Alternatively, the delivery tube may be brazed or welded to one side of the inner wall of theexhaust shaft 66 along the longitudinal length thereof to resist vibrational contact, as illustrated in FIG. 8. - In accordance with the present invention, the lesions formed by this system and procedure are generally elongated in nature. The ablating
end 70 is thus provided by anelongated ablating surface 65 which extends rearwardly from the distal end a distance of at least about seven (7) times to about thirty (30) times the outer diameter of the ablating end, which incidentally is about the same as the outer diameter of theshaft 66. Hence, the length of the ablating surface is at least three (3) cm long, more preferably at least four (4) cm long, and most preferably at least five (5) cm long. Alternatively, the ablatingsurface 65 has a length of between about three (3) cm to about eight (8) cm. - In most applications, uniform cryothermic cooling along the full length of the ablating surface is imperative for effective operation. This task, alone, may be difficult to accomplish due primarily to the relatively small internal dimensions of the probe, as well as the generally curved nature of the boiler chambers in most of the cryoprobes (FIG. 4). FIG. 6 represents a typical cross-sectional view of an
ablating end 70 of one of the probe devices of the present invention in which theablating surface 65 is formed to contact the heart tissue for localized, transmural ablation thereof.Ablating end 70 therefore is preferably provided by a material exhibiting high thermal conductivity properties suitable for efficient heat transfer during cryogenic cooling of the tip. Such materials preferably include silver, gold and oxygen free copper or the like. - The ablating
end 70 is preferably provided by a closed-end, elongated tube having aninterior wall 80 which defines theboiler chamber 75, and is about 1.0 mm to about 1.5 mm thick, and most preferably about 1.25 mm thick. This portion is specifically shaped for use in one or more ablation procedures and is formed for penetration through the muscular walls of the heart. The distal end ofexhaust shaft 66 is preferably inserted through anopening 81 into theboiler chamber 75 such that theexterior surface 82 at the tip of theexhaust shaft 66 seatably abuts against theinterior wall 80 of theablating end 70 for mounting engagement therebetween Preferably, silver solder or the like may be applied to fixably mount the ablating end to the end of the exhaust shaft. Alternatively, the proximal end of ablatingend 70 can be mounted directly to the distal end of exhaust shaft 66 (i.e., in an end-to-end manner) using electron-beam welding techniques. In either mounting technique, a hermetic seal must be formed to eliminate cryogen leakage. - Proximate the distal end of
delivery tube 76 is adelivery portion 83 which extends through theopening 81 and intoboiler chamber 75 of theablating end 70. This closed-end delivery portion includes a plurality of relativelysmall diameter apertures 85 which extend through thedelivery portion 83 intodelivery passageway 77 to communicate the pressurized cryogen between the delivery passageway and theboiler chamber 75. Using the Joule-Thompson effect, the cryogen flows through the delivery passageway in the direction ofarrow 86 and into thedelivery portion 83 where the cryogen expands through the apertures from about 600-900 psi to about 50-200 psi in the boiler chamber. As the cryogen expands, it impinges upon theinterior wall 80 of the ablating end cooling theablating surface 65. Subsequently, the expended cryogen flows in the direction ofarrow 87 passing through theexhaust passageway 78 and out through the delivery hose. - The number of apertures required to uniformly cool the ablating end is primarily dependent upon the length of the
boiler chamber 75, the diameter of the apertures, the type of cryogen employed and the pressure of the cryogen. Generally, for the preferred cryogen of nitrous oxide (N2O), thesedelivery apertures 85 are equally spaced-apart at about 5 mm to about 12 mm intervals, and extend from the proximal end of the boiler chamber to the distal end thereof. The preferred diameters of theapertures 85 range from about 0.004 inch to about 0.010 inch. These diameters may vary of course. - For most probes, three to four apertures or sets of apertures spaced-apart longitudinally along delivery end portion are sufficient. Only one
aperture 85 may be required at each longitudinal spaced location along the delivery portion 83 (FIG. 8). This one aperture may be strategically positioned radially about the delivery portion to direct the stream of cryogen onto the portion of theinterior wall 80 directly beneath or near the predetermined portion of the ablatingsurface 65 which is to contact the heart wall tissue for a particular procedure. Hence, the spaced-apart apertures may be strategically positioned to collectively direct the cryogen onto particular surfaces of the ablating end to assure maximum cooling of those portions. In some instances, however (as shown in FIG. 7), more than oneaperture 85 may be radially positioned about thedelivery portion 83 at any one longitudinal spaced location, proximate a plane extending transversely therethrough, for additional cryogenic cooling of the ablating surface. This may be especially important where the probe is to be employed in more than one procedure. - Due to the elongated and curved nature of the ablating
surface 65, it is difficult to maintain a generally uniform temperature gradient along the desired portions of the ablating surface during cryogenic cooling. This may be due in part to the pressure decrease in thedelivery passageway 77 of thedelivery portion 83 as the cryogen passes therethrough. To compensate for this pressure loss as the cryogen passes through the delivery portion, the diameters of theapertures delivery portion 83 to the distal end thereof. Thus, as the cryogen travels through thedelivery portion 83 of the delivery tube, a more uniform volume of cryogen may be distributed throughout theboiler chamber 75 even though the cryogenic pressure incrementally decreases from the proximal end of thedelivery portion 83. - Moreover, the delivery volume of the cyrogenic cooling also may be controlled by varying the number of apertures at particular portions of the ablating end i.e., increasing or decreasing the number of apertures at a particular location. This directed cooling will have a localized cooling effect, and is exemplified in the
ablating end 70 of FIG. 4. In this embodiment, the increased number of apertures along theinner bight portion 88 ofdelivery portion 83 delivers a more direct and greater volume of cryogen against theinner bight portion 88, as compared to theouter bight portion 90. - An insulative coating or
tubing 89 is preferably included extending circumferentially around portions of thecryoprobe shaft 66 near theablation end 70. This insulative tubing provides an insulatory barrier aroundshaft 66 to prevent inadvertent direct contact between the shaft, which will be cooled by the expended cryogen flowing through theexhaust passageway 75, and any organs or tissue of the percutaneous penetration. The insulative tubing is preferably spaced from theshaft 66 to define an air gap between the inner surface of the tubing and the outer surface of the shaft. - The
insulative tubing 89 preferably extends around theelongated shaft 66 from the base of theablation end 70 to the fitting 71. In some instances, however, the tubing may only need to extend from the base of the ablation end to a midportion of the elongated shaft. Theinsulative tubing 89 is preferably provided by heat shrink polyolefin tubing, silicone, TEFLON@, or the like. - In the preferred form, as shown in FIG. 7, the transverse, cross-sectional dimension of the
ablating end 70 is circular-shaped having a substantially uniform thickness. However, it will be understood that the ablatingsurface 65 may include a generallyflat contact surface 91 formed for increased area contact with the heart tissue without requiring a substantial increase in the diameter of the ablating surface. As best viewed in FIGS. 8A-8C,contact surface 91 may be generally flat or have a much larger radius than that of the ablating end. Moreover, the spaced-apart apertures 85 are preferably oriented and formed to deliver the cryogen into direct impingement with the underside of thecontact surface 91 of ablatingend 70. In this arrangement, thedelivery portion 83 of thedelivery tube 76 may be mounted to one side of theinterior wall 80, as set forth above. - Alternatively, the contact surface can be provided by a blunted edge or the like to create a relatively narrow lesion. Although not illustrated, the transverse cross-sectional dimension of this embodiment would appear teardrop-shaped.
- FIGS.6A-6D illustrate an embodiment of the
probe 57 in which an insulative jacket orsleeve 304 is disposed on the probe so as to be movable relative thereto. Thesleeve 304 has a window or cut-outportion 305 which exposes a selected area of theprobe 57. FIG. 6A shows thesleeve 304 located around the probe shaft, while FIG. 6B shows the sleeve after it has been slid over part of theprobe ablating surface 65. FIG. 6C shows thesleeve 304 after it has been slid completely over the ablatingsurface 65 to a position where thewindow 305 exposes one area of thesurface 65 for ablating tissue. FIG. 6D shows thesleeve 304 rotated to a different position where thewindow 305 exposes a different area of thesurface 65 for ablating tissue. Thesleeve 304 may be slidable and rotatable relative to the probe as show in FIGS. 6A-6D. Alternatively, thesleeve 304 may be fixed axially with respect to theprobe 57 but rotatable relative thereto so that the window is able to expose different areas of the ablating surface. Further still, thesleeve 304 may be fixed on theprobe 57 such that only a selected area ofablation surface 65 is exposed throughwindow 305. Thesleeve 304 may be formed of any suitable material, for example, a flexible polymer having low thermal conductivity. - The preferred cryogen employed in the devices of the present invention is nitrous oxide (N2O) which is normally stored in a compressed gas cylinder (not shown). Other cryogenic fluids may be employed which include liquid nitrogen or liquified air stored in a Dewar vessel (not shown), freon 13, freon 14, freon 22, and normally gaseous hydrocarbons.
- To cool the ablating end of the cryoprobe, cryogen is selectively delivered through the
delivery passageway 77 ofdelivery tube 76 into the delivery conduit thereof. As the cryogen flows throughdelivery apertures 85, the gas expands into theboiler chamber 75, cooling the ablating surface using the well known Joule-Thompson effect. Theelongated ablating surface 65 is then immediately cooled to a temperature of preferably between about −50° C. to about −80° C., when nitrous oxide is employed. Direct conductive contact of the cooled, elongated ablatingsurface 65 with the selected heart tissue causes cryogenic ablation thereof. Subsequently, a localized, elongated, transmural lesion is formed at a controlled location which sufficiently prevents or is resistant to electrical conduction therethrough. - To assure preclusion of electrical conduction of reentrant pathways in the atria, the lesions must be transmural in nature. Hence, the minimum length of time for conductive contact of the ablating surface with the selected heart tissue necessary to cause localized, transmural ablation thereof is to a large degree a function of the thickness of the heart wall tissue, the heat transfer loss due do the convective and conductive properties of the blood in fluid contact with the ablating surface, as well as the type of cryogen employed and the rate of flow thereof. In most instances, when employing nitrous oxide as the cryogen, tissue contact is preferably in the range of about 2-4 minutes.
- As mentioned, while the closed-heart surgical system and procedure of the present invention may be performed through open-chest surgery, the preferred technique is conducted through closed-chest methods. FIGS. 5 and 9 illustrate
system 56 for closed-chest, closed-heart surgery positioned in a patient P on an operating table T. The patient is prepared for cardiac surgery in the conventional manner, and general anesthesia is induced. To surgically access the right atrium, the patient is positioned on the patient's left side so that the right lateral side of the chest is disposed upward. Preferably, a wedge or block W having a top surface angled at approximately 20° to 45° is positioned under the right side of the patient's body so that the right side of the patient's body is somewhat higher than the left side. It will be understood, however, that a similar wedge or block W is positioned under the left side of patient P (not shown) when performing the surgical procedure on the left atrium In either position, the patient's right arm A or left arm (not shown) is allowed to rotate downward to rest on table T, exposing either the right lateral side or the left lateral side of the patient's chest. - Initially one small incision 2-3 cm in length is made between the ribs on the right side of the patient P, usually in the third, fourth, or fifth intercostal spaces, and most preferably the fourth as shown in FIG. 11A. When additional maneuvering space is necessary, the intercostal space between the ribs may be widened by spreading of the adjacent ribs. A thoracoscopic access device68 (e.g. a retractor, trocar sleeve or cannulae), providing an
access port 67, is then positioned in the incision to retract away adjacent tissue and protect it from trauma as instruments are introduced into the chest cavity. Thisaccess device 68 has an outer diameter preferably less than 14 mm and an axial passage of a length less than about 12 mm. It will be understood to those of ordinary skill in the art that additional thoracoscopic trocars or the like may be positioned within intercostal spaces in the right lateral chest inferior and superior to theretractor 68, as well as in the right anterior (or ventral) portion of the chest if necessary. In other instances, instruments may be introduced directly through small, percutaneous intercostal incisions in the chest. - Referring again to FIGS. 5 and 9, the
retractor 68, such as that described in detail in commonly assigned U.S. patent application Ser. No. 08/610,619 filed Mar. 4, 1996, surgical access to the body cavity of patient P through the first intercostalpercutaneous penetration 92 in thetissue 93. Briefly,retractor 68 includes an anchoringframe 95 having apassageway 67 therethrough which defines a longitudinal retractor axis. The anchoringframe 95 is positionable through the intercostalpercutaneous penetration 92 into the body cavity. Aflexible tensioning member 96 is attached to anchoringframe 95 and extendible from the anchoring frame out of the body throughintercostal penetration 92 to deform into a non-circular shape when introduced between two ribs. The tensioningmember 96 is selectively tensionable to spread the tissue radially outward from the longitudinal axis. Hence, it is the tension imposed on theflexible tensioning member 96 which effects retraction of the tissue, rather than relying on the structural integrity of a tubular structure such as a trocar sheath. - Once the
retractor 68 has been positioned and anchored in the patient's chest, visualization within the thoracic cavity may be accomplished in any of several ways. An endoscope 97 (FIG. 5) of conventional construction is positioned through a percutaneous intercostal penetration into the patient's chest, usually through the port of thesoft tissue retractor 68. Avideo camera 98 is mounted to the proximal end ofendoscope 97, and is connected to avideo monitor 100 for viewing the interior of the thoracic cavity.Endoscope 97 is manipulated so as to provide a view of the right side of the heart, and particularly, a right side view of the right atrium. Usually, an endoscope of the type having an articulated distal end such as the Distalcam 360, available from Welch-Allyn of Skameateles Falls, N.Y., or a endoscope having a distal end disposed at an angle between 30i and 90i will be used, which is commercially available from, for example, Olympus Corp., Medical Instruments Division, Lake Success, N.Y. A light source (not shown) is also provided onendoscope 97 to illuminate the thoracic cavity. - Further, the surgeon may simply view the chest cavity directly through the
access port 67 of theretractor 68. Moreover, during the closed heart procedure of the present invention, it may be desirable to visualize the interior of the heart chambers. In these instances a transesophageal echocardiography may be used, wherein an ultrasonic probe is placed in the patient's esophagus or stomach to ultrasonically image the interior of the heart. A thoracoscopic ultrasonic probe may also be placed throughaccess device 68 into the chest cavity and adjacent the exterior of the heart for ultrasonically imaging the interior of the heart. - An endoscope may also be employed having an optically transparent bulb such as an inflatable balloon or transparent plastic lens over its distal end which is then introduced into the heart. As disclosed in commonly assigned, co-pending U.S. patent application Ser. No. 08/425,179, filed Apr. 20, 1995, the balloon may be inflated with a transparent inflation fluid such as saline to displace blood away from distal end and may be positioned against a site such a lesion, allowing the location, shape, and size of cryolesion to be visualized.
- As a further visualization alternative, an endoscope may be utilized which employs a specialized light filter, so that only those wavelengths of light not absorbed by blood are transmitted into the heart. The endoscope utilizes a CCD chip designed to receive and react to such light wavelengths and transmit the image received to a video monitor. In this way, the endoscope can be positioned in the heart through
access port 67 and used to see through blood to observe a region of the heart. A visualization system based on such principles is described in U.S. Pat. No. 4,786,155, which is incorporated herein by reference. - Finally, the heart treatment procedure and system of the present invention may be performed while the heart remains beating. Hence, the trauma and risks associated with cardiopulmonary bypass (CPB) and cardioplegic arrest can be avoided. In other instances, however, arresting the heart may be advantageous. Should it be desirable to place the patient on cardiopulmonary bypass, the patient's right lung is collapsed and the patient's heart is arrested. Suitable techniques for arresting cardiac function and establishing CPB without a thoracotomy are described in commonly-assigned, co-pending U.S. patent application Ser. No. 08/282,192, filed Jul. 28, 1994 and U.S. patent application Ser. No. 08/372,741, filed Jan. 17, 1995, all of which are incorporated herein by reference. Although it is preferred to use the endovascular systems described above, any system for arresting a patient's heart and placing the patient on CPB may be employed.
- As illustrated in FIG. 10, CPB is established by introducing a
venous cannula 101 into afemoral vein 102 in patient P to withdraw deoxygenated blood therefrom.Venous cannula 101 is connected to acardiopulmonary bypass system 104 which receives the withdrawn blood, oxygenates the blood, and returns the oxygenated blood to anarterial return cannula 105 positioned in afemoral artery 106. - A
pulmonary venting catheter 107 may also be utilized to withdraw blood from thepulmonary trunk 108.Pulmonary venting catheter 107 may be introduced from the neck through the interiorjugular vein 110 andsuperior vena cava 111, or from the groin throughfemoral vein 102 andinferior vena cava 103. An alternative method of venting blood frompulmonary trunk 108 is described in U.S. Pat. No. 4,889,137, which is incorporated herein by reference. In the technique described therein, an endovascular device is positioned from the interior jugular vein in the neck through the right atrium, right ventricle, and pulmonary valve into the pulmonary artery so as to hold open the tricuspid and pulmonary valves. - For purposes of arresting cardiac function, an
aortic occlusion catheter 113 is positioned in afemoral artery 106 by a percutaneous technique such as the Seldinger technique, or through a surgical cut-down. Theaortic occlusion catheter 113 is advanced, usually over a guidewire (not shown), until anocclusion balloon 115 at its distal end is disposed in the ascendingaorta 116 between the coronary ostia and the brachiocephalic artery. Blood may be vented from ascendingaorta 116 through aport 120 at the distal end of theaortic occlusion catheter 113 in communication with an inner lumen inaortic occlusion catheter 113, through which blood may flow to the proximal end of the catheter. The blood may then be directed to a blood filter/recovery system 121 to remove emboli, and then returned to the patient's arterial system viaCPB system 104. - When it is desired to arrest cardiac function,
occlusion balloon 115 is inflated until it completely occludes ascendingaorta 116, blocking blood flow therethrough. A cardioplegic fluid such as potassium chloride (KCl) is preferably mixed with oxygenated blood from the CPB system and then delivered to the myocardium in one or both of two ways. Cardioplegic fluid may be delivered in an anterograde manner, retrograde manner, or a combination thereof. In the anterograde delivery, the cardioplegic fluid is delivered from acardioplegia pump 122 through an inner lumen inaortic occlusion catheter 113 and theport 120 distal toocclusion balloon 115 into the ascending aorta upstream ofocclusion balloon 115. In the retrograde delivery, the cardioplegic fluid may be delivered through aretroperfusion catheter 123 positioned in the coronary sinus from a peripheral vein such as an internal jugular vein in the neck. - With cardiopulmonary bypass established, cardiac function arrested, and the right lung collapsed, the patient is prepared for surgical intervention within the heart H. At this point in the procedure, whether cardiac function is arrested and the patient is placed on CPB, or the patient's heart remains beating, the heart treatment procedure and system of the present invention remain substantially similar. The primary difference is that when the procedure of the present invention is performed on an arrested heart, the blood pressure in the internal chambers of the heart is significantly less. Hence, it is not necessary to form a hemostatic seal between the device and the heart wall penetration to inhibit blood loss through the penetration thereby reducing or eliminating the need for purse-string sutures around such penetrations, as will be described below.
- In the preferred embodiment, however, the procedure is conducted while the heart is still beating. Accordingly, it is necessary to form a hemostatic seal between the ablation device and the penetration. Preferably, purse-
string sutures - As best viewed shown in FIG. 11A, in order to gain access to the right atrium of the heart, a pericardiotomy is performed using thoracoscopic instruments introduced through
retractor access port 67. Instruments suitable for use in this procedure, including thoracoscopic angledscissors 130 and thoracoscopic graspingforceps 131, are described in commonly assigned U.S. Pat. No. 5,501,698, issued Mar. 26, 1996, which is incorporated herein by reference. - After incising a T-shaped opening in the pericardium132 (about 5.0 cm in length across and about 4.0 cm in length down, FIG. 11A), the exterior of the heart H is sufficiently exposed to allow the closed-chest, closed-heart procedure to be performed. To further aid in visualization and access to the heart H, the cut
pericardial tissue 133 is retracted away from thepericardial opening 135 with stay sutures 136 (FIG. 11C) extending out of the chest cavity. This technique allows the surgeon to raise and lower the cut pericardial wall in a manner which reshapes thepericardial opening 135 and retracting the heart H slightly, if necessary, to provide maximum access for a specific procedure. - To install
stay suture 136, acurved suture needle 137 attached to one end of asuture thread 138 is introduced into the chest cavity throughpassageway 67 with of a thoracoscopic needle driver 140 (FIG. 11B). Once thesuture needle 137 andthread 138 have been driven through the cut pericardial tissue, thesuture thread 138 is snared by asuture snare device 141. This is accomplished by positioning ahooked end 142 ofsuture snare device 141 through at least one additionalpercutaneous intercostal penetration 143 positioned about the chest to enable penetration into the thoracic cavity. In the preferred arrangement, a trocar needle (not shown) is employed which not only forms the penetration, but also provides access into the thoracic cavity without snaring tissue during removal of the snare device. - Accordingly, both sides of the
suture thread 138 are snared and pulled through the chest wall for manipulation of the stay suture from outside of the body cavity. The ends of thestay suture 136 are coupled to a surgical clamp (not shown) for angled manipulation and tension adjusting. While only two stay sutures are illustrated, it will be appreciated that more stay sutures may be employed as needed to further manipulate the pericardial opening. - Turning now to FIG. 11C, a first 4-0 purse-
string suture 58, for example, is placed in the heart wall proximate the site at which it is desired to initiate the first heart wall penetration 146 (FIG. 11D). Again, this is accomplished by using a thoracoscopic needle driver to drive the suture needle through the heart wall to form a running stitch in a circular pattern approximately 1.0-3.0 mm in diameter. A double-armed suture may also be used, wherein the suture thread 145 (about 3 mm to about 10 mm in diameter) has needles (not shown) at both ends, allowing each needle to be used to form one semi-circular portion of the purse-string.Suture thread 138 is long enough to allow both ends of the suture to be drawn outside of the chest cavity once purse-string suture 58 has been placed. The suture needle is then cut fromthread 145 using thoracoscopic scissors. - To tension the purse-
string suture 58, thesuture threads 145 are pulled upon gathering the stitched circular pattern of tissue together before commencement of the formation of a penetration through the heart wall within the purse-string suture. One or a pair ofthoracoscopic cinching instruments 147, such as a Rumel tourniquet, may be employed to grasp a loop of purse-string suture 58. As best viewed in FIG. 11D, cinchinginstrument 147 comprises ashaft 148 with aslidable hook 150 at its distal end thereof for this purpose.Hook 150 may be retracted proximally to frictionally retainsuture thread 145 against the distal end ofshaft 148. By retracting or withdrawing the cinchinginstrument 147, the purse-string suture 58 is cinched tightly, thereby gathering heart wall tissue together to form a hemostatic seal. - The cinching instrument may be clamped in position to maintain tension on
suture thread 145. Preferably, however, a slidable tensioning sleeve 151 (FIG. 11D), commonly referred to as a snugger, may be provided in which the suture threads are positioned through a bore extending therethrough. The snugger is then slid along the suture thread until it abuts against theepicardial surface 152 of the heart wall. The cinching instrument is then pulled proximally relative to tensioningsleeve 151 to obtain the desired degree of tension onsuture thread 145. Tensioningsleeve 151 is configured to frictionally couple to suturethread 145 to maintain tension on the suture. - An
incision device 153 is introduced throughaccess device 68 into the chest cavity for piercing the heart H. Ablade 155 positioned on the distal end of a manipulatingshaft 156 is advanced to pierce the heart wall within the bounds of purse-string suture 58. Theblade 155 is preferably about 5.0 mm in length and about 3.0 mm wide terminating at the tip thereof. FIG. 11D illustrates that as theincision device 153 is manually moved further into contact with theepicardial surface 152 of the heart wall,blade 155 will be caused to pierce therethrough to form a penetration of about 1.0-2.0 mm across. - In the preferred form, the
blade 155 is rigidly mounted toshaft 156 for direct one-to-one manipulation of the blade. Alternatively, however, the incision device may employ a spring loaded mechanism or the like which advances the blade forwardly from a retracted position, retracted in a protective sleeve of the shaft, to an extended position, extending the blade outside of the sleeve and into piercing contact with the tissue. In this embodiment, a button or the like may be provided near the proximal end of the shaft for operation of the blade between the retracted and extended positions. - To facilitate formation of the penetration by the incision device, a thoracoscopic grasping instrument (not shown) may be employed to grasp the heart wall near purse-
string suture 58 to counter the insertion force ofblade 155 andincision device 153. Asblade 155 penetrates the heart wall,incision device 153 is advanced to extend transmurally into the heart through thepenetration 146 formed in heart wall. - As above-indicated in FIGS. 3A and 3B, the entire procedure is preferably performed through a series of only five purse-strings sutures58, 60, 61, 62 and 63, and the corresponding
cardiac penetrations penetrations penetration 161 is positioned in the left atrium LA; and twopenetrations pulmonary vein trunk 108. Such small incisions are significantly less traumatic on the heart tissue muscle than the elongated transmural incisions of the prior MAZE techniques. - Referring now to FIGS.3A, 12A-12C and 13, the system and procedure of the present invention will be described in detail. Preferably, the first series of lesions is formed on the right atrium RA to form a posterior longitudinal right
atrial lesion 50 and a tricuspidvalve annulus lesion 51. It will be appreciated, however, that the transmural lesions can be formed in any order without departing from the true spirit and nature of the present invention. - By strategically placing the first
heart wall penetration 146 of first purse-string suture 58 at the base of the right atrial appendage RAA where the anticipated intersection between the longitudinal rightatrial lesion 50 and the tricuspidvalve annulus lesion 51 are to occur (FIG. 12C), these two lesions can be formed through a series of three independent ablations. As best viewed in FIG. 12A, the upper section segment 162 (half of the longitudinal right atrial lesion 50) is formed using a right angle probe 163 (FIG. 24) having afirst elbow portion 166 positioned between the generally straight elongatedshaft 66 and the generally straight ablating end. The first elbow portion has an arc length of about 85° to about 95° and a radius of curvature of about 3.2 mm to about 6.4 mm. The ablatingend 70 is preferably about 2.0 mm to about 4.0 mm in diameter, and about 2.0 cm to about 6.0 cm in length. In this configuration, the ablatingsurface 65 extends, circumferentially, from adistal end 165 thereof to just past anelbow portion 166 of theright angle probe 163. - Initially, the
probe ablating end 70 and theshaft 66 ofprobe 163 is introduced into the thoracic cavity through theretractor 68 by manipulating a handle (not shown) releasably coupled to fitting 71. To facilitate location of the first penetration with the probe, thedistal end 165 is guided along theshaft 156 of incision device 153 (FIG. 11D) until positioned proximate thefirst penetration 146. Subsequently, theblade 155 of incision device is withdrawn from the first penetration whereby the distal end of the probe is immediately inserted through the first penetration. Not only does this technique facilitate insertion of the probe but also minimizes loss of blood through the penetration. - Once the
distal end 165 of theright angle probe 163 has been inserted and negotiated through the first penetration, the first purse-string suture may require adjustment to ensure the formation of a proper hemostatic seal between the penetration and the shaft of the probe. If the loss of blood should occur, the purse-string suture can be easily tightened through either a Rumel tourniquet or tensioningsleeve 151. - FIG. 12A best illustrates that the
right angle probe 163 is preferably inserted through thepenetration 146 until anelbow portion 166 thereof just passes through the penetration. Although the angular manipulation of the end of the right angle probe is limited due to the access provided by the retractor, the insertion should be easily accommodated since the heart wall tissue of the right atrium is substantially resilient and flexible. Again, a thoracoscopic grasping instrument (not shown) may be employed to grasp the heart wall near the first purse-string suture 58 to counter the insertion force ofright angle probe 163 through thefirst penetration 146. Once the ablating end is inserted to the desired depth and through the assistance of either direct viewing or laparoscopic viewing, the elongated ablatingend 70 is oriented to position a longitudinal axis thereof generally parallel to the right atrioventricular groove. Thisupper section segment 162 of the longitudinal rightatrial lesion 50 extends generally from thefirst penetration 146 to the orifice of thesuperior vena cava 111. By retracting the probe rearwardly out of the passageway of theretractor 68 generally in the direction ofarrow 167, the ablating surface will be caused to sufficiently contact the right atrial endocardium. - As mentioned above, the probe may use any method to ablate the heart tissue. When using a cryogenic ablating system, the cryogen stored in a Dewar vessel or pressurized cylinder is selectively released where it passes into the
boiler chamber 75 of thedevice 163, thereby cooling the probe ablating surface for localized ablation of heart tissue. As previously stated, to warrant proper transmural ablation of the interior wall of the right atrium, continuous contact of the ablating surface therewith should occur for about 2-4 minutes. Visually, however, transmural cryosurgical ablation of the tissue is generally represented by a localized lightening or discoloration of theepicardial surface 168 of the ablated heart tissue which can be directly viewed through theaccess port 67 ofaccess device 68. This method of determining cryoablation of the tissue can be used in combination with the timed probe contact therewith. As a result, theupper section segment 162 of the longitudinal rightatrial lesion 50 will be formed. - Once the desired elongated portion of heart tissue has been ablated, caution must be observed before the ablating
surface 65 probe can be separated from the contacted endocardial surface of the heart tissue. Due to the extremely low temperatures of the ablating surface (i.e., about −50° to about −80°) and the moistness of the heart tissue, cryoadhesion can occur. Accordingly, the probe tip must be properly thawed or defrosted to enable safe separation after the tissue has been properly ablated. - For example, after sufficient transmural cryoablation of the heart tissue, thawing is commenced by halting the flow of cryogen through the probe and maintaining continuous contact between the probe ablating surface and the cryoablated tissue. After about 10-20 seconds, and preferably about 15 seconds, the conductive and convective heat transfer or heat sink effect from the surrounding tissue and blood is sufficient to reverse the cryoadhesion. Of course, it will be appreciated that such heat transfer is more efficient when the procedure is performed on a beating heart as opposed to an arrested heart. Alternatively, the system may also be provided with a defrost mode which serves to warm the tissue to room temperature. This may be accomplished by raising the pressure of the cryogen adjacent the ablating surface such that its temperature increases, for example, by restricting the exhaust gas flow.
- Furthermore, to facilitate thawing of the exterior surface of the ablated tissue, a room temperature or slightly heated liquid may be wetted or impinged upon the exterior surface of the ablated area. In the preferred embodiment, such liquid may include saline or other non-toxic liquid introduced into the thoracic cavity through the
retractor passageway 67. - Generally, multiple lesions can be formed through a single purse-string suture either through the use of assorted uniquely shaped ablating devices or through the manipulation of a single ablating device. Accordingly, while maintaining the hemostatic seal between the probe shaft and the penetration, the respective ablating device can be manipulated through the respective penetration to strategically contact the corresponding elongated ablating surface with another selected portion of the interior surface of the muscular wall for transmural ablation thereof. For instance, without removing the right angle cryoprobe from the first penetration, the ablating
surface 65 is rotated approximately 180° about the longitudinal axis to re-position the distal end generally in a direction toward the orifice of theinferior vena cava 103. As shown in FIG. 12B, such positioning enables the formation of the remaininglower section segment 170 of the longitudinal rightatrial lesion 50. However, since thelower section segment 170 of the lesion is shorter in length than that of the upper section segment, the length of the elongated ablating surface contacting the interior wall of right atrium must be adjusted accordingly. This length adjustment is accomplished by partially withdrawing theprobe ablating surface 65 from thefirst penetration 146 by the appropriate length to ablate thelower section segment 170. Due to the substantial flexibility and resiliency of the heart tissue, such maneuverability of the probe and manipulation of the tissue is permissible. - Similar to the formation of the
upper section segment 162 of the longitudinal rightatrial lesion 50, theright angle probe 163 is retracted rearwardly, generally in the direction ofarrow 167, causing the ablatingsurface 65 of the probe to sufficiently contact the endocardium of the right atrium. After the cryogen has continuously cooled theelongated ablating surface 65 of the probe for about 2-4 minutes, the remaining lower section segment of the longitudinal rightatrial lesion 50 will be formed. Thereafter, the probe is defrosted to reverse the effects of cryoadhesion. It will be understood that while it is beneficial to employ the same right angle probe to perform both the upper and lower section segments of the longitudinal right atrial lesion, a second right angle probe having an ablating surface shorter in length than that of the first right angle probe could easily be employed. - Utilizing the same first penetration, the tricuspid
valve annulus lesion 51 can be formed employing one of at least two probes. Preferably, theright angle probe 163 may again be used by rotating theelongated ablating surface 65 about the probe shaft longitudinal axis to reposition the distal end trans-pericardially, generally in a direction across the lower atrial free wall and toward the tricuspid valve 171 (FIGS. 12C and 13). The distal end of theprobe ablating surface 65, however, must extend all the way to thetricuspid valve annulus 172. Hence, in some instances, due to the limited maneuvering space provided through the retractor passageway, the formation of the tricuspidvalve annulus lesion 51 with the right angle probe may be difficult to perform. - In these instances, a special shaped tricuspid valve annulus probe173 (FIGS. 13 and 25) is employed which is formed and dimensioned to enable contact of the
probe ablating surface 65 with appropriate portion of the right atrium interior wall all the way from thefirst penetration 146 to thetricuspid valve annulus 172 to form the tricuspidvalve annulus lesion 51. The ablatingend 70 and theshaft 66 of this probe cooperate to form one of thestraighter probes 57 of the set shown in FIG. 4. - FIG. 25 best illustrates the tricuspid
valve annulus probe 173 which includes anelongated shaft 66 having afirst elbow portion 166 positioned between a generally straightfirst portion 175 and a generally straightsecond portion 176 having a length of about 2.0 cm to about 6.0 cm. The first elbow portion has an arc length of about 20° to about 40° and a radius of curvature of about 13.0 cm to about 18.0 cm. Further, asecond elbow portion 177 is positioned between thesecond portion 176 and athird portion 178 of the shaft, angling the third portion back toward the longitudinal axis of thefirst portion 175 of theelongated shaft 66. Thethird portion 178 includes a length of about 2.0 cm to about 6.0 cm, while the second elbow portion has an arc length of about 5° to about 20° and a radius of curvature of about 15.0 cm to about 20.0 cm. The ablatingend 70 is relatively straight and is coupled to the distal end of thethird portion 178 of theelongated shaft 66 in a manner angling the ablating end back away from the longitudinal axis and having an arc length of about 5° to about 20° and a radius of curvature of about 13.0 cm to about 18.0 cm. The ablatingend 70 is formed to extend from the first penetration and to therim 172 of thetricuspid valve 171 from outside of the body cavity. For this probe, the ablatingsurface 65 is preferably about 2.0 cm to about 6.0 cm in length. It will be understood that while the illustrations and descriptions of the probes are generally two dimensional, the configurations of the shaft and ablating end combinations could be three dimensional in nature. - Using the insertion technique employed by the
right angle probe 163 during the formation of the longitudinal rightatrial lesion 50, upon withdrawal of the right angle probe from thefirst penetration 146, the distal end of the tricuspidvalve annulus probe 173 is immediately inserted therethrough to facilitate alignment and minimize the loss of blood. - Regardless of what instrument is employed, once the
probe ablating surface 65 is strategically oriented and retracted to contact the endocardial surface, the cryogen is selectively released into the boiler chamber to subject the desired tissue to localized cryothermia. Due to the nature of the transmural ablation near the tricuspid valve annulus, the need for dividing all atrial myocardial fibers traversing the ablated portion is effectively eliminated. Thus, the application of the nerve hook utilized in the prior MAZE procedures is no longer necessary. - As illustrated in FIG. 13, the distal end of the probe must extend to the base of the
tricuspid valve annulus 172. This lesion is difficult to create since the right atrial free-wall in this region lies beneath the atrioventricular groove fat pad (not shown). To facilitate orientation of the ablating end of the probe relative the valve annulus and to better assure the formation of a lesion which is transmural in nature, an alternative tricuspid valve clamping probe 180 (FIG. 26) may be employed rather than or in addition to the tricuspidvalve annulus probe 173. - This probe includes a
primary shaft 66 and ablatingend 70 which are cooperatively shaped and dimensioned substantially similar to the tricuspidvalve annulus probe 173. Aclamping device 181 of clampingprobe 180 includes a mountingmember 179 providing anengagement slot 182 formed for sliding receipt of apin member 184 coupled toprimary shaft 66. This arrangement pivotally couples theclamping device 181 to theprimary shaft 66 for selective cooperating movement of a clampingjaw portion 183 of theclamping device 181 and theablating end 70 between a released position, separating the clamping jaw portion from the ablating end 70 (phantom lines of FIG. 26), and a clamped position, urging the clamping jaw portion against the ablating end 70 (solid lines of FIG. 26). - The clamping
jaw portion 183 is shaped and dimensioned substantially similar to the corresponding ablatingend 70 to enable clamping of the heart tissue therebetween when the tricuspidvalve clamping probe 180 is moved to the clamped position. At the opposite end of the clampingjaw portion 183 is ahandle portion 185 for manipulation of the jaw portion between the released and clamped positions in a pliers-type motion. - To perform this portion of the procedure using the tricuspid
valve clamping probe 180, the clamping jaw is moved toward the released position to enable the distal end of the ablating end to be negotiated through thefirst penetration 146. Using direct viewing through the retractor or visually aided with an endoscope, the ablating end is moved into contact with the predetermined portion of the right atrium interior wall all the way from thefirst penetration 146 to thetricuspid valve annulus 172. Subsequently, the clamping jaw portion is moved to the clamped position, viahandle portion 185, to contact theepicardial surface 168 of the heart wall opposite the tissue ablated by the probe. This arrangement increases the force against the ablatingsurface 65 to facilitate contact and heat transfer. Cryogen is then provided to the boiler chamber to cool the ablatingsurface 65 thereby forming the tricuspidvalve annulus lesion 51. Once the probe is removed from thefirst penetration 146, the first purse-string suture 58 is further tightened to prevent blood loss. - The
engagement slot 182 of mountingmember 179 is formed to permit release of thepin member 184 therefrom. Hence, theclamping device 181 can be released fromprimary shaft 66 of theclamping probe 180. This arrangement is beneficial during operative use providing the surgeon the option to introduce theclamping probe 180 into the thoracic cavity as an assembled unit, or to first introduce theablation end 70 andprimary shaft 66, and then introduce of theclamping device 181 for assembly within the thoracic cavity. - Turning now to FIG. 14, a second 4-0 purse-
string suture 59 is placed in the right atrial appendage RAA proximate a lateral midpoint thereof in the same manner as above-discussed. This portion of the heart is again accessible from the right side of the thoracic cavity through thefirst access device 68. Asecond penetration 157 is formed central to the second purse-string suture wherein blood loss from the second penetration is prevented through a second tensioning sleeve 186. Subsequently, the distal end of a right angle probe or a right atrium counter lesion probe 187 (FIGS. 15 and 27), is inserted throughsecond penetration 157 and extended into the right atrial appendage chamber. Second purse-string suture 59 may then be adjusted through second tensioning sleeve 186, as necessary to maintain a hemostatic seal between the penetration and the probe. - The right atrium
counter lesion probe 187 includes anelongated shaft 66 having afirst elbow portion 166 positioned between a relatively straightfirst portion 175 and a generally straightsecond portion 176, whereby the first elbow portion has an arc length of about 85° to about 95° and a radius of curvature of about 1.9 cm to about 3.2 cm. The second portion is preferably about 2.0 cm to about 6.0 cm in length. Further, asecond elbow portion 177 is positioned between thesecond portion 176 and a generally straightthird portion 178 of the shaft which is about 2.0 cm to about 6.0 cm in length. The second elbow portion has an arc length of about 40° to about 70° and a radius of curvature of about 3.2 cm to about 5.7 cm, angling thethird portion 178 back toward the longitudinal axis of thefirst portion 175 of theelongated shaft 66. The ablatingend 70 is coupled to the distal end of thethird portion 178 of theelongated shaft 66, and includes an arc length of about 85° to about 95° and a radius of curvature of about 6.0 mm to about 19.0 mm to curve the distal end thereof back toward the longitudinal axis of thefirst portion 175 of theshaft 66. Thus, this equates to an ablating surface length of preferably about 4.0 cm to about 8.0 cm in length. - This configuration enables the
ablating end 70 ofprobe 187 to access the right lateral midpoint of the atrial appendage RAA where thesecond penetration 157 is to placed. FIGS. 14 and 15 best illustrate that the position of thissecond penetration 157 is higher up than the first penetration, relative the heart, when accessed from thepredetermined intercostal penetration 92. Upon insertion of the distal end of the probe through thesecond penetration 157, the ablatingend 70 is inserted into the right atrium chamber to the proper depth. The handle (not shown) of theprobe 187 is manipulated and oriented from outside the thoracic cavity to position the distal end of the ablatingsurface 65 in a direction generally toward the first purse-string suture 58. The probe is retracted rearwardly out of the retractor passageway, generally in the direction ofarrow 167 in FIG. 14, to urge the ablatingsurface 65 of the probe into contact with the endocardial surface of the interior wall of the right atrial appendage RAA. As a result, theperpendicular lesion 53 of the right atrial appendage is transmurally formed. - The next lesion to be created is the
anteromedial counter lesion 55 which is to be formed through thesecond penetration 157. This lesion is positioned just anterior to the apex of the triangle of Koch and the membranous portion of the interatrial septum. Without removing the right atriumcounter lesion probe 187 from thesecond penetration 157, theelongated ablating surface 65 is urged further inwardly through thesecond penetration 157 toward the rear atrial endocardium of the right atrial appendage RAA (FIG. 15). Upon contact of the ablatingsurface 65 with the rear atrial wall, theprobe 187 is slightly rotated upwardly in the direction ofarrows 191 in FIG. 15 to exert a slight force against the rear endocardial surface. Again, this ensures ablative contact therebetween to enable formation of the anteromedial countersurgical lesion 55. Subsequently, the probe is properly defrosted and withdrawn from thesecond penetration 157 whereby the second purse-string suture 59 is cinched tighter to prevent blood loss therefrom. It will be understood that since these two lesions are formed through cryothermic techniques, the need for atrial retraction and endocardial suturing employed in connection with the formation of the transmural incision of the MAZE III procedure can be eliminated. - The next step in the procedure is an atrial septotomy to from an anterior limbus of the
fossa ovalis lesion 192. The formation of this lesion will likely be performed without direct or laparoscopic visual assistance since the ablation occurs along internal regions of theinteratrial septum wall 193. Initially, as best illustrated in FIGS. 16-18, two side-by-side purse-string sutures epicardial surface 168 proximate thepulmonary trunk 108 using the same techniques utilized for the first and second purse-string sutures. The third purse-string suture 61 is positioned on one side of theseptum wall 193 for access to the right atrium chamber, while the fourth purse-string suture 62 is positioned on the opposite side of the septum wall for access to the left atrium chamber. - FIG. 17 further illustrates that the introduction of thoracoscopic instruments and access to the third and fourth purse-strings are preferably provided through the
retractor 68. After the third andfourth tensioning sleeves retractor 68, the incision device may incorporate an angled end or blade for oblique entry through the heart wall tissue in the direction ofarrow 197 to form the third andfourth penetrations 158, 160 (FIG. 18). Alternatively, the incision device may include a blade end which is capable of selective articulation for pivotal movement of the blade end relative the elongated shaft. Use of a thoracoscopic grasping instrument facilitates grasping of the epicardium near thepulmonary trunk 108 to counter the insertion force of the angled blade during formation of therespective penetrations - To create the lesion across the anterior limbus of the
fossa ovalis lesion 192, a special atrial septum clamping probe 198 (FIGS. 17 and 28) is provided having opposed rightangled jaw portions fourth penetrations septum clamping probe 198 includes aprimary clamping member 202 having a generally straight, elongated clampingshaft 66 with afirst elbow portion 166 positioned between the clampingshaft 66 and a generally straight outer jaw portion 200 (ablating end 70), whereby the first elbow portion has an arc length of about 85° to about 95° and a radius of curvature of about 3.2 mm to about 6.4 mm. The ablating surface extends just beyondelbow portion 166 and is of a length of preferably about 2.0 cm to about 6.0 cm. - In accordance with the special atrial
septum clamping probe 198 of the present invention, anattachment device 203 is coupled to the clampingshaft 205 which includes aninner jaw portion 201 formed and dimensioned to cooperate with the outer jaw portion 200 (i.e., the elongated ablating surface 65) of clampingmember 202 for clamping engagement of theinteratrial septum wall 193 therebetween (FIG. 17). Hence, the inner jaw portion and the outer jaw portion move relative to one another between a clamped condition (FIG. 17 and in phantom lines in FIG. 28) and an unclamped condition (FIG. 14A and in solid lines in FIG. 28). In the unclamped condition, theinner jaw portion 201 of theattachment device 203 is positioned away from theouter jaw portion 200 to permit initial insertion of thedistal end 165 of theouter jaw portion 200 of theclamping probe 198 into thefourth penetration 160, as will be discussed. - The
attachment device 203 is preferably provided by a generally straight,elongated attachment shaft 206 having afirst elbow portion 207 positioned between theattachment shaft 206 and a generally straightinner jaw portion 201. FIG. 28 best illustrates that the first elbow portion ofinner jaw portion 201 has an arc length and radius of curvature substantially similar to that of theouter jaw portion 200. Further, the length of the inner jaw portion is preferably about 2.0 mm to about 6.0 mm. - In the preferred form, the
attachment shaft 206 is slidably coupled to the clampingshaft 66 through aslidable coupling device 208 enabling sliding movement of theinner jaw portion 201 between the clamped and unclamped conditions. Preferably, a plurality ofcoupling devices 208 are provided spaced-apart along theattachment shaft 206. Each coupling device includes a groove 210 (FIG. 29) formed for a sliding, snap-fit receipt of the clampingshaft 66 therein for sliding movement of the attachment device in a direction along the longitudinal axis thereof. - The coupling devices are preferably composed of TEFLON®, plastic, polyurethane or the like, which is sufficiently resilient and bendable to enable the snap-fit engagement. Further, such materials include sufficient lubricating properties to provide slidable bearing support as the clamping
shaft 66 is slidably received ingroove 210 to moveinner jaw portion 201 between the clamped and unclamped conditions. Moreover, the coupling device configuration may permit rotational motion of theinner jaw portion 201 about the attachment shaft longitudinal axis, when moved in the unclamped condition. This ability further aids manipulation of theclamping probe 198 when introduced through theaccess device 68 and insertion through the correspondingfourth penetration 160. - In the clamped condition, the
inner jaw portion 201 is moved into alignment with theouter jaw portion 200 of the clampingmember 202 for cooperative clamping of theseptum wall 193 therebetween. Analignment device 211 is preferably provided which is coupled between the clampingmember 202 and theslidable attachment device 203 to ensure proper alignment relative one another while in the clamped condition. This is particularly necessary since theinner jaw portion 201 is capable of rotational movement about the clamping shaft longitudinal axis, when moved in the unclamped condition. In the preferred embodiment, FIG. 30 best illustrates thatalignment device 211 is provided by a set of spaced-apartrail members outer jaw portion 200 to the clampingshaft 66 of the clampingmember 202. Therail members slot 213 therebetween which is dimensioned for sliding receipt of anelbow portion 207 of theinner jaw portion 201. - To further facilitate alignment between the inner jaw portion and the outer jaw portion, the
elbow portion 207 of theinner jaw portion 201 may include a rectangular cross-section dimensioned for squared receipt in theslot 213 formed between therail members - Due to the relatively close spacing and placement of the third and fourth purse-
string sutures retractor 68, substantial precision is required for simultaneous insertion of the jaw portion distal ends 165, 215. This problem is further magnified by the limited scope of visualization provided by either direct viewing through the retractor and/or with the endoscope. Accordingly, theseptum clamping probe 198 includes staggered length jaw portions which position thedistal end 165 of theouter jaw portion 200 slightly beyond thedistal end 215 of theinner jaw portion 201 to facilitate alignment and insertion through thepenetrations member 202 is initially introduced throughaccess device 68 for positioning of the distal end proximate the fourth purse-string suture 62. Upon alignment of the outer jawdistal end 165 with thefourth penetration 160, the clampingmember 202 is manipulated in the direction ofarrow 197 for insertion of the outer jaw portion partially into the left atrium chamber. The initial insertion depth of the tip is to be by an amount sufficient to retain theouter jaw portion 200 in the fourth penetration, while permitting the shorter lengthinner jaw portion 201 of the attachment device to move from the unclamped condition toward the clamped condition (FIGS. 18A and 18B). - It will be understood that the
slidable attachment device 203, at this moment, will either be unattached to the right angle probe or will be prepositioned in the unclamped condition. In the former event, theslidable attachment device 203 will be introduced through theaccess device 68 and slidably coupled or snap fit to the clampingshaft 66 of the clampingmember 202 viacoupling devices 208. As theinner jaw portion 201 is advanced in the direction ofarrow 216 toward the clamped condition, theattachment shaft 206 is rotated about its longitudinal axis, if necessary, until theelbow portion 207 is aligned for receipt in theslot 213 formed between the spaced-apartrails members inner jaw portion 201 will be aligned co-planar with theouter jaw portion 200 of the clampingmember 202. - The length of the
inner jaw portion 201 is preferably shorter than the length of theouter jaw portion 200 of clamping member 202 (preferably by about 5 mm). With thedistal end 165 of theouter jaw portion 200 partially penetrating thefourth penetration 160 and thedistal end 215 of theinner jaw portion 201 aligned with the third penetration 158 (FIG. 18B), the jaw portions are moved in the direction ofarrow 197 to position the jaws through the penetrations, on opposite sides of theseptum wall 193, and into the atrial chambers. - As shown in FIG. 17, the
jaw portions arrows interatrial septum wall 193. Subsequently, the cryogen is released into the boiler chamber of the outer jaw portion of the clamping member thereby cooling theablating surface 65 and subjecting the septal wall to cryothermia. - Due in part to the substantial thickness of this heart tissue, to secure proper transmural ablation of the interior septal wall of the right atrium, continuous contact of the ablating
surface 65 therewith should transpire for at least 3-4 minutes to create the anterior limbus of the fossa ovalis ablation. Theclamping probe 198 and the septum wall are to be properly defrosted and subsequently withdrawn from the third andfourth penetrations string sutures - The length of the outer jaw portion is preferably between about 3 cm to about 5 cm, while the length of the inner jaw portion is generally about 5 mm less than the length of the outer jaw portion. Further, the diameter of the inner and outer jaw portions is preferably between about 2-4 mm. The determination of the diameter and/or length of the particular jaw portions and combinations thereof to be utilized will depend upon the particular applications and heart dimensions.
- The clamping arrangement of this probe enables a substantial clamping force urged between the two opposed jaw portions for more efficient heat conduction. This configuration more effectively ablates the relatively thicker septum wall since greater leverage can be attained. Accordingly, in the preferred embodiment, only the outer jaw portion200 (i.e., the ablating surface 65) of the clamping
member 202 needs to be cooled to be effective. It will be appreciated, however, that theattachment device 203 may include the boiler chamber to cool the inner jaw portion as well for ablation of both sides of theseptum wall 193. - In an alternative embodiment of the
clamping probe 198, as shown in FIG. 31, the outer andinner jaw portions gap 217 at and between theouter elbow portion 166 and theinner elbow portion 207. Thisgap 217 is formed to accommodate the typicallythicker tissue juncture 218 where theseptum wall 193 intersects the outeratrial wall 220. Hence, when theclamping probe 198 is moved to the clamped condition, thegap 217 is formed to receive thistissue juncture 218 so that a more constant compression force may be applied across the septum wall between the opposing jaws. This may be especially problematic when the tissue juncture is significantly thicker than the septum wall which, due to the disparity in thickness, may not enable the distal ends of the respective jaw portions to effectively contact the septum wall for transmural ablation thereof. - While FIG. 31 illustrates that the
gap 217 is primarily formed through the offset curvature at theelbow portion 207 ofinner jaw portion 201, it will be understood that theouter jaw portion 200 alone or a combination thereof may be employed to form thegap 217. Further, in some instances, theclamping probe 198 may be derived from the right angle probe set forth above. - After completion of the above-mentioned series of elongated lesions formed through the retractor, the right atrial appendage RAA may be excised along the direction of
solid line 221 in FIG. 3 andbroken line 222 in FIG. 19, to be described below. This excision is optional depending upon the particular circumstance since the risk of a fatal clot or thromboembolism is not as great as compared to left atrial appendage LAA. Should this excision be performed, the right atrial appendage RAA will, preferably, first be sutured closed alongbroken line 222 using conventional thoracoscopic instruments. This closure must be hemostatic to prevent blood loss when the right atrial appendage is excised. Once a hemostatic seal is attained, the appendage is excised using thoracoscopic scissors or an incision device. - While suturing is the preferred technique for hemostatically sealing the right atrial chamber, the right atrial appendage may first be surgically closed along
broken line 222 using staples. In this procedure, a thoracoscopic stapling device would be inserted into the thoracic cavity through theretractor passageway 67 for access to the appendage. Moreover, the right atrial appendage may be conductively isolated by applying a specially designed cryoprobe clamping device (not shown) formed to be placed across the base of the appendage to engage the exterior surface thereof. This lesion will extend completely around the base along theline - The next series of lesions are accessed through the left atrium LA. Accordingly, a
second access device 223, preferably theretractor 68, placed between the ribs on the left side of the patient P, usually in the third or fourth intercostal space, and most preferably the third intercostal space as shown in FIG. 11A. Again, this percutaneous penetration is positioned so that thoracoscopic instruments introduced through it may be directed toward the left atrium LA of the heart H. When additional maneuvering space is necessary, the intercostal space between the ribs may be through spreading of the adjacent ribs, or portions of the ribs can be easily removed to widen the percutaneous penetration. Further, the right lung will be re-inflated for use, while the left lung will be deflated to promote access while surgery is being performed. Other lung ventilation techniques may be employed such as high frequency ventilation without departing from the true spirit and nature of the present invention. - Subsequently, a pericardiotomy is performed to gain access to the left side of the heart H utilizing thoracoscopic instruments introduced through the
retractor 68. Using the same technique mentioned above, a fifth 4-0 purse-string suture 63 is then formed in the atrial epicardium of left atrial appendage LAA proximate a lateral midpoint thereof. Through afifth penetration 161 formed central to the fifth purse-string suture 63, the orifices of the pulmonary veins can be accessed to procure conductive isolation from the remainder of the left atrium LA. - In the preferred embodiment, the pulmonary
vein isolation lesion 52 is formed using a two or more step process to completely encircle and electrically isolate the four pulmonary veins. In the preferred form, a four-step technique is employed initially commencing with the use of a C-shaped,probe 225. As best viewed in FIGS. 19A and 32, the probe includes anelongated shaft 66 and a C-shapedablating end 70 mounted to the distal end of theshaft 66. The C-shapedablating end 70 is shaped and dimensioned such that a distal end of the ablating end curves around and terminates in a region proximate the longitudinal axis extending through the shaft. The ablating end preferably includes an arc length of about 120° to about 180°, and a radius of the arc between about 6.0 mm to about 25.0 mm. This equates to an ablating surface length of preferably about 3.0 cm to about 6.0 cm. - With the aid of a thoracoscopic grasping instrument (not shown in FIG. 19A), the distal end of
probe 225 is inserted throughfifth penetration 161 to a position past thesemi-circular ablating surface 65. Afifth tensioning sleeve 226 may be cinched tighter in the event to prevent blood loss therefrom. - To create the
first segment 227 of the pulmonaryvein isolation lesion 52, the distal end of the all-purpose probe is preferably positioned to contact the pulmonaryendocardial surface 228 of the left atrium LA about 3-10 mm superior to the right superiorpulmonary vein orifice 230. Through the manipulation of the probe handle from outside the body, abight portion 232 of the ablatingsurface 65 is positioned about 3-10 mm outside of and partially encircling the right superior and left superior pulmonary vein orifices 230, 231. Once aligned, the ablatingsurface 65 of the probe is urged into ablative contact with the desired pulmonaryendocardial surface 228 to form about {fraction (1/3)} of the pulmonary vein isolation lesion 52 (i.e., the first segment 227). - Without removing the
probe 225 from thefifth penetration 161, theprobe 225 is rotated approximately 180° about the longitudinal axis of theprobe shaft 66 to reorient theablating surface 65 to form thesecond segment 233 of the pulmonaryvein isolation lesion 52. FIG. 19B best illustrates that thebight portion 232 of the probe is positioned on the other side of pulmonary trunk to contact the pulmonary endocardium about 3-10 mm just outside of and partially encircling the right inferior and left inferior pulmonary vein orifices 235, 236. To ensure segment continuity, the distal end of the probe is positioned to overlap the distal of thefirst segment 227 by at least about 5 mm. Once theprobe bight portion 232 is aligned to extend around the pulmonary vein orifices, the ablatingsurface 65 thereof is urged into ablative contact with the desired pulmonary endocardium to form thesecond segment 233 of the pulmonaryvein isolation lesion 52. After ablative contact and subsequent probe defrosting, the probe is retracted rearwardly from thefifth penetration 161 and removed from thesecond retractor 68. An articulating probe (not shown) may also be employed for this procedure which includes an ablating end capable of selected articulation of the ablating surface to vary the curvature thereof. In this probe, the articulation of the end may be manually or automatically controlled through control devices located at the handle portion of the probe. This probe may be particularly suitable for use in the formation of the pulmonary vein isolation lesion due to the anatomical access difficulties. - Immediately following removal of the
probe 225, a right angle probe is to be inserted through thefifth penetration 161 of the left atrial appendage LAA, in the manner above discussed, to create athird segment 237 of the pulmonaryvein isolation lesion 52. The formation of this segment may require a different right angle probe, having a shorter length ablating surface 65 (about 2.0 cm to about 6.0 cm) than that of the firstright angle probe 163 utilized in the previous ablative procedures. As shown in FIGS. 19C, the ablatingsurface 65 is oriented just outside the left superiorpulmonary vein orifice 231 by at least about 5 mm. Again, to ensure proper segment continuity, it is important to overlap the distal end of the ablatingsurface 65 with the corresponding end of the lesion during the formation of thethird segment 237 of the pulmonaryvein isolation lesion 52. After the probe is manually urged into contact with the desired pulmonaryendocardial surface 228, cryothermia is induced for the designated period to transmurally ablate thethird segment 237 of the pulmonaryvein isolation lesion 52 Subsequently, the right angleprobe ablating surface 65 is properly defrosted to reverse cryoadhesion and enable separation from the tissue. - Similar to the use of the
probe 225, without removing the right angle probe from thefifth penetration 161, the probe is rotated approximately 180° about the longitudinal axis of the probe shaft to position the ablatingsurface 65 just outside the left inferiorpulmonary vein orifice 236 by at least about 5 mm (FIG. 19D). Again, to ensure proper segment continuity, it is important to overlap both the distal end and the elbow portion of the ablatingsurface 65 with the corresponding ends of the second andthird segments fourth segment 238 of the pulmonaryvein isolation lesion 52. Fiberoptic visualization or the like is employed to facilitate proper continuity between the segments and placement of the probe. Once the probe is urged into contact with the desired left atrium interior surface, cryothermia is induced for the designated period to ablate the fourth segment of the pulmonaryvein isolation lesion 52. After the right angleprobe ablating surface 65 is properly defrosted, the probe is retracted rearwardly from thefifth penetration 161 and removed from thesecond retractor 68. - Formation of this last segment (i.e., fourth segment238) completes the reentrant path isolation encircling the pulmonary veins (i.e., the pulmonary vein isolation cryolesion 52). It will be appreciated, of course, that the order of the segment formation which collectively defines the pulmonary
vein isolation lesion 52 may vary. It is imperative, however, that there be continuity between the four segments. If the four-step procedure is performed properly, the opposed ends of the four segments should all overlap and interconnect to form one unitary ablation transmurally encircling thepulmonary trunk 108. - In accordance with the system and procedure of the present invention, an alternative two-step endocardial procedure may be performed to isolate the pulmonary veins. As shown in FIGS. 20A and 33, an S-shaped
end probe 240 is provided having a uniquely shaped, opened-loopedablating surface 65 formed to substantially extend around or encircle the pulmonary vein orifices. The S-shapedprobe 240 includes anelongated shaft 66 having a substantially straightfirst portion 175 and a C-shapedsecond portion 176 mounted to the distal end of the first portion and terminating at a position proximate the longitudinal axis of thefirst portion 175 ofshaft 66. Mounted to the distal end of the C-shapedsecond portion 176 is a C-shapedablating end 70 which curves back in the opposite direction such that the two C-shaped sections cooperate to form an S-shaped end. This unique shape enables the ablatingsurface 65 of ablatingend 70 to have an arc length of between about 290° to about 310°, with a radius of curvature of about 1.2 cm to about 3.0 cm. - FIG. 33 illustrates that the C-shaped
ablating end 70 is shaped and dimensioned such that a distal end of the ablating end curves around and terminates in a region proximate the longitudinal axis extending through the shaft. Consequently, the ablatingend 70, having a radius of about 12.0 mm to about 25.0 mm, can then extend substantially around the endocardial surface of the pulmonary vein trunk. This is accomplished by providing the C-shapedsecond portion 176 having a radius of curvature of at least bout 5 mm to about 7 mm which enables the unimpeded flow of cryogen through the delivery tube of theshaft 66. The elimination or substantial reduction of this C-shapedsecond portion 176 positioned just before the C-shapedablating end 70 would create such an acute angle that the flow of cryogen about that angle may be impeded. - Using thoracoscopic grasping instruments, the distal end of this probe is carefully inserted through the fifth purse-
string suture penetration 161. Due in part to the unique near-circular shape of the ablatingsurface 65, initial insertion through the fifth penetration may be one of the most difficult and problematic portions of this procedure. - As shown in FIG. 20A, after the
ablating surface 65 of theprobe 240 is successfully inserted through thefifth penetration 161, the looped ablatingsurface 65 is aligned and positioned to substantially encircle the pulmonary vein orifices. Through manipulation of the probe handle from outside the thoracic cavity, theprobe ablating surface 65 is urged into contact with the pulmonaryendocardial surface 228 about 3-10 mm just outside of the pulmonary vein orifices. Upon proper alignment and ablative contact with the epicardial tissue, afirst segment 241 of this technique is formed (FIG. 20B) which preferably constitutes at least about {fraction (3/4)} of the pulmonary vein isolation lesion. After proper defrosting, the loop probe is removed from the fifth penetration and withdrawn through the retractor. - To complete this alternative two-step procedure, an alternative right angle probe, above-mentioned, is inserted through the
fifth penetration 161 upon removal of the S-shapedprobe 240. FIG. 20B illustrates that both the distal end and the elbow portion of theprobe ablating surface 65 are aligned to overlap the corresponding ends of thefirst segment 241 during the formation of asecond segment 242 of the pulmonaryvein isolation lesion 52. This ensures continuity between the two connecting segments. - It will be understood that other shape probes may be employed to isolate the pulmonary trunk. The particular customized shape may depend upon the individual anatomical differences of the patient, especially since atrial fibrillation patients often have enlarged or distorted atria.
- It may be beneficial to access and perform portions of either the four-step procedure or the two-step procedure through the right side of the thoracic cavity. In these instances, access may be achieved through the
first access device 68 and thefourth penetration 160 of the fourth purse-string suture 62. Moreover, due to the arduous nature of the formation, placement and alignment between these segments composing the endocardial pulmonary vein isolation lesion in either the two or four segment procedure, it may be necessary to ablate an epicardial lesion 243 in theepicardial surface 168 encircling thepulmonary trunk 108 to ensure effective transmural tissue ablation for pulmonary vein isolation. Referring to FIGS. 21 and 33, an epicardial pulmonaryvein loop probe 240, substantially similar to the probe employed in the procedure of FIG. 20A, is provided for introduction through the passageway of the retractor. This probe instrument includes an open-loopedablating surface 65 defining an opening 245 (FIG. 33) formed for passage of thepulmonary trunk 108 therethrough. Using thoracoscopic grasping instruments, theprobe 240 is situated under the pulmonary veins wherein thepulmonary trunk 108 is urged through theopening 245 in the looped ablating surface. Once the ablatingsurface 65 is aligned to contact a pulmonaryepicardial surface 168 of thepulmonary trunk 108 at a position opposite the epicardial pulmonaryvein isolation lesion 52, cryogenic liquid is introduced into the boiler chamber of theloop probe 240 for cryogenic cooling of the ablatingsurface 65. After contact for the designated period (2-4 minutes) and proper probe defrosting, the loop probe is separated from the pulmonary trunk and retracted rearwardly out of theretractor 68. - Alternatively, this pulmonary epicardial surface isolation may be performed from the right side of the thoracic cavity through the first access device68 (not shown). In this alternative method, the open-looped
ablating surface 65 of theloop probe 240 is positioned behind thesuperior vena cava 111, across the anterior surface of the right pulmonary veins, and underneath theinferior vena cava 103. Once properly positioned, theepicardial surface 168 of thepulmonary trunk 108 can be ablated. - Turning now to FIG. 22, formation of the left atrial
anteromedial lesion 246 will be described in detail. Thislesion 246 is relatively short extending only about 5-7 mm from the anteromedial portion of the left atrial appendage LAA to the pulmonaryvein isolation lesion 52 proximate a central portion between the left superior and inferior pulmonary vein orifices 231, 236. Due to the position of this lesion and the flexible nature of the appendage tissue, any one of a number of probes already mentioned, such as the probes illustrated in FIG. 32, the right angle probe (FIG. 24) or the pulmonary vein to mitral valve probe (FIG. 34), can be employed for this task. Typically, theprobe device 247 of FIG. 34 is employed which includes anelongated shaft 66 having afirst elbow portion 166 positioned between a relatively straightfirst portion 175 and a generally straightsecond portion 176. The first elbow portion has an arc length of about 45° to about 65° and a radius of curvature of about 3.2 cm to about 5.7 cm. Further, asecond elbow portion 177 is positioned between thesecond portion 176 and theablating end 70, angling the ablating end back toward the longitudinal axis of thefirst portion 175 of theelongated shaft 66. The ablatingend 70 preferably includes thesecond elbow portion 177, having an arc length of about 80° to about 100°, and a radius of curvature of about 6.0 mm to about 1.9 mm. This translates to an ablating surface of about 2.0 cm to about 6.0 cm in length. - One of the above-mentioned probes will be introduced through the
second retractor 68 where the distal end of the probe will be inserted through the samefifth penetration 161 central to the fifth purse-string suture 63. Once the selectedprobe 247, as shown in FIG. 22, is properly aligned, the ablatingsurface 65 is urged into contact with the atrial endocardial surface of the left atrial appendage LAA for localized ablation. Subsequently, the left atrialanteromedial lesion 246 will be formed. - Since the left atrial wall at the anteromedial portion thereof is exceedingly thin, this transmural ablation could be performed from outside the heart H. Hence, upon contact of the ablating surface of a selected probe (not shown) with the atrial epicardial surface of the left atrial appendage LAA, localized, transmural cryothermia may be applied externally/epicardially to form this left atrial
anteromedial lesion 246. - The last lesion to be performed through the
fifth penetration 161 is the posterior vertical leftatrial lesion 248, also known as the coronary sinus lesion (FIG. 23), extending from the pulmonaryvein isolation lesion 52 to theannulus 250 of the mitral valve MV. This lesion may be critical since improper ablation may enable atrial conduction to continue in either direction beneath the pulmonary veins. This may result in a long macro-reentrant circuit that propagates around the posterior-inferior left atrium, the atrial septum, the anterior-superior left atrium, the lateral wall of the left atrium beneath the excised left atrial appendage, and back to the posterior inferior left atrium. - Therefore, it is imperative that the coronary sinus be ablated circumferentially and transmurally in the exact plane of the atriotomy or lesion. Proper transmural and circumferential ablation near the coronary sinus effectively eliminates the need for dividing all atrial myocardial fibers traversing the fat pad of the underlying atrioventricular groove.
- In the preferred embodiment, a modified probe251 (FIG. 35) is employed to ablate this critical
coronary sinus lesion 248. Thisprobe 251 includes anelongated shaft 66 having afirst elbow portion 166 positioned between a generally straightfirst portion 175 and a generally straightsecond portion 176. The first elbow portion has an arc length of about 30° to about 50° and a radius of curvature of about 1.2 cm to about 3.0 cm. Mounted at the distal end of thesecond portion 176 is the ablating end which is substantially similar in shape to the ablating end of the probe of FIG. 32. The ablatingend 70 curves back toward the longitudinal axis of thefirst portion 175 of theelongated shaft 66. - Again, this interior region of the heart H is accessed through the
fifth penetration 161, via thesecond access device 223. The distal end of theprobe 251, is positioned through the penetration in the same manner as previous ablations. The unique curvature of thisprobe 251 enables manipulation of the ablatingsurface 65 from outside the thoracic cavity into proper alignment. FIG. 23 best illustrates that ablatingsurface 65 is moved into contact with the endocardial surface of the left atrial wall atrium for localized ablation extending from the pulmonaryvein isolation lesion 52 to themitral valve annulus 250. Particular care, as mentioned above, is taken to assure that this lesion extends through the coronary sinus for circumferential electrical isolation thereof. After contact for the designated period of 2-4 minutes, the ablatingsurface 65 of the probe is properly defrosting and theprobe 251 is retracted rearwardly from thefifth penetration 161 for removal from the retractor. Subsequently, thefifth penetration 161 is further cinched to prevent blood lose through the fifth purse-string suture 63. - Due to the criticality of the circumferential ablation of the coronary sinus during formation of the pulmonary vein to mitral
valve annulus lesion 248, an epicardial ablation may be performed on a portion of the outside heart wall opposite the endocardial ablation of the coronary sinus. Thus, the placement of this additional lesion (not shown) must be in the same plane as the coronary sinus lesion 248 (i.e., to the mitral valve annulus lesion) to assure circumferential ablation of the coronary sinus. This is performed by introducing a standard probe through theretractor 68, and strategically contacting the epicardial surface at the desired location opposite the coronary sinus lesion. - Upon completion of the above-mentioned series of elongated lesions, the left atrial appendage LAA is excised along the direction of
broken line 252 in FIG. 23, similar to that of the prior procedures. This excision is considered more imperative than the excision of the right atrial appendage RAA since the threat of thromboembolism or clotting would more likely be fatal, induce strokes or cause other permanent damage. In the preferred form, this excision is performed in the same manner as the excision of the right atrial appendage (i.e., through suturing or stapling. After hemostatic closure is attained, the left atrial appendage LAA is excised using thoracoscopic scissors or an incision device. This left appendagectomy will extend completely around the base of the left atrial appendage along thesolid line 252 in FIG. 3 or the broken line 253 in FIG. 23, which corresponds to the left atrial appendage excision in prior procedures. - Alternatively, the probes may be formed and dimensioned for contact with the
epicardial surface 168 of the heart H. In these instances, no purse-string suture may be necessary for elongated transmural ablation. As an example, as best viewed in FIG. 36, a right-angleclamp type probe 255 is provided having anouter clamping portion 256 coupled to and formed to cooperate with a right angle probe orinner clamping portion 257 for transmural ablation of the heart wall through contact withepicardial surface 168 of the heart H. In this embodiment, anouter jaw portion 258 ofouter clamping portion 256 is relatively thin (about 0.5 mm to about 2.0 mm in diameter) and preferably needle shaped to facilitate piercing of the heart wall atpuncture 260. At the end of the needle-shapedouter clamping portion 256 is apointed end 261 which enables piercing of the heart wall without requiring an initial incision and subsequent purse-string suture to prevent blood loss through thepuncture 260. - Similar to clamping
probe 198, when properly positioned, the outer andinner jaw portions inner clamping portion 257 are moved inwardly in the direction ofarrows outer jaw portion 258 contactingendocardial surface 228, and theinner jaw portion 262 contacting epicardial surface 168) to clamp the heart wall therebetween. FIG. 36 illustrates thatinner jaw portion 262 includesablation end 70 havingablation surface 65 which contacts epicardialsurface 168 for ablation. Upon withdrawal of the needle-shapedouter jaw portion 258 from the heart wall, thepuncture 260 may be closed through a single suture (not shown). - In these embodiments, an
alignment device 263 is provided which cooperates between the outer andinner clamping portions outer jaw portion 258 and theinner jaw portion 262. This alignment device may be provided by any conventional alignment mechanism such as those alignment devices employed in theclamping probe 198. - To ensure transmural ablation, the needle-shaped
outer jaw portion 258 may incorporate a temperature sensor 265 (FIG. 36) embedded in or positioned on the outer jaw portion to measure the temperature of the endocardial surface. Measurement of the proper surface temperature will better ensure transmural ablation. These temperature sensors may be provided by a variety of conventional temperature sensors. - Referring to FIGS.37-40, another
probe 280 is shown. Acryogen delivery tube 282 is positioned within anouter tube 284. Atip 286 seals an end of theouter tube 284. Thedelivery tube 282 is coupled to the source of cryogen (not shown) for delivering the cryogen to aboiler chamber 288. The cryogen is exhausted from theboiler chamber 288 through the annular area between thedelivery tube 282 andouter tube 284. Thedelivery tube 282 has anend cap 290 which receives first andsecond tubes boiler chamber 288 from thedelivery tube 282. Thefirst tube 292 has anexhaust port 296 which extends further into theboiler chamber 288 than anexhaust port 298 of thesecond tube 294 so that the cryogen is distributed throughout theboiler chamber 288. Although FIG. 38 depicts only the first andsecond outlet tubes -
Ablating surface 300 of theouter tube 284 is preferably made of a highly thermally conductive material such as copper. Referring to the end view of FIG. 40, theablating surface 300 preferably has a ribbedinner surface 302 for enhanced thermal conduction between theboiler chamber 288 and theablating surface 300. Theprobe 280 may take any of the configurations described herein. - Referring to FIGS. 41 and 42, another
probe 306 is shown which has a device for adjusting the delivery rate of cryogen. Thedelivery tube 308 includes aninner tube 310 and anouter tube 312. The inner andouter tubes holes boiler chamber 318. Theouter tube 312 is slidable relative to theinner tube 310 and can be locked relative to theinner tube 310 at a number of discrete positions where theholes 314 in theinner tube 310 are aligned with theholes 316 in theouter tube 312. Theholes 314 in theinner tube 310 are larger thanholes 316 in theouter tube 312 so that when theouter tube 312 is in the position of FIG. 41 a larger amount of cyrogen is delivered than when theouter tube 312 is in the position of FIG. 42. Thus, the amount of cyrogen delivered, and therefore the rate of ablation and temperature of theprobe 306, can be changed by moving theouter tube 312 relative to theinner tube 310. Thedelivery tube 308 may be used in the manner described above with any of the probe configurations described herein. - Referring to FIGS. 43 and 44, still another
probe 318 is shown which includessuction ports 320 for ensuring intimate contact between theablating surface 322 and the tissue. Thesuction ports 320 are coupled to alongitudinal channel 324 which is coupled to a vacuum source for applying suction. Acryogen delivery tube 326 delivers cryogen toboiler chamber 328 in the manner described herein. - Referring to FIGS.45-47, a
probe 330 having amalleable shaft 332 is shown. Amalleable metal rod 334 is coextruded with apolymer 336 to form theshaft 332. Atip 338 having aboiler chamber 340 is attached to theshaft 332. Therod 334 permits the user to shape theshaft 332 as necessary so that thetip 338 can reach the tissue to be ablated. Thetip 338 hasfittings 342 which are received in acryogen exhaust path 344 and acryogen delivery path 346 in theshaft 332. Therod 334 is preferably made of stainless steel and thepolymer 336 is preferably polyurethane. Thetip 338 may be made of a suitable thermally conductive material such as copper. Cryogen is delivered throughports 348 in adelivery tube 350 and is expanded in theboiler chamber 340. The cryogen is then withdrawn through theexhaust path 344. - Finally, as set forth in the parent application incorporated herein by reference, access devices may be placed in the heart walls to enable the passage of the probes through the wells of the access devices.
- While the present invention has been primarily directed toward ablation from the endocardial surfaces of the atria, it will be understood that many lesions or portions of the lesions may be created through ablation of the endocardial surfaces of the atria employing the present probes. While the specific embodiments of the invention described herein will refer to a closed-chest surgical procedure and system for the treatment of medically refractory atrial fibrillation, it is understood that the invention will be useful in ablation of other tissue structures, including surgical treatment of Wolfe-Parkinson-White (WPW) Syndrome, ventricular fibrillation, congestive heart failure and other procedures in which interventional devices are introduced into the interior of the heart, coronary arteries, or great vessels. The present invention facilitates the performance of such procedures through percutaneous penetrations within intercostal spaces, eliminating the need for a median sternotomy or other form of gross thoracotomy. However, as will be apparent although not preferred, the system and procedure of the present invention could be performed in an open-chest surgical procedure as well.
Claims (20)
1. A method for treatment of a heart comprising the steps of:
forming a penetration through a muscular wall of the heart into an interior chamber thereof;
positioning a distal end of an elongated ablating device having an elongated ablating surface through the penetration; and
contacting the elongated ablating surface of the ablating device with a first selected portion of an interior surface of the muscular wall for transmural ablation thereof.
2. The method of claim 1 further including the step of:
manipulating the device through said penetration to strategically contact the elongated ablating surface with a second selected portion of the interior surface of the muscular wall for transmural ablation thereof.
3. The method of claim 1 further including the steps of:
repeating the forming, positioning and contacting steps to form a plurality of strategically positioned lesions.
4. The method of claim 3 wherein,
the lesions are formed to create a predetermined conduction pathway in the muscular wall.
5. The method of claim 1 wherein,
the interior chamber is selected from a right atrium and a left atrium.
6. The method of claim 1 wherein,
the ablating surface is disposed at an angle of at most about 90 degrees relative to the longitudinal axis of the shaft.
7. The method of claim 1 further including the step of:
forming a hemostatic seal between the device and the penetration to inhibit blood loss through the penetration.
8. The method of claim 7 wherein:
the seal forming step is carried out by placing a purse-string suture in the muscular wall of the heart around the penetration.
9. The method of claim 1 wherein,
the heart remains beating throughout the forming, positioning, and contacting steps.
10. The method of claim 1 further including the step of:
arresting the patient's heart.
11. The method of claim 10 wherein,
the arresting step is performed by endovascularly occluding the ascending aorta.
12. The method of claim 1 wherein,
the ablating device is a radiofrequency probe.
13. The method of claim 1 wherein,
the ablating device is a laser probe.
14. The method of claim 1 wherein,
the ablating device is a microwave probe.
15. The method of claim 1 wherein,
the ablating device is a fluid delivery probe.
16. A method for ablating medically refractory atrial fibrillation of the heart comprising the steps of:
forming a penetration through a wall of the heart;
positioning a distal end of an ablating device having an elongated ablating surface through the penetration;
forming a hemostatic seal between the ablating device and the penetration to inhibit blood loss therethrough;
contacting the elongated ablating surface with at least one selected portion of an interior surface of the heart for transmural ablation thereof to form at least one elongated transmural lesion.
17. The method of claim 16 , further comprising the step of:
repeating the forming, positioning, and contacting steps to form a plurality of lesions, the plurality of lesions cooperating to generally form a conduction pathway between the sinoatrial node and the atrioventricular node.
18. The method of claim 16 wherein,
the interior chamber is selected from a right atrium and a left atrium.
19. The method of claim 16 , wherein at least one hemostatic seal is formed by tightening a purse-string suture in the heart wall around the respective penetration.
20. A system for transmurally ablating heart tissue in a body cavity surrounded by a chest wall comprising:
a probe having an elongated shaft positionable through the chest wall and into a penetration extending through a wall of the patient's heart, said shaft having a substantially elongated ablating surface proximate a distal end thereof for manipulative contact with at least one selected surface of the wall of the heart for transmural ablation thereof; and
a sealing device fixable to the heart tissue around said penetration for forming a hemostatic seal around the shaft and the transmural penetration to inhibit blood loss therebetween.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/171,390 US20030024537A1 (en) | 1996-10-22 | 2002-06-12 | Device and method for forming a lesion |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US73503696A | 1996-10-22 | 1996-10-22 | |
US08/943,683 US6161543A (en) | 1993-02-22 | 1997-10-15 | Methods of epicardial ablation for creating a lesion around the pulmonary veins |
US60674200A | 2000-06-29 | 2000-06-29 | |
US10/171,390 US20030024537A1 (en) | 1996-10-22 | 2002-06-12 | Device and method for forming a lesion |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US60674200A Continuation | 1996-10-22 | 2000-06-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
US20030024537A1 true US20030024537A1 (en) | 2003-02-06 |
Family
ID=27112828
Family Applications (11)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/943,683 Expired - Lifetime US6161543A (en) | 1993-02-22 | 1997-10-15 | Methods of epicardial ablation for creating a lesion around the pulmonary veins |
US09/954,393 Abandoned US20020017306A1 (en) | 1996-10-22 | 2001-09-12 | Surgical system and procedure for treatment of medically refractory atrial fibrillation |
US10/032,303 Abandoned US20020068970A1 (en) | 1996-10-22 | 2001-12-21 | Device and method for forming a lesion |
US10/171,390 Abandoned US20030024537A1 (en) | 1996-10-22 | 2002-06-12 | Device and method for forming a lesion |
US10/171,411 Expired - Fee Related US7387126B2 (en) | 1996-10-22 | 2002-06-12 | Surgical system and procedure for treatment of medically refractory atrial fibrillation |
US10/172,732 Abandoned US20030029462A1 (en) | 1996-10-22 | 2002-06-14 | Device and method for forming a lesion |
US11/785,392 Expired - Fee Related US8002771B2 (en) | 1996-10-22 | 2007-04-17 | Surgical system and procedure for treatment of medically refractory atrial fibrillation |
US11/935,582 Expired - Fee Related US7517345B2 (en) | 1996-10-22 | 2007-11-06 | Surgical system and procedure for treatment of medically refractory atrial fibrillation |
US12/102,592 Abandoned US20080183168A1 (en) | 1996-10-22 | 2008-04-14 | Surgical system and procedure for treatment of medically refractory atrial fibrillation |
US12/403,123 Expired - Fee Related US8177780B2 (en) | 1996-10-22 | 2009-03-12 | Surgical system and procedure for treatment of medically refractory atrial fibrillation |
US13/470,886 Expired - Fee Related US8535301B2 (en) | 1996-10-22 | 2012-05-14 | Surgical system and procedure for treatment of medically refractory atrial fibrillation |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/943,683 Expired - Lifetime US6161543A (en) | 1993-02-22 | 1997-10-15 | Methods of epicardial ablation for creating a lesion around the pulmonary veins |
US09/954,393 Abandoned US20020017306A1 (en) | 1996-10-22 | 2001-09-12 | Surgical system and procedure for treatment of medically refractory atrial fibrillation |
US10/032,303 Abandoned US20020068970A1 (en) | 1996-10-22 | 2001-12-21 | Device and method for forming a lesion |
Family Applications After (7)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/171,411 Expired - Fee Related US7387126B2 (en) | 1996-10-22 | 2002-06-12 | Surgical system and procedure for treatment of medically refractory atrial fibrillation |
US10/172,732 Abandoned US20030029462A1 (en) | 1996-10-22 | 2002-06-14 | Device and method for forming a lesion |
US11/785,392 Expired - Fee Related US8002771B2 (en) | 1996-10-22 | 2007-04-17 | Surgical system and procedure for treatment of medically refractory atrial fibrillation |
US11/935,582 Expired - Fee Related US7517345B2 (en) | 1996-10-22 | 2007-11-06 | Surgical system and procedure for treatment of medically refractory atrial fibrillation |
US12/102,592 Abandoned US20080183168A1 (en) | 1996-10-22 | 2008-04-14 | Surgical system and procedure for treatment of medically refractory atrial fibrillation |
US12/403,123 Expired - Fee Related US8177780B2 (en) | 1996-10-22 | 2009-03-12 | Surgical system and procedure for treatment of medically refractory atrial fibrillation |
US13/470,886 Expired - Fee Related US8535301B2 (en) | 1996-10-22 | 2012-05-14 | Surgical system and procedure for treatment of medically refractory atrial fibrillation |
Country Status (4)
Country | Link |
---|---|
US (11) | US6161543A (en) |
EP (2) | EP1864619B1 (en) |
AU (1) | AU5003197A (en) |
WO (1) | WO1998017187A1 (en) |
Cited By (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020087151A1 (en) * | 2000-12-29 | 2002-07-04 | Afx, Inc. | Tissue ablation apparatus with a sliding ablation instrument and method |
US20020128642A1 (en) * | 1998-10-23 | 2002-09-12 | Afx, Inc. | Directional microwave ablation instrument with marking device |
US20030220639A1 (en) * | 2002-02-19 | 2003-11-27 | Afx, Inc. | Apparatus and method for assessing transmuarlity of a tissue ablation |
US20030236505A1 (en) * | 2000-07-21 | 2003-12-25 | Frank Bonadio | Cannula |
US20040138652A1 (en) * | 2000-04-12 | 2004-07-15 | Afx, Inc. | Electrode arrangement for use in a medical instrument |
US20040243117A1 (en) * | 2002-12-11 | 2004-12-02 | Lentz David J. | Catheter system for performing a single step cryoablation |
US20040243118A1 (en) * | 2001-06-01 | 2004-12-02 | Ayers Gregory M. | Device and method for positioning a catheter tip for creating a cryogenic lesion |
US20040254607A1 (en) * | 2003-06-10 | 2004-12-16 | Cryocath Technologies Inc. | Minimally invasive surgical clamp having treatment elements |
US20040254606A1 (en) * | 2003-06-10 | 2004-12-16 | Dan Wittenberger | Surgical clamp having trasmurality assessment capabilities |
US20050075629A1 (en) * | 2002-02-19 | 2005-04-07 | Afx, Inc. | Apparatus and method for assessing tissue ablation transmurality |
US20050154404A1 (en) * | 2003-10-09 | 2005-07-14 | Liddicoat John R. | Apparatus and method for the ligation of tissue |
US20050283146A1 (en) * | 2004-06-17 | 2005-12-22 | Lentz David J | Thermally extended spiral cryotip for a cryoablation catheter |
US20060063121A1 (en) * | 2004-09-22 | 2006-03-23 | Barry David L | Containment apparatus for multi-pass ovens |
US20060116673A1 (en) * | 2000-01-18 | 2006-06-01 | Jules Gauthier | Ablation instrument and method |
US20060178662A1 (en) * | 2005-02-04 | 2006-08-10 | Ripley Kenneth L | Warming gradient control for a cryoablation applicator |
US7099717B2 (en) * | 2002-01-03 | 2006-08-29 | Afx Inc. | Catheter having improved steering |
US20060206107A1 (en) * | 1999-05-28 | 2006-09-14 | Afx, Inc. | Monopole tip for ablation catheter and methods for using same |
US20070129719A1 (en) * | 2005-05-26 | 2007-06-07 | Amar Kendale | Apparatus and methods for performing minimally-invasive surgical procedures |
US20070149960A1 (en) * | 2003-06-10 | 2007-06-28 | Cryocath Technologies Inc. | Surgical clamp having transmurality assessment capabilities |
US20070185479A1 (en) * | 2006-02-06 | 2007-08-09 | Liming Lau | Methods and devices for performing ablation and assessing efficacy thereof |
US20070208329A1 (en) * | 2004-12-10 | 2007-09-06 | Jim Ward | Ablative treatment of atrial fibrillation via the coronary sinus |
US20070225697A1 (en) * | 2006-03-23 | 2007-09-27 | Ketan Shroff | Apparatus and methods for cardiac ablation |
US20080039879A1 (en) * | 2006-08-09 | 2008-02-14 | Chin Albert K | Devices and methods for atrial appendage exclusion |
US20080125795A1 (en) * | 1999-05-20 | 2008-05-29 | Aaron V. Kaplan | Methods and apparatus for transpericardial left atrial appendage closure |
US20090082797A1 (en) * | 2007-09-20 | 2009-03-26 | Fung Gregory W | Devices and methods for remote suture management |
US20090093809A1 (en) * | 2007-10-05 | 2009-04-09 | Anderson Evan R | Devices and methods for minimally-invasive surgical procedures |
US20090143791A1 (en) * | 2007-03-30 | 2009-06-04 | Sentreheart, Inc. | Devices, systems, and methods for closing the left atrial appendage |
US20090209986A1 (en) * | 2008-02-15 | 2009-08-20 | Stewart Michael C | Devices, Tools and Methods for Atrial Appendage Exclusion |
US20100179527A1 (en) * | 2009-01-15 | 2010-07-15 | Boston Scientific Scimed, Inc. | Controlling Depth of Cryoablation |
US20100199077A1 (en) * | 2009-01-30 | 2010-08-05 | Freescale Semiconductor, Inc. | Authenticated debug access for field returns |
US20100241113A1 (en) * | 2009-03-20 | 2010-09-23 | Boston Scientific Scimed, Inc. | Protecting the phrenic nerve while ablating cardiac tissue |
US20110024614A1 (en) * | 2006-10-19 | 2011-02-03 | Syft Technologies Limited | Sift-ms instrument |
US7918865B2 (en) | 2005-04-07 | 2011-04-05 | Sentreheart, Inc. | Apparatus and method for the ligation of tissue |
US20110087247A1 (en) * | 2009-04-01 | 2011-04-14 | Fung Gregory W | Tissue ligation devices and controls therefor |
US20110276075A1 (en) * | 2010-04-13 | 2011-11-10 | Sentreheart, Inc. | Methods and devices for accessing and delivering devices to a heart |
US9408608B2 (en) | 2013-03-12 | 2016-08-09 | Sentreheart, Inc. | Tissue ligation devices and methods therefor |
US9498206B2 (en) | 2011-06-08 | 2016-11-22 | Sentreheart, Inc. | Tissue ligation devices and tensioning devices therefor |
US9936956B2 (en) | 2015-03-24 | 2018-04-10 | Sentreheart, Inc. | Devices and methods for left atrial appendage closure |
US10130369B2 (en) | 2015-03-24 | 2018-11-20 | Sentreheart, Inc. | Tissue ligation devices and methods therefor |
US10258408B2 (en) | 2013-10-31 | 2019-04-16 | Sentreheart, Inc. | Devices and methods for left atrial appendage closure |
US10292710B2 (en) | 2016-02-26 | 2019-05-21 | Sentreheart, Inc. | Devices and methods for left atrial appendage closure |
Families Citing this family (643)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6161543A (en) | 1993-02-22 | 2000-12-19 | Epicor, Inc. | Methods of epicardial ablation for creating a lesion around the pulmonary veins |
US5797960A (en) * | 1993-02-22 | 1998-08-25 | Stevens; John H. | Method and apparatus for thoracoscopic intracardiac procedures |
US6423055B1 (en) | 1999-07-14 | 2002-07-23 | Cardiofocus, Inc. | Phototherapeutic wave guide apparatus |
US6676656B2 (en) * | 1994-09-09 | 2004-01-13 | Cardiofocus, Inc. | Surgical ablation with radiant energy |
US6579285B2 (en) * | 1994-09-09 | 2003-06-17 | Cardiofocus, Inc. | Photoablation with infrared radiation |
US8025661B2 (en) | 1994-09-09 | 2011-09-27 | Cardiofocus, Inc. | Coaxial catheter instruments for ablation with radiant energy |
US6152920A (en) * | 1997-10-10 | 2000-11-28 | Ep Technologies, Inc. | Surgical method and apparatus for positioning a diagnostic or therapeutic element within the body |
US6142994A (en) * | 1994-10-07 | 2000-11-07 | Ep Technologies, Inc. | Surgical method and apparatus for positioning a diagnostic a therapeutic element within the body |
US6071274A (en) | 1996-12-19 | 2000-06-06 | Ep Technologies, Inc. | Loop structures for supporting multiple electrode elements |
US6409722B1 (en) | 1998-07-07 | 2002-06-25 | Medtronic, Inc. | Apparatus and method for creating, maintaining, and controlling a virtual electrode used for the ablation of tissue |
US5897553A (en) | 1995-11-02 | 1999-04-27 | Medtronic, Inc. | Ball point fluid-assisted electrocautery device |
US20110077672A1 (en) * | 1995-06-07 | 2011-03-31 | Fleischman Sidney D | Devices For Installing Stasis Reducing Means In Body Tissue |
US6132438A (en) * | 1995-06-07 | 2000-10-17 | Ep Technologies, Inc. | Devices for installing stasis reducing means in body tissue |
US7052493B2 (en) * | 1996-10-22 | 2006-05-30 | Epicor Medical, Inc. | Methods and devices for ablation |
US6840936B2 (en) * | 1996-10-22 | 2005-01-11 | Epicor Medical, Inc. | Methods and devices for ablation |
US6237605B1 (en) | 1996-10-22 | 2001-05-29 | Epicor, Inc. | Methods of epicardial ablation |
US6805128B1 (en) | 1996-10-22 | 2004-10-19 | Epicor Medical, Inc. | Apparatus and method for ablating tissue |
US6311692B1 (en) | 1996-10-22 | 2001-11-06 | Epicor, Inc. | Apparatus and method for diagnosis and therapy of electrophysiological disease |
US6719755B2 (en) | 1996-10-22 | 2004-04-13 | Epicor Medical, Inc. | Methods and devices for ablation |
US20040260278A1 (en) * | 1996-10-22 | 2004-12-23 | Anderson Scott C. | Apparatus and method for ablating tissue |
US6071279A (en) * | 1996-12-19 | 2000-06-06 | Ep Technologies, Inc. | Branched structures for supporting multiple electrode elements |
US6913604B2 (en) * | 1997-02-27 | 2005-07-05 | Cryocath Technologies Inc. | Cryosurgical catheter |
WO2000032126A1 (en) * | 1997-02-27 | 2000-06-08 | Cryocath Technologies Inc. | Cryosurgical catheter |
US7591814B2 (en) * | 1997-02-27 | 2009-09-22 | Cryocath Technologies Inc. | Extended treatment zone catheter |
US6669689B2 (en) | 1997-02-27 | 2003-12-30 | Cryocath Technologies Inc. | Cryosurgical catheter |
US6235019B1 (en) | 1997-02-27 | 2001-05-22 | Cryocath Technologies, Inc. | Cryosurgical catheter |
US6090096A (en) * | 1997-04-23 | 2000-07-18 | Heartport, Inc. | Antegrade cardioplegia catheter and method |
US6012457A (en) | 1997-07-08 | 2000-01-11 | The Regents Of The University Of California | Device and method for forming a circumferential conduction block in a pulmonary vein |
US6024740A (en) | 1997-07-08 | 2000-02-15 | The Regents Of The University Of California | Circumferential ablation device assembly |
US6117101A (en) * | 1997-07-08 | 2000-09-12 | The Regents Of The University Of California | Circumferential ablation device assembly |
US6096037A (en) | 1997-07-29 | 2000-08-01 | Medtronic, Inc. | Tissue sealing electrosurgery device and methods of sealing tissue |
AUPO820897A0 (en) * | 1997-07-24 | 1997-08-14 | Cardiac Crc Nominees Pty Limited | An intraoperative endocardial and epicardial ablation probe |
US6267760B1 (en) | 1998-05-05 | 2001-07-31 | Scimed Life Systems, Inc. | Surgical method and apparatus for positioning a diagnostic or therapeutic element within the body and forming an incision in tissue with minimal blood loss |
US6468272B1 (en) | 1997-10-10 | 2002-10-22 | Scimed Life Systems, Inc. | Surgical probe for supporting diagnostic and therapeutic elements in contact with tissue in or around body orifices |
US6645200B1 (en) | 1997-10-10 | 2003-11-11 | Scimed Life Systems, Inc. | Method and apparatus for positioning a diagnostic or therapeutic element within the body and tip electrode for use with same |
US6610055B1 (en) | 1997-10-10 | 2003-08-26 | Scimed Life Systems, Inc. | Surgical method for positioning a diagnostic or therapeutic element on the epicardium or other organ surface |
US6464699B1 (en) | 1997-10-10 | 2002-10-15 | Scimed Life Systems, Inc. | Method and apparatus for positioning a diagnostic or therapeutic element on body tissue and mask element for use with same |
US6071281A (en) * | 1998-05-05 | 2000-06-06 | Ep Technologies, Inc. | Surgical method and apparatus for positioning a diagnostic or therapeutic element within the body and remote power control unit for use with same |
US6120496A (en) * | 1998-05-05 | 2000-09-19 | Scimed Life Systems, Inc. | Surgical method and apparatus for positioning a diagnostic or therapeutic element within the body and coupling device for use with same |
US6416505B1 (en) | 1998-05-05 | 2002-07-09 | Scimed Life Systems, Inc. | Surgical method and apparatus for positioning a diagnostic or therapeutic element within the body and pressure application probe for use with same |
US8709007B2 (en) | 1997-10-15 | 2014-04-29 | St. Jude Medical, Atrial Fibrillation Division, Inc. | Devices and methods for ablating cardiac tissue |
WO1999044519A2 (en) | 1998-03-02 | 1999-09-10 | Atrionix, Inc. | Tissue ablation system and method for forming long linear lesion |
US6685640B1 (en) * | 1998-03-30 | 2004-02-03 | Focus Surgery, Inc. | Ablation system |
US6527767B2 (en) | 1998-05-20 | 2003-03-04 | New England Medical Center | Cardiac ablation system and method for treatment of cardiac arrhythmias and transmyocardial revascularization |
US6837885B2 (en) * | 1998-05-22 | 2005-01-04 | Scimed Life Systems, Inc. | Surgical probe for supporting inflatable therapeutic devices in contact with tissue in or around body orifices and within tumors |
US6537248B2 (en) | 1998-07-07 | 2003-03-25 | Medtronic, Inc. | Helical needle apparatus for creating a virtual electrode used for the ablation of tissue |
US6706039B2 (en) | 1998-07-07 | 2004-03-16 | Medtronic, Inc. | Method and apparatus for creating a bi-polar virtual electrode used for the ablation of tissue |
US8308719B2 (en) | 1998-09-21 | 2012-11-13 | St. Jude Medical, Atrial Fibrillation Division, Inc. | Apparatus and method for ablating tissue |
US7044134B2 (en) | 1999-11-08 | 2006-05-16 | Ev3 Sunnyvale, Inc | Method of implanting a device in the left atrial appendage |
US7128073B1 (en) | 1998-11-06 | 2006-10-31 | Ev3 Endovascular, Inc. | Method and device for left atrial appendage occlusion |
US20070066972A1 (en) * | 2001-11-29 | 2007-03-22 | Medwaves, Inc. | Ablation catheter apparatus with one or more electrodes |
US7004938B2 (en) * | 2001-11-29 | 2006-02-28 | Medwaves, Inc. | Radio-frequency-based catheter system with improved deflection and steering mechanisms |
US6592577B2 (en) | 1999-01-25 | 2003-07-15 | Cryocath Technologies Inc. | Cooling system |
US7147633B2 (en) | 1999-06-02 | 2006-12-12 | Boston Scientific Scimed, Inc. | Method and apparatus for treatment of atrial fibrillation |
US6626899B2 (en) | 1999-06-25 | 2003-09-30 | Nidus Medical, Llc | Apparatus and methods for treating tissue |
SE514718C2 (en) * | 1999-06-29 | 2001-04-09 | Jan Otto Solem | Apparatus for treating defective closure of the mitral valve apparatus |
US6997951B2 (en) * | 1999-06-30 | 2006-02-14 | Edwards Lifesciences Ag | Method and device for treatment of mitral insufficiency |
US8540704B2 (en) | 1999-07-14 | 2013-09-24 | Cardiofocus, Inc. | Guided cardiac ablation catheters |
US9033961B2 (en) | 1999-07-14 | 2015-05-19 | Cardiofocus, Inc. | Cardiac ablation catheters for forming overlapping lesions |
US7935108B2 (en) | 1999-07-14 | 2011-05-03 | Cardiofocus, Inc. | Deflectable sheath catheters |
US8900219B2 (en) | 1999-07-14 | 2014-12-02 | Cardiofocus, Inc. | System and method for visualizing tissue during ablation procedures |
US20070282324A1 (en) * | 1999-07-19 | 2007-12-06 | Matthias Vaska | Apparatus and method for diagnosis and therapy of electrophysiological disease |
WO2001005306A1 (en) | 1999-07-19 | 2001-01-25 | Epicor, Inc. | Apparatus and method for ablating tissue |
US10307147B2 (en) | 1999-08-09 | 2019-06-04 | Edwards Lifesciences Corporation | System for improving cardiac function by sealing a partitioning membrane within a ventricle |
US7582051B2 (en) | 2005-06-10 | 2009-09-01 | Cardiokinetix, Inc. | Peripheral seal for a ventricular partitioning device |
US8529430B2 (en) | 2002-08-01 | 2013-09-10 | Cardiokinetix, Inc. | Therapeutic methods and devices following myocardial infarction |
US8388672B2 (en) | 1999-08-09 | 2013-03-05 | Cardiokinetix, Inc. | System for improving cardiac function by sealing a partitioning membrane within a ventricle |
US8246671B2 (en) | 1999-08-09 | 2012-08-21 | Cardiokinetix, Inc. | Retrievable cardiac devices |
US7674222B2 (en) | 1999-08-09 | 2010-03-09 | Cardiokinetix, Inc. | Cardiac device and methods of use thereof |
US8257428B2 (en) | 1999-08-09 | 2012-09-04 | Cardiokinetix, Inc. | System for improving cardiac function |
US7303526B2 (en) * | 1999-08-09 | 2007-12-04 | Cardiokinetix, Inc. | Device for improving cardiac function |
US7887477B2 (en) | 1999-08-09 | 2011-02-15 | Cardiokinetix, Inc. | Method of improving cardiac function using a porous membrane |
US9694121B2 (en) | 1999-08-09 | 2017-07-04 | Cardiokinetix, Inc. | Systems and methods for improving cardiac function |
US6852120B1 (en) * | 1999-08-10 | 2005-02-08 | Biosense Webster, Inc | Irrigation probe for ablation during open heart surgery |
US6575966B2 (en) * | 1999-08-23 | 2003-06-10 | Cryocath Technologies Inc. | Endovascular cryotreatment catheter |
US20040167503A1 (en) * | 1999-08-25 | 2004-08-26 | Cardiofocus, Inc. | Malleable surgical ablation instruments |
US20040147911A1 (en) * | 1999-08-25 | 2004-07-29 | Cardiofocus, Inc. | Surgical ablation instruments for forming an encircling lesion |
US6231561B1 (en) | 1999-09-20 | 2001-05-15 | Appriva Medical, Inc. | Method and apparatus for closing a body lumen |
US6689150B1 (en) | 1999-10-27 | 2004-02-10 | Atritech, Inc. | Filter apparatus for ostium of left atrial appendage |
US6551303B1 (en) | 1999-10-27 | 2003-04-22 | Atritech, Inc. | Barrier device for ostium of left atrial appendage |
EP1229845A2 (en) * | 1999-11-05 | 2002-08-14 | Microheart, Inc. | Method and apparatus for demand injury in stimulating angiogenesis |
US6748258B1 (en) * | 1999-11-05 | 2004-06-08 | Scimed Life Systems, Inc. | Method and devices for heart treatment |
US6676679B1 (en) | 1999-11-05 | 2004-01-13 | Boston Scientific Corporation | Method and apparatus for recurrent demand injury in stimulating angiogenesis |
US6542781B1 (en) | 1999-11-22 | 2003-04-01 | Scimed Life Systems, Inc. | Loop structures for supporting diagnostic and therapeutic elements in contact with body tissue |
US6529756B1 (en) | 1999-11-22 | 2003-03-04 | Scimed Life Systems, Inc. | Apparatus for mapping and coagulating soft tissue in or around body orifices |
US7706882B2 (en) | 2000-01-19 | 2010-04-27 | Medtronic, Inc. | Methods of using high intensity focused ultrasound to form an ablated tissue area |
US8241274B2 (en) | 2000-01-19 | 2012-08-14 | Medtronic, Inc. | Method for guiding a medical device |
US8221402B2 (en) | 2000-01-19 | 2012-07-17 | Medtronic, Inc. | Method for guiding a medical device |
US6872226B2 (en) * | 2001-01-29 | 2005-03-29 | 3F Therapeutics, Inc. | Method of cutting material for use in implantable medical device |
US6402781B1 (en) * | 2000-01-31 | 2002-06-11 | Mitralife | Percutaneous mitral annuloplasty and cardiac reinforcement |
US7507252B2 (en) | 2000-01-31 | 2009-03-24 | Edwards Lifesciences Ag | Adjustable transluminal annuloplasty system |
US8048070B2 (en) | 2000-03-06 | 2011-11-01 | Salient Surgical Technologies, Inc. | Fluid-assisted medical devices, systems and methods |
WO2003024349A1 (en) | 2001-09-05 | 2003-03-27 | Tissuelink Medical, Inc. | Fluid-assisted medical devices, systems and methods |
EP1267729A2 (en) * | 2000-03-23 | 2003-01-02 | SciMed Life Systems, Inc. | Pressure sensor for therapeutic delivery device and method |
US6926712B2 (en) | 2000-03-24 | 2005-08-09 | Boston Scientific Scimed, Inc. | Clamp having at least one malleable clamp member and surgical method employing the same |
US6692491B1 (en) | 2000-03-24 | 2004-02-17 | Scimed Life Systems, Inc. | Surgical methods and apparatus for positioning a diagnostic or therapeutic element around one or more pulmonary veins or other body structures |
US7214223B2 (en) * | 2000-03-24 | 2007-05-08 | Boston Scientific Scimed, Inc. | Photoatherolytic catheter apparatus and method |
US20020107514A1 (en) * | 2000-04-27 | 2002-08-08 | Hooven Michael D. | Transmural ablation device with parallel jaws |
WO2001082811A1 (en) * | 2000-04-27 | 2001-11-08 | Medtronic, Inc. | System and method for assessing transmurality of ablation lesions |
US6546935B2 (en) | 2000-04-27 | 2003-04-15 | Atricure, Inc. | Method for transmural ablation |
EP1278471B1 (en) | 2000-04-27 | 2005-06-15 | Medtronic, Inc. | Vibration sensitive ablation apparatus |
US6558382B2 (en) * | 2000-04-27 | 2003-05-06 | Medtronic, Inc. | Suction stabilized epicardial ablation devices |
US6514250B1 (en) * | 2000-04-27 | 2003-02-04 | Medtronic, Inc. | Suction stabilized epicardial ablation devices |
US20040138651A1 (en) * | 2000-05-03 | 2004-07-15 | Grabek James R. | Pericardial maze procedure |
US6511500B1 (en) | 2000-06-06 | 2003-01-28 | Marc Mounir Rahme | Use of autonomic nervous system neurotransmitters inhibition and atrial parasympathetic fibers ablation for the treatment of atrial arrhythmias and to preserve drug effects |
EP1289439B1 (en) | 2000-06-13 | 2005-03-16 | Atrionix, Inc. | Surgical ablation probe for forming a circumferential lesion |
US7588554B2 (en) | 2000-06-26 | 2009-09-15 | Boston Scientific Scimed, Inc. | Method and apparatus for treating ischemic tissue |
US20020068885A1 (en) | 2000-07-13 | 2002-06-06 | Harhen Edward Paul | Energy application with inflatable annular lens |
WO2002005868A2 (en) | 2000-07-13 | 2002-01-24 | Transurgical, Inc. | Thermal treatment methods and apparatus with focused energy application |
US20060030881A1 (en) | 2004-08-05 | 2006-02-09 | Cardiokinetix, Inc. | Ventricular partitioning device |
US9332992B2 (en) | 2004-08-05 | 2016-05-10 | Cardiokinetix, Inc. | Method for making a laminar ventricular partitioning device |
US9332993B2 (en) | 2004-08-05 | 2016-05-10 | Cardiokinetix, Inc. | Devices and methods for delivering an endocardial device |
US10064696B2 (en) | 2000-08-09 | 2018-09-04 | Edwards Lifesciences Corporation | Devices and methods for delivering an endocardial device |
US7762943B2 (en) | 2004-03-03 | 2010-07-27 | Cardiokinetix, Inc. | Inflatable ventricular partitioning device |
US7862500B2 (en) | 2002-08-01 | 2011-01-04 | Cardiokinetix, Inc. | Multiple partitioning devices for heart treatment |
US7399271B2 (en) | 2004-01-09 | 2008-07-15 | Cardiokinetix, Inc. | Ventricular partitioning device |
US8398537B2 (en) | 2005-06-10 | 2013-03-19 | Cardiokinetix, Inc. | Peripheral seal for a ventricular partitioning device |
US9078660B2 (en) | 2000-08-09 | 2015-07-14 | Cardiokinetix, Inc. | Devices and methods for delivering an endocardial device |
WO2002017809A1 (en) * | 2000-08-29 | 2002-03-07 | Kaplan Aaron V | Methods and apparatus for transpericardial left atrial appendage closure |
EP1339311A4 (en) * | 2000-09-19 | 2008-04-30 | Focus Surgery Inc | Tissue treatment method and apparatus |
US6926669B1 (en) | 2000-10-10 | 2005-08-09 | Medtronic, Inc. | Heart wall ablation/mapping catheter and method |
US6916306B1 (en) | 2000-11-10 | 2005-07-12 | Boston Scientific Scimed, Inc. | Steerable loop structures for supporting diagnostic and therapeutic elements in contact with body tissue |
US7785323B2 (en) | 2000-12-04 | 2010-08-31 | Boston Scientific Scimed, Inc. | Loop structure including inflatable therapeutic device |
US7740623B2 (en) | 2001-01-13 | 2010-06-22 | Medtronic, Inc. | Devices and methods for interstitial injection of biologic agents into tissue |
US20040138621A1 (en) | 2003-01-14 | 2004-07-15 | Jahns Scott E. | Devices and methods for interstitial injection of biologic agents into tissue |
US7510576B2 (en) | 2001-01-30 | 2009-03-31 | Edwards Lifesciences Ag | Transluminal mitral annuloplasty |
US6672312B2 (en) * | 2001-01-31 | 2004-01-06 | Transurgical, Inc. | Pulmonary vein ablation with myocardial tissue locating |
DE60224650T2 (en) | 2001-03-14 | 2008-12-24 | Boston Scientific Scimed, Inc., Marple Grove | Method and device for the treatment of atrial fibrillation |
US6743225B2 (en) * | 2001-03-27 | 2004-06-01 | Uab Research Foundation | Electrophysiologic measure of endpoints for ablation lesions created in fibrillating substrates |
JP4453801B2 (en) * | 2001-04-20 | 2010-04-21 | パワー メディカル インターベンションズ, エルエルシー | Bipolar or ultrasonic surgical device |
WO2002085192A2 (en) * | 2001-04-23 | 2002-10-31 | Transurgical, Inc. | Improvements in ablation therapy |
US6699240B2 (en) * | 2001-04-26 | 2004-03-02 | Medtronic, Inc. | Method and apparatus for tissue ablation |
US6663627B2 (en) | 2001-04-26 | 2003-12-16 | Medtronic, Inc. | Ablation system and method of use |
US6807968B2 (en) | 2001-04-26 | 2004-10-26 | Medtronic, Inc. | Method and system for treatment of atrial tachyarrhythmias |
US7959626B2 (en) | 2001-04-26 | 2011-06-14 | Medtronic, Inc. | Transmural ablation systems and methods |
US6972016B2 (en) * | 2001-05-01 | 2005-12-06 | Cardima, Inc. | Helically shaped electrophysiology catheter |
US6771996B2 (en) | 2001-05-24 | 2004-08-03 | Cardiac Pacemakers, Inc. | Ablation and high-resolution mapping catheter system for pulmonary vein foci elimination |
US6767346B2 (en) | 2001-09-20 | 2004-07-27 | Endocare, Inc. | Cryosurgical probe with bellows shaft |
US6936045B2 (en) * | 2001-09-20 | 2005-08-30 | Endocare, Inc. | Malleable cryosurgical probe |
CA2461217A1 (en) * | 2001-09-27 | 2003-04-03 | Roni Zvuloni | Cryoplasty apparatus and method |
WO2003026476A2 (en) * | 2001-09-27 | 2003-04-03 | Galil Medical Ltd. | Apparatus and method for cryosurgical treatment of tumors of the breast |
US6695838B2 (en) | 2001-09-28 | 2004-02-24 | Ethicon, Inc. | System and method for performing cardiac tissue ablation |
US20030065318A1 (en) * | 2001-09-28 | 2003-04-03 | Rajesh Pendekanti | Method and tool for epicardial ablation around pulmonary vein |
US6907297B2 (en) | 2001-09-28 | 2005-06-14 | Ethicon, Inc. | Expandable intracardiac return electrode and method of use |
US6652518B2 (en) | 2001-09-28 | 2003-11-25 | Ethicon, Inc. | Transmural ablation tool and method |
CA2460501A1 (en) * | 2001-09-28 | 2003-04-10 | Institut De Cardiologie De Montreal | Method for identification and visualization of atrial tissue |
US6955640B2 (en) * | 2001-09-28 | 2005-10-18 | Cardiac Pacemakers, Inc. | Brachytherapy for arrhythmias |
US6585733B2 (en) * | 2001-09-28 | 2003-07-01 | Ethicon, Inc. | Surgical treatment for atrial fibrillation using radiofrequency technology |
US20030065327A1 (en) * | 2001-09-28 | 2003-04-03 | Ethicon, Inc. | Biopolar ablation electrodes and method of use |
US7285116B2 (en) * | 2004-05-15 | 2007-10-23 | Irvine Biomedical Inc. | Non-contact tissue ablation device and methods thereof |
US8974446B2 (en) * | 2001-10-11 | 2015-03-10 | St. Jude Medical, Inc. | Ultrasound ablation apparatus with discrete staggered ablation zones |
US7776025B2 (en) * | 2001-10-29 | 2010-08-17 | Edwards Lifesciences Corporation | Method for providing medicament to tissue |
US20030088240A1 (en) * | 2001-11-02 | 2003-05-08 | Vahid Saadat | Methods and apparatus for cryo-therapy |
US7785324B2 (en) | 2005-02-25 | 2010-08-31 | Endoscopic Technologies, Inc. (Estech) | Clamp based lesion formation apparatus and methods configured to protect non-target tissue |
US7749157B2 (en) * | 2001-12-04 | 2010-07-06 | Estech, Inc. (Endoscopic Technologies, Inc.) | Methods and devices for minimally invasive cardiac surgery for atrial fibrillation |
US9072522B2 (en) * | 2001-12-04 | 2015-07-07 | Atricure, Inc. | Adjustable clamp systems and methods |
US7591818B2 (en) * | 2001-12-04 | 2009-09-22 | Endoscopic Technologies, Inc. | Cardiac ablation devices and methods |
US7399300B2 (en) * | 2001-12-04 | 2008-07-15 | Endoscopic Technologies, Inc. | Cardiac ablation devices and methods |
US7753908B2 (en) | 2002-02-19 | 2010-07-13 | Endoscopic Technologies, Inc. (Estech) | Apparatus for securing an electrophysiology probe to a clamp |
US20090281541A1 (en) * | 2008-05-09 | 2009-11-12 | Estech, Inc. | Conduction block systems and methods |
US7226448B2 (en) | 2001-12-04 | 2007-06-05 | Estech, Inc. (Endoscopic Technologies, Inc.) | Cardiac treatment devices and methods |
US6656175B2 (en) | 2001-12-11 | 2003-12-02 | Medtronic, Inc. | Method and system for treatment of atrial tachyarrhythmias |
SE524709C2 (en) * | 2002-01-11 | 2004-09-21 | Edwards Lifesciences Ag | Device for delayed reshaping of a heart vessel and a heart valve |
WO2003055417A1 (en) | 2001-12-28 | 2003-07-10 | Edwards Lifesciences Ag | Delayed memory device |
US7479139B2 (en) * | 2002-01-04 | 2009-01-20 | Galil Medical Ltd. | Apparatus and method for protecting tissues during cryoablation |
ATE332107T1 (en) * | 2002-01-16 | 2006-07-15 | John W Lehmann | CRYOSURGICAL CATHETER |
US7967816B2 (en) | 2002-01-25 | 2011-06-28 | Medtronic, Inc. | Fluid-assisted electrosurgical instrument with shapeable electrode |
US20030181942A1 (en) | 2002-01-25 | 2003-09-25 | Sutton Gregg S. | Atrial appendage blood filtration systems |
US20070293855A1 (en) * | 2002-02-15 | 2007-12-20 | Sliwa John W Jr | Methods and devices for ablation |
US6932816B2 (en) | 2002-02-19 | 2005-08-23 | Boston Scientific Scimed, Inc. | Apparatus for converting a clamp into an electrophysiology device |
US7756583B2 (en) | 2002-04-08 | 2010-07-13 | Ardian, Inc. | Methods and apparatus for intravascularly-induced neuromodulation |
US8347891B2 (en) | 2002-04-08 | 2013-01-08 | Medtronic Ardian Luxembourg S.A.R.L. | Methods and apparatus for performing a non-continuous circumferential treatment of a body lumen |
DE10218426A1 (en) * | 2002-04-24 | 2003-11-06 | Biotronik Mess & Therapieg | Ablation device for cardiac tissue, in particular for producing linear lesions between two vascular orifices in the heart |
US7294143B2 (en) | 2002-05-16 | 2007-11-13 | Medtronic, Inc. | Device and method for ablation of cardiac tissue |
US7118566B2 (en) | 2002-05-16 | 2006-10-10 | Medtronic, Inc. | Device and method for needle-less interstitial injection of fluid for ablation of cardiac tissue |
US6893442B2 (en) * | 2002-06-14 | 2005-05-17 | Ablatrics, Inc. | Vacuum coagulation probe for atrial fibrillation treatment |
US9439714B2 (en) | 2003-04-29 | 2016-09-13 | Atricure, Inc. | Vacuum coagulation probes |
US8235990B2 (en) | 2002-06-14 | 2012-08-07 | Ncontact Surgical, Inc. | Vacuum coagulation probes |
US7572257B2 (en) | 2002-06-14 | 2009-08-11 | Ncontact Surgical, Inc. | Vacuum coagulation and dissection probes |
US7063698B2 (en) | 2002-06-14 | 2006-06-20 | Ncontact Surgical, Inc. | Vacuum coagulation probes |
US20040082859A1 (en) | 2002-07-01 | 2004-04-29 | Alan Schaer | Method and apparatus employing ultrasound energy to treat body sphincters |
US7291161B2 (en) * | 2002-10-02 | 2007-11-06 | Atricure, Inc. | Articulated clamping member |
US7087064B1 (en) | 2002-10-15 | 2006-08-08 | Advanced Cardiovascular Systems, Inc. | Apparatuses and methods for heart valve repair |
US7083620B2 (en) | 2002-10-30 | 2006-08-01 | Medtronic, Inc. | Electrosurgical hemostat |
US7981152B1 (en) | 2004-12-10 | 2011-07-19 | Advanced Cardiovascular Systems, Inc. | Vascular delivery system for accessing and delivering devices into coronary sinus and other vascular sites |
US9149602B2 (en) | 2005-04-22 | 2015-10-06 | Advanced Cardiovascular Systems, Inc. | Dual needle delivery system |
US7331972B1 (en) | 2002-11-15 | 2008-02-19 | Abbott Cardiovascular Systems Inc. | Heart valve chord cutter |
US7404824B1 (en) | 2002-11-15 | 2008-07-29 | Advanced Cardiovascular Systems, Inc. | Valve aptation assist device |
US7335213B1 (en) | 2002-11-15 | 2008-02-26 | Abbott Cardiovascular Systems Inc. | Apparatus and methods for heart valve repair |
US7485143B2 (en) * | 2002-11-15 | 2009-02-03 | Abbott Cardiovascular Systems Inc. | Apparatuses and methods for heart valve repair |
US8187324B2 (en) | 2002-11-15 | 2012-05-29 | Advanced Cardiovascular Systems, Inc. | Telescoping apparatus for delivering and adjusting a medical device in a vessel |
US7682305B2 (en) * | 2002-12-06 | 2010-03-23 | Endoscopic Technologies, Inc. | Methods and devices for cardiac surgery |
US6893433B2 (en) * | 2002-12-11 | 2005-05-17 | Cryocor, Inc. | System and method for performing a single step cryoablation |
US7491212B2 (en) * | 2003-02-19 | 2009-02-17 | Smith & Nephew, Inc. | Transmitting an actuating force along a curved instrument |
CN1764419A (en) | 2003-02-20 | 2006-04-26 | 普罗里森姆股份有限公司 | Cardiac ablation devices |
US20040167466A1 (en) * | 2003-02-21 | 2004-08-26 | Drasler William J. | Delivering cooled fluid to sites inside the body |
EP1605866B1 (en) | 2003-03-03 | 2016-07-06 | Syntach AG | Electrical conduction block implant device |
US20040175893A1 (en) * | 2003-03-07 | 2004-09-09 | Applied Materials, Inc. | Apparatuses and methods for forming a substantially facet-free epitaxial film |
US8187288B2 (en) * | 2003-03-10 | 2012-05-29 | Boston Scientific Scimed, Inc. | Re-shapeable medical device |
US7186251B2 (en) * | 2003-03-27 | 2007-03-06 | Cierra, Inc. | Energy based devices and methods for treatment of patent foramen ovale |
US6905493B2 (en) * | 2003-04-01 | 2005-06-14 | Cryocor, Inc. | Mechanically extended spiral cryotip for a cryoablation catheter |
US20040199154A1 (en) * | 2003-04-02 | 2004-10-07 | Cryocath Technologies Inc. | Device for tissue ablation |
US20040204705A1 (en) | 2003-04-10 | 2004-10-14 | Scimed Life Systems, Inc. | Cryotreatment devices and methods of forming conduction blocks |
US7288092B2 (en) | 2003-04-23 | 2007-10-30 | Atricure, Inc. | Method and apparatus for ablating cardiac tissue with guide facility |
KR100466866B1 (en) * | 2003-04-24 | 2005-01-24 | 전명기 | Electrode for radiofrequency tissue ablation |
US7497857B2 (en) | 2003-04-29 | 2009-03-03 | Medtronic, Inc. | Endocardial dispersive electrode for use with a monopolar RF ablation pen |
EP1631233A2 (en) * | 2003-05-01 | 2006-03-08 | Sinus Rhythm Technologies, Inc. | Methods and devices for creating electrical block at specific targeted sites in cardia tissue |
US7361171B2 (en) | 2003-05-20 | 2008-04-22 | Raydiance, Inc. | Man-portable optical ablation system |
US8182417B2 (en) | 2004-11-24 | 2012-05-22 | Intuitive Surgical Operations, Inc. | Articulating mechanism components and system for easy assembly and disassembly |
US7410483B2 (en) | 2003-05-23 | 2008-08-12 | Novare Surgical Systems, Inc. | Hand-actuated device for remote manipulation of a grasping tool |
US7090637B2 (en) * | 2003-05-23 | 2006-08-15 | Novare Surgical Systems, Inc. | Articulating mechanism for remote manipulation of a surgical or diagnostic tool |
US8562640B2 (en) | 2007-04-16 | 2013-10-22 | Intuitive Surgical Operations, Inc. | Tool with multi-state ratcheted end effector |
US8100824B2 (en) | 2003-05-23 | 2012-01-24 | Intuitive Surgical Operations, Inc. | Tool with articulation lock |
US20040267338A1 (en) * | 2003-06-25 | 2004-12-30 | Kent Harrison | Targeted tissue cooling within a body |
US7540853B2 (en) * | 2003-06-30 | 2009-06-02 | Cardiac Pacemakers, Inc. | Method and apparatus for diverting blood flow during ablation procedures |
US7344543B2 (en) * | 2003-07-01 | 2008-03-18 | Medtronic, Inc. | Method and apparatus for epicardial left atrial appendage isolation in patients with atrial fibrillation |
US7794454B2 (en) * | 2003-07-11 | 2010-09-14 | Medtronic Cryocath Lp | Method and device for epicardial ablation |
US7678104B2 (en) * | 2003-07-17 | 2010-03-16 | Biosense Webster, Inc. | Ultrasound ablation catheter and method for its use |
WO2005018507A2 (en) * | 2003-07-18 | 2005-03-03 | Ev3 Santa Rosa, Inc. | Remotely activated mitral annuloplasty system and methods |
US10182734B2 (en) * | 2003-07-18 | 2019-01-22 | Biosense Webster, Inc. | Enhanced ablation and mapping catheter and method for treating atrial fibrillation |
US20050035097A1 (en) * | 2003-08-11 | 2005-02-17 | Richard Stoltz | Altering the emission of an ablation beam for safety or control |
US8173929B1 (en) | 2003-08-11 | 2012-05-08 | Raydiance, Inc. | Methods and systems for trimming circuits |
US8921733B2 (en) | 2003-08-11 | 2014-12-30 | Raydiance, Inc. | Methods and systems for trimming circuits |
US9022037B2 (en) | 2003-08-11 | 2015-05-05 | Raydiance, Inc. | Laser ablation method and apparatus having a feedback loop and control unit |
EP3045136B1 (en) | 2003-09-12 | 2021-02-24 | Vessix Vascular, Inc. | Selectable eccentric remodeling and/or ablation of atherosclerotic material |
US7438714B2 (en) * | 2003-09-12 | 2008-10-21 | Boston Scientific Scimed, Inc. | Vacuum-based catheter stabilizer |
US7998112B2 (en) | 2003-09-30 | 2011-08-16 | Abbott Cardiovascular Systems Inc. | Deflectable catheter assembly and method of making same |
US20050090817A1 (en) * | 2003-10-22 | 2005-04-28 | Scimed Life Systems, Inc. | Bendable endoscopic bipolar device |
US7238180B2 (en) | 2003-10-30 | 2007-07-03 | Medicalcv Inc. | Guided ablation with end-fire fiber |
WO2005044124A1 (en) * | 2003-10-30 | 2005-05-19 | Medical Cv, Inc. | Apparatus and method for laser treatment |
US7238179B2 (en) * | 2003-10-30 | 2007-07-03 | Medical Cv, Inc. | Apparatus and method for guided ablation treatment |
US7232437B2 (en) | 2003-10-30 | 2007-06-19 | Medical Cv, Inc. | Assessment of lesion transmurality |
SE526861C2 (en) | 2003-11-17 | 2005-11-15 | Syntach Ag | Tissue lesion creation device and a set of devices for the treatment of cardiac arrhythmia disorders |
US7326195B2 (en) * | 2003-11-18 | 2008-02-05 | Boston Scientific Scimed, Inc. | Targeted cooling of tissue within a body |
US8002770B2 (en) | 2003-12-02 | 2011-08-23 | Endoscopic Technologies, Inc. (Estech) | Clamp based methods and apparatus for forming lesions in tissue and confirming whether a therapeutic lesion has been formed |
US20050223494A1 (en) * | 2004-02-20 | 2005-10-13 | Stm International | Medical equipment handling device |
US9398967B2 (en) | 2004-03-02 | 2016-07-26 | Syntach Ag | Electrical conduction block implant device |
US7976539B2 (en) | 2004-03-05 | 2011-07-12 | Hansen Medical, Inc. | System and method for denaturing and fixing collagenous tissue |
US8491636B2 (en) | 2004-03-23 | 2013-07-23 | Medtronic Cryopath LP | Method and apparatus for inflating and deflating balloon catheters |
US9555223B2 (en) | 2004-03-23 | 2017-01-31 | Medtronic Cryocath Lp | Method and apparatus for inflating and deflating balloon catheters |
US7727228B2 (en) | 2004-03-23 | 2010-06-01 | Medtronic Cryocath Lp | Method and apparatus for inflating and deflating balloon catheters |
US7322973B2 (en) * | 2004-03-31 | 2008-01-29 | Cryocath Technologies Inc. | Method and apparatus for preventing atrial fibrillation |
US7993397B2 (en) | 2004-04-05 | 2011-08-09 | Edwards Lifesciences Ag | Remotely adjustable coronary sinus implant |
US7582083B2 (en) | 2004-05-10 | 2009-09-01 | Boston Scientific Scimed, Inc. | Probe based low temperature lesion formation apparatus, systems and methods |
US7288088B2 (en) * | 2004-05-10 | 2007-10-30 | Boston Scientific Scimed, Inc. | Clamp based low temperature lesion formation apparatus, systems and methods |
US7291142B2 (en) * | 2004-05-10 | 2007-11-06 | Boston Scientific Scimed, Inc. | Low temperature lesion formation apparatus, systems and methods |
US8333764B2 (en) | 2004-05-12 | 2012-12-18 | Medtronic, Inc. | Device and method for determining tissue thickness and creating cardiac ablation lesions |
ATE399579T1 (en) | 2004-05-14 | 2008-07-15 | Medtronic Inc | SYSTEM FOR USING HIGH-INTENSITY FOCUSED ULTRASOUND TO FORM AN ABLATED AREA OF TISSUE |
US20050261672A1 (en) * | 2004-05-18 | 2005-11-24 | Mark Deem | Systems and methods for selective denervation of heart dysrhythmias |
WO2005120375A2 (en) * | 2004-06-02 | 2005-12-22 | Medtronic, Inc. | Loop ablation apparatus and method |
WO2005120377A1 (en) | 2004-06-02 | 2005-12-22 | Medtronic, Inc. | Clamping ablation tool |
EP1750608B1 (en) | 2004-06-02 | 2012-10-03 | Medtronic, Inc. | Ablation device with jaws |
DE602005021096D1 (en) | 2004-06-02 | 2010-06-17 | Medtronic Inc | COMPOUND BIPOLAR ABLATION DEVICE |
US7828808B2 (en) | 2004-06-07 | 2010-11-09 | Novare Surgical Systems, Inc. | Link systems and articulation mechanisms for remote manipulation of surgical or diagnostic tools |
US7678117B2 (en) | 2004-06-07 | 2010-03-16 | Novare Surgical Systems, Inc. | Articulating mechanism with flex-hinged links |
US8926635B2 (en) | 2004-06-18 | 2015-01-06 | Medtronic, Inc. | Methods and devices for occlusion of an atrial appendage |
US8663245B2 (en) | 2004-06-18 | 2014-03-04 | Medtronic, Inc. | Device for occlusion of a left atrial appendage |
US8409219B2 (en) | 2004-06-18 | 2013-04-02 | Medtronic, Inc. | Method and system for placement of electrical lead inside heart |
US7367975B2 (en) * | 2004-06-21 | 2008-05-06 | Cierra, Inc. | Energy based devices and methods for treatment of anatomic tissue defects |
US8920414B2 (en) | 2004-09-10 | 2014-12-30 | Vessix Vascular, Inc. | Tuned RF energy and electrical tissue characterization for selective treatment of target tissues |
US9713730B2 (en) | 2004-09-10 | 2017-07-25 | Boston Scientific Scimed, Inc. | Apparatus and method for treatment of in-stent restenosis |
US8396548B2 (en) | 2008-11-14 | 2013-03-12 | Vessix Vascular, Inc. | Selective drug delivery in a lumen |
US8876820B2 (en) * | 2004-10-20 | 2014-11-04 | Atricure, Inc. | Surgical clamp |
US7833221B2 (en) * | 2004-10-22 | 2010-11-16 | Ethicon Endo-Surgery, Inc. | System and method for treatment of tissue using the tissue as a fiducial |
WO2006052940A2 (en) * | 2004-11-05 | 2006-05-18 | Asthmatx, Inc. | Medical device with procedure improvement features |
US7949407B2 (en) | 2004-11-05 | 2011-05-24 | Asthmatx, Inc. | Energy delivery devices and methods |
US7785252B2 (en) * | 2004-11-23 | 2010-08-31 | Novare Surgical Systems, Inc. | Articulating sheath for flexible instruments |
US9700334B2 (en) | 2004-11-23 | 2017-07-11 | Intuitive Surgical Operations, Inc. | Articulating mechanisms and link systems with torque transmission in remote manipulation of instruments and tools |
US7211110B2 (en) | 2004-12-09 | 2007-05-01 | Edwards Lifesciences Corporation | Diagnostic kit to assist with heart valve annulus adjustment |
US7727231B2 (en) | 2005-01-08 | 2010-06-01 | Boston Scientific Scimed, Inc. | Apparatus and methods for forming lesions in tissue and applying stimulation energy to tissue in which lesions are formed |
US20060155269A1 (en) * | 2005-01-12 | 2006-07-13 | Prorhythm, Inc. | Epicardial ablation using focused ultrasound |
US7828795B2 (en) * | 2005-01-18 | 2010-11-09 | Atricure, Inc. | Surgical ablation and pacing device |
US20060201130A1 (en) * | 2005-01-31 | 2006-09-14 | Danitz David J | Articulating mechanisms with joint assembly and manual handle for remote manipulation of instruments and tools |
US20080015569A1 (en) | 2005-02-02 | 2008-01-17 | Voyage Medical, Inc. | Methods and apparatus for treatment of atrial fibrillation |
US9510732B2 (en) | 2005-10-25 | 2016-12-06 | Intuitive Surgical Operations, Inc. | Methods and apparatus for efficient purging |
US7930016B1 (en) | 2005-02-02 | 2011-04-19 | Voyage Medical, Inc. | Tissue closure system |
US7860556B2 (en) | 2005-02-02 | 2010-12-28 | Voyage Medical, Inc. | Tissue imaging and extraction systems |
US11478152B2 (en) | 2005-02-02 | 2022-10-25 | Intuitive Surgical Operations, Inc. | Electrophysiology mapping and visualization system |
US7918787B2 (en) | 2005-02-02 | 2011-04-05 | Voyage Medical, Inc. | Tissue visualization and manipulation systems |
US8078266B2 (en) | 2005-10-25 | 2011-12-13 | Voyage Medical, Inc. | Flow reduction hood systems |
US8137333B2 (en) | 2005-10-25 | 2012-03-20 | Voyage Medical, Inc. | Delivery of biological compounds to ischemic and/or infarcted tissue |
US7860555B2 (en) | 2005-02-02 | 2010-12-28 | Voyage Medical, Inc. | Tissue visualization and manipulation system |
US8050746B2 (en) | 2005-02-02 | 2011-11-01 | Voyage Medical, Inc. | Tissue visualization device and method variations |
US10064540B2 (en) | 2005-02-02 | 2018-09-04 | Intuitive Surgical Operations, Inc. | Visualization apparatus for transseptal access |
US7862562B2 (en) * | 2005-02-25 | 2011-01-04 | Boston Scientific Scimed, Inc. | Wrap based lesion formation apparatus and methods configured to protect non-target tissue |
US20060235372A1 (en) * | 2005-04-06 | 2006-10-19 | Ward Jim L | Facilitating tools for cardiac tissue ablation |
US7740627B2 (en) * | 2005-04-29 | 2010-06-22 | Medtronic Cryocath Lp | Surgical method and apparatus for treating atrial fibrillation |
US7794455B2 (en) * | 2005-04-29 | 2010-09-14 | Medtronic Cryocath Lp | Wide area ablation of myocardial tissue |
US7500989B2 (en) * | 2005-06-03 | 2009-03-10 | Edwards Lifesciences Corp. | Devices and methods for percutaneous repair of the mitral valve via the coronary sinus |
US8135050B1 (en) | 2005-07-19 | 2012-03-13 | Raydiance, Inc. | Automated polarization correction |
US20070038297A1 (en) * | 2005-08-12 | 2007-02-15 | Bobo Donald E Jr | Medical implant with reinforcement mechanism |
US20080221673A1 (en) * | 2005-08-12 | 2008-09-11 | Donald Bobo | Medical implant with reinforcement mechanism |
US20070073280A1 (en) * | 2005-09-16 | 2007-03-29 | Medicalcv, Inc. | End-fire guided ablation |
US20070073281A1 (en) * | 2005-09-16 | 2007-03-29 | Medicalcv, Inc. | Guided ablation with motion control |
US7972359B2 (en) | 2005-09-16 | 2011-07-05 | Atritech, Inc. | Intracardiac cage and method of delivering same |
US7682304B2 (en) * | 2005-09-21 | 2010-03-23 | Medtronic, Inc. | Composite heart valve apparatus manufactured using techniques involving laser machining of tissue |
US20070073391A1 (en) * | 2005-09-28 | 2007-03-29 | Henry Bourang | System and method for delivering a mitral valve repair device |
US9808280B2 (en) * | 2005-10-12 | 2017-11-07 | Atricure, Inc. | Diaphragm entry for posterior surgical access |
US9561044B2 (en) * | 2005-10-12 | 2017-02-07 | Atricure, Inc. | Diaphragm entry for posterior surgical access |
US8211011B2 (en) | 2006-11-09 | 2012-07-03 | Ncontact Surgical, Inc. | Diaphragm entry for posterior surgical access |
US8721597B2 (en) * | 2006-11-09 | 2014-05-13 | Ncontact Surgical, Inc. | Diaphragm entry for posterior surgical access |
US8221310B2 (en) | 2005-10-25 | 2012-07-17 | Voyage Medical, Inc. | Tissue visualization device and method variations |
US7632308B2 (en) | 2005-11-23 | 2009-12-15 | Didier Loulmet | Methods, devices, and kits for treating mitral valve prolapse |
US20070173926A1 (en) * | 2005-12-09 | 2007-07-26 | Bobo Donald E Jr | Anchoring system for medical implant |
US20070135686A1 (en) * | 2005-12-14 | 2007-06-14 | Pruitt John C Jr | Tools and methods for epicardial access |
US8232687B2 (en) | 2006-04-26 | 2012-07-31 | Raydiance, Inc. | Intelligent laser interlock system |
US8189971B1 (en) | 2006-01-23 | 2012-05-29 | Raydiance, Inc. | Dispersion compensation in a chirped pulse amplification system |
US7444049B1 (en) | 2006-01-23 | 2008-10-28 | Raydiance, Inc. | Pulse stretcher and compressor including a multi-pass Bragg grating |
AU2007210011A1 (en) | 2006-01-27 | 2007-08-09 | Medtronic, Inc. | Device and system for surgical dissection and or guidance of other medical devices into body |
US20070185477A1 (en) * | 2006-02-07 | 2007-08-09 | Hooven Michael D | Removable Cryogenic Probe Appliance |
US7637946B2 (en) | 2006-02-09 | 2009-12-29 | Edwards Lifesciences Corporation | Coiled implant for mitral valve repair |
US20070198046A1 (en) * | 2006-02-17 | 2007-08-23 | Medicalcv, Inc. | Surgical visualization tool |
US7822347B1 (en) | 2006-03-28 | 2010-10-26 | Raydiance, Inc. | Active tuning of temporal dispersion in an ultrashort pulse laser system |
US7794387B2 (en) | 2006-04-26 | 2010-09-14 | Medtronic, Inc. | Methods and devices for stabilizing tissue |
US8019435B2 (en) | 2006-05-02 | 2011-09-13 | Boston Scientific Scimed, Inc. | Control of arterial smooth muscle tone |
US20100198065A1 (en) * | 2009-01-30 | 2010-08-05 | VyntronUS, Inc. | System and method for ultrasonically sensing and ablating tissue |
WO2007134258A2 (en) | 2006-05-12 | 2007-11-22 | Vytronus, Inc. | Device for ablating body tissue |
US10499937B2 (en) | 2006-05-19 | 2019-12-10 | Recor Medical, Inc. | Ablation device with optimized input power profile and method of using the same |
WO2007140331A2 (en) | 2006-05-25 | 2007-12-06 | Medtronic, Inc. | Methods of using high intensity focused ultrasound to form an ablated tissue area containing a plurality of lesions |
US8409244B2 (en) | 2007-04-16 | 2013-04-02 | Intuitive Surgical Operations, Inc. | Tool with end effector force limiter |
US7862554B2 (en) | 2007-04-16 | 2011-01-04 | Intuitive Surgical Operations, Inc. | Articulating tool with improved tension member system |
US9561045B2 (en) | 2006-06-13 | 2017-02-07 | Intuitive Surgical Operations, Inc. | Tool with rotation lock |
US20080009843A1 (en) * | 2006-06-14 | 2008-01-10 | De La Torre Ralph | Surgical ablation system with chest wall platform |
US9055906B2 (en) | 2006-06-14 | 2015-06-16 | Intuitive Surgical Operations, Inc. | In-vivo visualization systems |
US20070299435A1 (en) * | 2006-06-23 | 2007-12-27 | Crowe John E | Apparatus and method for ablating tissue |
US20080097476A1 (en) | 2006-09-01 | 2008-04-24 | Voyage Medical, Inc. | Precision control systems for tissue visualization and manipulation assemblies |
JP2010502313A (en) | 2006-09-01 | 2010-01-28 | ボエッジ メディカル, インコーポレイテッド | Method and apparatus for the treatment of atrial fibrillation |
US10004388B2 (en) | 2006-09-01 | 2018-06-26 | Intuitive Surgical Operations, Inc. | Coronary sinus cannulation |
US20080065205A1 (en) * | 2006-09-11 | 2008-03-13 | Duy Nguyen | Retrievable implant and method for treatment of mitral regurgitation |
AU2007310991B2 (en) | 2006-10-18 | 2013-06-20 | Boston Scientific Scimed, Inc. | System for inducing desirable temperature effects on body tissue |
ES2560006T3 (en) | 2006-10-18 | 2016-02-17 | Vessix Vascular, Inc. | Induction of desirable temperature effects on body tissue |
US10335131B2 (en) | 2006-10-23 | 2019-07-02 | Intuitive Surgical Operations, Inc. | Methods for preventing tissue migration |
US7955328B2 (en) * | 2006-11-10 | 2011-06-07 | Ethicon Endo-Surgery, Inc. | Tissue dissector and/or coagulator with a slit in an insulating tip to control the direction of energy |
US20080183036A1 (en) | 2006-12-18 | 2008-07-31 | Voyage Medical, Inc. | Systems and methods for unobstructed visualization and ablation |
US8131350B2 (en) | 2006-12-21 | 2012-03-06 | Voyage Medical, Inc. | Stabilization of visualization catheters |
US8758229B2 (en) | 2006-12-21 | 2014-06-24 | Intuitive Surgical Operations, Inc. | Axial visualization systems |
US20080161743A1 (en) * | 2006-12-28 | 2008-07-03 | Crowe John E | Ablation device having a piezoelectric pump |
US20080161705A1 (en) * | 2006-12-29 | 2008-07-03 | Podmore Jonathan L | Devices and methods for ablating near AV groove |
US10166070B2 (en) | 2007-01-02 | 2019-01-01 | Baylis Medical Company Inc. | Electrosurgical pericardial puncture |
US8308720B2 (en) * | 2007-01-02 | 2012-11-13 | Baylis Medical Company Inc. | Cardiac electrosurgery |
US8702692B2 (en) | 2007-01-02 | 2014-04-22 | Baylis Medical Company Inc. | Cardiac electrosurgery |
US9179932B2 (en) | 2007-01-02 | 2015-11-10 | Baylis Medical Company Inc. | Cardiac electrosurgery |
US7993338B2 (en) * | 2007-01-31 | 2011-08-09 | St. Jude Medical, Atrial Fibrillation Division, Inc. | Switching methods and apparatus |
US20100010302A1 (en) * | 2007-02-26 | 2010-01-14 | Vision-Sciences Inc. | Endoscopic reflector |
US20080255447A1 (en) * | 2007-04-16 | 2008-10-16 | Henry Bourang | Diagnostic catheter |
US9314298B2 (en) | 2007-04-17 | 2016-04-19 | St. Jude Medical, Atrial Fibrillation Divisions, Inc. | Vacuum-stabilized ablation system |
WO2008134457A1 (en) | 2007-04-27 | 2008-11-06 | Voyage Medical, Inc. | Complex shape steerable tissue visualization and manipulation catheter |
US8657805B2 (en) | 2007-05-08 | 2014-02-25 | Intuitive Surgical Operations, Inc. | Complex shape steerable tissue visualization and manipulation catheter |
EP3025636B1 (en) | 2007-05-11 | 2017-11-01 | Intuitive Surgical Operations, Inc. | Visual electrode ablation systems |
US8628522B2 (en) * | 2007-05-21 | 2014-01-14 | Estech, Inc. (Endoscopic Technologies, Inc.) | Cardiac ablation systems and methods |
US8100820B2 (en) | 2007-08-22 | 2012-01-24 | Edwards Lifesciences Corporation | Implantable device for treatment of ventricular dilation |
US8235985B2 (en) | 2007-08-31 | 2012-08-07 | Voyage Medical, Inc. | Visualization and ablation system variations |
CN101868190B (en) * | 2007-11-21 | 2012-12-12 | 恩多凯尔有限公司 | Expandable multi-tubular cryoprobe |
CN101868188B (en) * | 2007-11-21 | 2013-10-16 | 恩多凯尔有限公司 | Flexible multi-tubular cryoprobe |
US10136909B2 (en) * | 2007-12-20 | 2018-11-27 | Atricure, Inc. | Magnetic introducer systems and methods |
US8998892B2 (en) | 2007-12-21 | 2015-04-07 | Atricure, Inc. | Ablation device with cooled electrodes and methods of use |
US8353907B2 (en) | 2007-12-21 | 2013-01-15 | Atricure, Inc. | Ablation device with internally cooled electrodes |
EP2227174B1 (en) | 2007-12-28 | 2019-05-01 | Salient Surgical Technologies, Inc. | Fluid-assisted electrosurgical device |
US8617145B2 (en) | 2008-01-25 | 2013-12-31 | Intrepid Medical, Inc. | Methods of treating a cardiac arrhythmia by thoracoscopic production of a Cox maze III lesion set |
US8764745B2 (en) * | 2008-01-25 | 2014-07-01 | Medtronic ATS Medical, Inc. | Cryoprobe clamp having transmurality assessment window |
US8858609B2 (en) | 2008-02-07 | 2014-10-14 | Intuitive Surgical Operations, Inc. | Stent delivery under direct visualization |
JP5181791B2 (en) * | 2008-04-03 | 2013-04-10 | ソニー株式会社 | Voltage controlled variable frequency oscillation circuit and signal processing circuit |
US8858528B2 (en) | 2008-04-23 | 2014-10-14 | Ncontact Surgical, Inc. | Articulating cannula access device |
WO2009140359A2 (en) | 2008-05-13 | 2009-11-19 | Medtronic, Inc. | Tissue lesion evaluation |
US8133222B2 (en) | 2008-05-28 | 2012-03-13 | Medwaves, Inc. | Tissue ablation apparatus and method using ultrasonic imaging |
US8267951B2 (en) | 2008-06-12 | 2012-09-18 | Ncontact Surgical, Inc. | Dissecting cannula and methods of use thereof |
US9155588B2 (en) | 2008-06-13 | 2015-10-13 | Vytronus, Inc. | System and method for positioning an elongate member with respect to an anatomical structure |
US20110178514A1 (en) * | 2008-06-18 | 2011-07-21 | Alexander Levin | Cryosurgical Instrument Insulating System |
US9101735B2 (en) | 2008-07-07 | 2015-08-11 | Intuitive Surgical Operations, Inc. | Catheter control systems |
US10363057B2 (en) | 2008-07-18 | 2019-07-30 | Vytronus, Inc. | System and method for delivering energy to tissue |
US8125704B2 (en) | 2008-08-18 | 2012-02-28 | Raydiance, Inc. | Systems and methods for controlling a pulsed laser by combining laser signals |
US8465475B2 (en) | 2008-08-18 | 2013-06-18 | Intuitive Surgical Operations, Inc. | Instrument with multiple articulation locks |
US8845627B2 (en) * | 2008-08-22 | 2014-09-30 | Boston Scientific Scimed, Inc. | Regulating pressure to lower temperature in a cryotherapy balloon catheter |
US10182859B2 (en) | 2008-09-03 | 2019-01-22 | Endocare, Inc. | Medical device for the transport of subcooled cryogenic fluid through a linear heat exchanger |
WO2010028409A1 (en) * | 2008-09-03 | 2010-03-11 | Dobson, Melissa, K. | A cryogenic system and method of use |
US9408654B2 (en) | 2008-09-03 | 2016-08-09 | Endocare, Inc. | Modular pulsed pressure device for the transport of liquid cryogen to a cryoprobe |
US9089316B2 (en) | 2009-11-02 | 2015-07-28 | Endocare, Inc. | Cryogenic medical system |
US8333012B2 (en) | 2008-10-10 | 2012-12-18 | Voyage Medical, Inc. | Method of forming electrode placement and connection systems |
US8894643B2 (en) | 2008-10-10 | 2014-11-25 | Intuitive Surgical Operations, Inc. | Integral electrode placement and connection systems |
US9033885B2 (en) | 2008-10-30 | 2015-05-19 | Vytronus, Inc. | System and method for energy delivery to tissue while monitoring position, lesion depth, and wall motion |
US8414508B2 (en) | 2008-10-30 | 2013-04-09 | Vytronus, Inc. | System and method for delivery of energy to tissue while compensating for collateral tissue |
US9220924B2 (en) | 2008-10-30 | 2015-12-29 | Vytronus, Inc. | System and method for energy delivery to tissue while monitoring position, lesion depth, and wall motion |
US9192789B2 (en) | 2008-10-30 | 2015-11-24 | Vytronus, Inc. | System and method for anatomical mapping of tissue and planning ablation paths therein |
US11298568B2 (en) | 2008-10-30 | 2022-04-12 | Auris Health, Inc. | System and method for energy delivery to tissue while monitoring position, lesion depth, and wall motion |
US9468364B2 (en) | 2008-11-14 | 2016-10-18 | Intuitive Surgical Operations, Inc. | Intravascular catheter with hood and image processing systems |
JP5941281B2 (en) | 2008-11-17 | 2016-06-29 | バイトロナス, インコーポレイテッド | System and method for ablating body tissue |
WO2010056745A1 (en) | 2008-11-17 | 2010-05-20 | Minnow Medical, Inc. | Selective accumulation of energy with or without knowledge of tissue topography |
US8475379B2 (en) | 2008-11-17 | 2013-07-02 | Vytronus, Inc. | Systems and methods for ablating body tissue |
US9352174B2 (en) * | 2008-12-30 | 2016-05-31 | St. Jude Medical, Atrial Fibrillation Division, Inc. | Ablation system with blood leakage minimization and tissue protective capabilities |
WO2010080886A1 (en) | 2009-01-09 | 2010-07-15 | Recor Medical, Inc. | Methods and apparatus for treatment of mitral valve in insufficiency |
US9393023B2 (en) | 2009-01-13 | 2016-07-19 | Atricure, Inc. | Apparatus and methods for deploying a clip to occlude an anatomical structure |
US9254168B2 (en) | 2009-02-02 | 2016-02-09 | Medtronic Advanced Energy Llc | Electro-thermotherapy of tissue using penetrating microelectrode array |
EP2398416B1 (en) | 2009-02-23 | 2015-10-28 | Medtronic Advanced Energy LLC | Fluid-assisted electrosurgical device |
US8915908B2 (en) * | 2009-03-20 | 2014-12-23 | Atricure, Inc. | Cryogenic probe |
US8702703B2 (en) | 2009-05-12 | 2014-04-22 | Medtronic, Inc. | Sub-xiphoid ablation clamp and method of sub-xiphoid ablation |
US8430875B2 (en) | 2009-05-19 | 2013-04-30 | Estech, Inc. (Endoscopic Technologies, Inc.) | Magnetic navigation systems and methods |
US20100331838A1 (en) * | 2009-06-25 | 2010-12-30 | Estech, Inc. (Endoscopic Technologies, Inc.) | Transmurality clamp systems and methods |
WO2011008444A1 (en) | 2009-06-30 | 2011-01-20 | Boston Scientific Scimed, Inc. | Map and ablate open irrigated hybrid catheter |
EP2453821A1 (en) * | 2009-07-13 | 2012-05-23 | Boston Scientific Scimed, Inc. | Open-irrigated ablation catheter with turbulent flow |
US20110022078A1 (en) | 2009-07-23 | 2011-01-27 | Cameron Dale Hinman | Articulating mechanism |
US20110022041A1 (en) * | 2009-07-24 | 2011-01-27 | Frank Ingle | Systems and methods for titrating rf ablation |
US8442613B2 (en) | 2009-07-29 | 2013-05-14 | Boston Scientific Scimed, Inc | Mapping probe assembly with skived tube body frame |
US9572624B2 (en) | 2009-08-05 | 2017-02-21 | Atricure, Inc. | Bipolar belt systems and methods |
CN102497832B (en) | 2009-09-08 | 2015-09-09 | 显著外科技术公司 | For case assembly and the using method thereof of electro-surgical device, electrosurgical unit |
US10123821B2 (en) | 2009-09-10 | 2018-11-13 | Atricure, Inc. | Scope and magnetic introducer systems and methods |
WO2011034938A2 (en) * | 2009-09-15 | 2011-03-24 | Ceramoptec Industries, Inc. | Ablative/coagulative urological treatment device and method |
US8696653B2 (en) | 2009-10-02 | 2014-04-15 | Cardiofocus, Inc. | Cardiac ablation system with pulsed aiming light |
US8702688B2 (en) | 2009-10-06 | 2014-04-22 | Cardiofocus, Inc. | Cardiac ablation image analysis system and process |
US20110257563A1 (en) | 2009-10-26 | 2011-10-20 | Vytronus, Inc. | Methods and systems for ablating tissue |
WO2011056578A2 (en) | 2009-10-26 | 2011-05-12 | Cardiokinetix, Inc. | Ventricular volume reduction |
US20110184402A1 (en) * | 2009-11-02 | 2011-07-28 | Cpsi Biotech | Flexible Cryogenic Probe Tip |
EP2498706B1 (en) | 2009-11-13 | 2016-04-20 | St. Jude Medical, Inc. | Assembly of staggered ablation elements |
AU2010340025B2 (en) * | 2009-12-15 | 2014-11-20 | The Board Of Regents Of The University Of Nebraska | Sheath |
US11229479B2 (en) * | 2009-12-18 | 2022-01-25 | Atricure, Inc. | Adjustable clamp systems and methods |
US8926602B2 (en) * | 2010-01-28 | 2015-01-06 | Medtronic Cryocath Lp | Triple balloon catheter |
US8777849B2 (en) | 2010-02-12 | 2014-07-15 | Covidien Lp | Expandable thoracic access port |
US8574155B2 (en) * | 2010-02-12 | 2013-11-05 | Covidien Lp | Expandable surgical access port |
US8694071B2 (en) | 2010-02-12 | 2014-04-08 | Intuitive Surgical Operations, Inc. | Image stabilization techniques and methods |
US8579810B2 (en) | 2010-02-12 | 2013-11-12 | Covidien Lp | Expandable thoracic access port |
US8540628B2 (en) * | 2010-02-12 | 2013-09-24 | Covidien Lp | Expandable thoracic access port |
US20110208174A1 (en) * | 2010-02-23 | 2011-08-25 | Cpsi Biotech | Cryoclamp and method of use |
US9592090B2 (en) | 2010-03-11 | 2017-03-14 | Medtronic Advanced Energy Llc | Bipolar electrosurgical cutter with position insensitive return electrode contact |
US9814522B2 (en) | 2010-04-06 | 2017-11-14 | Intuitive Surgical Operations, Inc. | Apparatus and methods for ablation efficacy |
CA2795229A1 (en) | 2010-04-09 | 2011-10-13 | Vessix Vascular, Inc. | Power generating and control apparatus for the treatment of tissue |
US9192790B2 (en) | 2010-04-14 | 2015-11-24 | Boston Scientific Scimed, Inc. | Focused ultrasonic renal denervation |
US20110295249A1 (en) * | 2010-05-28 | 2011-12-01 | Salient Surgical Technologies, Inc. | Fluid-Assisted Electrosurgical Devices, and Methods of Manufacture Thereof |
US20110301414A1 (en) * | 2010-06-04 | 2011-12-08 | Robert Hotto | Intelligent endoscopy systems and methods |
US8473067B2 (en) | 2010-06-11 | 2013-06-25 | Boston Scientific Scimed, Inc. | Renal denervation and stimulation employing wireless vascular energy transfer arrangement |
US9138289B2 (en) | 2010-06-28 | 2015-09-22 | Medtronic Advanced Energy Llc | Electrode sheath for electrosurgical device |
US8920417B2 (en) | 2010-06-30 | 2014-12-30 | Medtronic Advanced Energy Llc | Electrosurgical devices and methods of use thereof |
US8906012B2 (en) | 2010-06-30 | 2014-12-09 | Medtronic Advanced Energy Llc | Electrosurgical devices with wire electrode |
US9408661B2 (en) | 2010-07-30 | 2016-08-09 | Patrick A. Haverkost | RF electrodes on multiple flexible wires for renal nerve ablation |
US9358365B2 (en) | 2010-07-30 | 2016-06-07 | Boston Scientific Scimed, Inc. | Precision electrode movement control for renal nerve ablation |
US9155589B2 (en) | 2010-07-30 | 2015-10-13 | Boston Scientific Scimed, Inc. | Sequential activation RF electrode set for renal nerve ablation |
US9463062B2 (en) | 2010-07-30 | 2016-10-11 | Boston Scientific Scimed, Inc. | Cooled conductive balloon RF catheter for renal nerve ablation |
US9084609B2 (en) | 2010-07-30 | 2015-07-21 | Boston Scientific Scime, Inc. | Spiral balloon catheter for renal nerve ablation |
EP2600784B1 (en) | 2010-08-05 | 2021-12-29 | Medtronic Ireland Manufacturing Unlimited Company | Cryoablation apparatuses, systems, and methods for renal neuromodulation |
US8597180B2 (en) | 2010-08-12 | 2013-12-03 | Covidien Lp | Expandable thoracic access port |
WO2012021748A1 (en) | 2010-08-12 | 2012-02-16 | Raydiance, Inc. | Polymer tubing laser micromachining |
US8864658B2 (en) | 2010-08-12 | 2014-10-21 | Covidien Lp | Expandable surgical access port |
US8961408B2 (en) | 2010-08-12 | 2015-02-24 | Covidien Lp | Expandable surgical access port |
US9247955B2 (en) | 2010-08-12 | 2016-02-02 | Covidien Lp | Thoracic access port |
US9498278B2 (en) | 2010-09-08 | 2016-11-22 | Covidien Lp | Asymmetrical electrodes for bipolar vessel sealing |
KR20140018183A (en) | 2010-09-16 | 2014-02-12 | 레이디안스, 아이엔씨. | Laser based processing of layered materials |
US8974451B2 (en) | 2010-10-25 | 2015-03-10 | Boston Scientific Scimed, Inc. | Renal nerve ablation using conductive fluid jet and RF energy |
US9060754B2 (en) | 2010-10-26 | 2015-06-23 | Medtronic Ardian Luxembourg S.A.R.L. | Neuromodulation cryotherapeutic devices and associated systems and methods |
US20120143294A1 (en) | 2010-10-26 | 2012-06-07 | Medtronic Adrian Luxembourg S.a.r.l. | Neuromodulation cryotherapeutic devices and associated systems and methods |
US9023040B2 (en) | 2010-10-26 | 2015-05-05 | Medtronic Advanced Energy Llc | Electrosurgical cutting devices |
US9220558B2 (en) | 2010-10-27 | 2015-12-29 | Boston Scientific Scimed, Inc. | RF renal denervation catheter with multiple independent electrodes |
US9017349B2 (en) | 2010-10-27 | 2015-04-28 | Atricure, Inc. | Appendage clamp deployment assist device |
US9655666B2 (en) * | 2010-10-29 | 2017-05-23 | Medtronic Ablatio Frontiers LLC | Catheter with coronary sinus ostium anchor |
US8636754B2 (en) | 2010-11-11 | 2014-01-28 | Atricure, Inc. | Clip applicator |
US9028485B2 (en) | 2010-11-15 | 2015-05-12 | Boston Scientific Scimed, Inc. | Self-expanding cooling electrode for renal nerve ablation |
US9668811B2 (en) | 2010-11-16 | 2017-06-06 | Boston Scientific Scimed, Inc. | Minimally invasive access for renal nerve ablation |
US9089350B2 (en) | 2010-11-16 | 2015-07-28 | Boston Scientific Scimed, Inc. | Renal denervation catheter with RF electrode and integral contrast dye injection arrangement |
US9326751B2 (en) | 2010-11-17 | 2016-05-03 | Boston Scientific Scimed, Inc. | Catheter guidance of external energy for renal denervation |
US9060761B2 (en) | 2010-11-18 | 2015-06-23 | Boston Scientific Scime, Inc. | Catheter-focused magnetic field induced renal nerve ablation |
US9023034B2 (en) | 2010-11-22 | 2015-05-05 | Boston Scientific Scimed, Inc. | Renal ablation electrode with force-activatable conduction apparatus |
US9192435B2 (en) | 2010-11-22 | 2015-11-24 | Boston Scientific Scimed, Inc. | Renal denervation catheter with cooled RF electrode |
US9486189B2 (en) | 2010-12-02 | 2016-11-08 | Hitachi Aloka Medical, Ltd. | Assembly for use with surgery system |
US20120143172A1 (en) * | 2010-12-02 | 2012-06-07 | Aloka Company, Ltd. | Assembly For Use With Surgery System |
US20120157993A1 (en) | 2010-12-15 | 2012-06-21 | Jenson Mark L | Bipolar Off-Wall Electrode Device for Renal Nerve Ablation |
WO2012100095A1 (en) | 2011-01-19 | 2012-07-26 | Boston Scientific Scimed, Inc. | Guide-compatible large-electrode catheter for renal nerve ablation with reduced arterial injury |
EP3590453B1 (en) * | 2011-02-01 | 2024-02-28 | Channel Medsystems, Inc. | Apparatus for cryogenic treatment of a body cavity or lumen |
US9427281B2 (en) | 2011-03-11 | 2016-08-30 | Medtronic Advanced Energy Llc | Bronchoscope-compatible catheter provided with electrosurgical device |
US9119665B2 (en) | 2011-03-21 | 2015-09-01 | Covidien Lp | Thoracic access port including foldable anchor |
EP2694150A1 (en) | 2011-04-08 | 2014-02-12 | Covidien LP | Iontophoresis drug delivery system and method for denervation of the renal sympathetic nerve and iontophoretic drug delivery |
US9138148B2 (en) * | 2011-04-13 | 2015-09-22 | St. Jude Medical, Inc. | High speed elastographic property mapping of lumens utilizing micropalpation delivered from an OCT-equipped catheter tip |
WO2012145703A1 (en) * | 2011-04-20 | 2012-10-26 | Kinamed, Inc. | Shapeable passer for surgical cable or suture |
EP2701623B1 (en) | 2011-04-25 | 2016-08-17 | Medtronic Ardian Luxembourg S.à.r.l. | Apparatus related to constrained deployment of cryogenic balloons for limited cryogenic ablation of vessel walls |
WO2012148966A2 (en) * | 2011-04-25 | 2012-11-01 | Brian Kelly | Apparatus and methods related to selective thermal insulation of cryogenic balloons for limited cryogenic ablation of vessel walls |
US9161771B2 (en) | 2011-05-13 | 2015-10-20 | Intuitive Surgical Operations Inc. | Medical instrument with snake wrist structure |
US8909316B2 (en) | 2011-05-18 | 2014-12-09 | St. Jude Medical, Cardiology Division, Inc. | Apparatus and method of assessing transvascular denervation |
US9039610B2 (en) | 2011-05-19 | 2015-05-26 | Covidien Lp | Thoracic access port |
WO2013013099A1 (en) * | 2011-07-19 | 2013-01-24 | Adagio Medical, Inc. | Methods and devices for the treatment of atrial fibrillation |
CN103813745B (en) | 2011-07-20 | 2016-06-29 | 波士顿科学西美德公司 | In order to visualize, be directed at and to melt transcutaneous device and the method for nerve |
WO2013016203A1 (en) | 2011-07-22 | 2013-01-31 | Boston Scientific Scimed, Inc. | Nerve modulation system with a nerve modulation element positionable in a helical guide |
US9387031B2 (en) | 2011-07-29 | 2016-07-12 | Medtronic Ablation Frontiers Llc | Mesh-overlayed ablation and mapping device |
US9198685B2 (en) * | 2011-08-24 | 2015-12-01 | Gyrus Ent, L.L.C. | Surgical instrument with malleable tubing |
US9592091B2 (en) | 2011-08-30 | 2017-03-14 | Biosense Webster (Israel) Ltd. | Ablation catheter for vein anatomies |
US9427579B2 (en) | 2011-09-29 | 2016-08-30 | Pacesetter, Inc. | System and method for performing renal denervation verification |
US9750565B2 (en) | 2011-09-30 | 2017-09-05 | Medtronic Advanced Energy Llc | Electrosurgical balloons |
WO2013055826A1 (en) | 2011-10-10 | 2013-04-18 | Boston Scientific Scimed, Inc. | Medical devices including ablation electrodes |
EP2765940B1 (en) | 2011-10-11 | 2015-08-26 | Boston Scientific Scimed, Inc. | Off-wall electrode device for nerve modulation |
US9420955B2 (en) | 2011-10-11 | 2016-08-23 | Boston Scientific Scimed, Inc. | Intravascular temperature monitoring system and method |
US9364284B2 (en) | 2011-10-12 | 2016-06-14 | Boston Scientific Scimed, Inc. | Method of making an off-wall spacer cage |
WO2013059202A1 (en) | 2011-10-18 | 2013-04-25 | Boston Scientific Scimed, Inc. | Integrated crossing balloon catheter |
US9162046B2 (en) | 2011-10-18 | 2015-10-20 | Boston Scientific Scimed, Inc. | Deflectable medical devices |
US9314588B2 (en) | 2011-10-28 | 2016-04-19 | Medtronic Cryocath Lp | Systems and methods for variable injection flow |
US8870864B2 (en) | 2011-10-28 | 2014-10-28 | Medtronic Advanced Energy Llc | Single instrument electrosurgery apparatus and its method of use |
CN104023662B (en) | 2011-11-08 | 2018-02-09 | 波士顿科学西美德公司 | Hole portion renal nerve melts |
CA2855003C (en) | 2011-11-08 | 2019-01-15 | Boston Scientific Scimed, Inc. | Handle assembly for a left atrial appendage occlusion device |
WO2013074813A1 (en) | 2011-11-15 | 2013-05-23 | Boston Scientific Scimed, Inc. | Device and methods for renal nerve modulation monitoring |
US9119632B2 (en) | 2011-11-21 | 2015-09-01 | Boston Scientific Scimed, Inc. | Deflectable renal nerve ablation catheter |
CA2797624A1 (en) | 2011-12-07 | 2013-06-07 | Covidien Lp | Thoracic access assembly |
US9265969B2 (en) | 2011-12-21 | 2016-02-23 | Cardiac Pacemakers, Inc. | Methods for modulating cell function |
US9174050B2 (en) | 2011-12-23 | 2015-11-03 | Vessix Vascular, Inc. | Methods and apparatuses for remodeling tissue of or adjacent to a body passage |
EP2797534A1 (en) | 2011-12-28 | 2014-11-05 | Boston Scientific Scimed, Inc. | Device and methods for nerve modulation using a novel ablation catheter with polymeric ablative elements |
US9050106B2 (en) | 2011-12-29 | 2015-06-09 | Boston Scientific Scimed, Inc. | Off-wall electrode device and methods for nerve modulation |
US9345528B2 (en) * | 2012-01-27 | 2016-05-24 | Medtronic Cryocath Lp | Large area cryoablation catheter with multi-geometry tip ECG/CRYO mapping capabilities |
US8934988B2 (en) | 2012-03-16 | 2015-01-13 | St. Jude Medical Ab | Ablation stent with meander structure |
US9113929B2 (en) | 2012-04-19 | 2015-08-25 | St. Jude Medical, Cardiology Division, Inc. | Non-electric field renal denervation electrode |
US9241752B2 (en) | 2012-04-27 | 2016-01-26 | Medtronic Ardian Luxembourg S.A.R.L. | Shafts with pressure relief in cryotherapeutic catheters and associated devices, systems, and methods |
WO2013162700A1 (en) | 2012-04-27 | 2013-10-31 | Medtronic Ardian Luxembourg Sarl | Cryotherapeutic devices for renal neuromodulation and associated systems and methods |
WO2013169927A1 (en) | 2012-05-08 | 2013-11-14 | Boston Scientific Scimed, Inc. | Renal nerve modulation devices |
US9226792B2 (en) | 2012-06-12 | 2016-01-05 | Medtronic Advanced Energy Llc | Debridement device and method |
CN104540465A (en) | 2012-08-24 | 2015-04-22 | 波士顿科学西美德公司 | Intravascular catheter with a balloon comprising separate microporous regions |
US9113911B2 (en) | 2012-09-06 | 2015-08-25 | Medtronic Ablation Frontiers Llc | Ablation device and method for electroporating tissue cells |
WO2014043687A2 (en) | 2012-09-17 | 2014-03-20 | Boston Scientific Scimed, Inc. | Self-positioning electrode system and method for renal nerve modulation |
WO2014047454A2 (en) | 2012-09-21 | 2014-03-27 | Boston Scientific Scimed, Inc. | Self-cooling ultrasound ablation catheter |
US10398464B2 (en) | 2012-09-21 | 2019-09-03 | Boston Scientific Scimed, Inc. | System for nerve modulation and innocuous thermal gradient nerve block |
US11234760B2 (en) | 2012-10-05 | 2022-02-01 | Medtronic Advanced Energy Llc | Electrosurgical device for cutting and removing tissue |
US9011488B2 (en) * | 2012-10-09 | 2015-04-21 | Covidien Lp | Method of closure for thoracotomy and thorascopy incisions |
US10835305B2 (en) | 2012-10-10 | 2020-11-17 | Boston Scientific Scimed, Inc. | Renal nerve modulation devices and methods |
US9622775B2 (en) | 2012-10-24 | 2017-04-18 | Arthrex, Inc. | Methods and instruments for forming a posterior knee portal and for inserting a cannula |
US9095321B2 (en) | 2012-11-21 | 2015-08-04 | Medtronic Ardian Luxembourg S.A.R.L. | Cryotherapeutic devices having integral multi-helical balloons and methods of making the same |
US9017317B2 (en) | 2012-12-06 | 2015-04-28 | Medtronic Ardian Luxembourg S.A.R.L. | Refrigerant supply system for cryotherapy including refrigerant recompression and associated devices, systems, and methods |
US10028764B2 (en) | 2013-02-21 | 2018-07-24 | Boston Scientific Scimed, Inc. | Ablation catheter with wireless temperature sensor |
US10195467B2 (en) | 2013-02-21 | 2019-02-05 | Boston Scientific Scimed, Inc. | Ablation catheter system with wireless radio frequency temperature sensor |
US9179997B2 (en) | 2013-03-06 | 2015-11-10 | St. Jude Medical, Cardiology Division, Inc. | Thermochromic polyvinyl alcohol based hydrogel artery |
US9956033B2 (en) | 2013-03-11 | 2018-05-01 | Boston Scientific Scimed, Inc. | Medical devices for modulating nerves |
US9693821B2 (en) | 2013-03-11 | 2017-07-04 | Boston Scientific Scimed, Inc. | Medical devices for modulating nerves |
EP2777739B1 (en) | 2013-03-12 | 2018-09-05 | St. Jude Medical, Cardiology Division, Inc. | Catheter system |
EP2777740A3 (en) | 2013-03-12 | 2015-01-21 | St. Jude Medical, Cardiology Division, Inc. | Catheter system |
EP2777741A3 (en) | 2013-03-12 | 2015-01-21 | St. Jude Medical, Cardiology Division, Inc. | Catheter system |
US9510902B2 (en) | 2013-03-13 | 2016-12-06 | St. Jude Medical, Cardiology Division, Inc. | Ablation catheters and systems including rotational monitoring means |
US9808311B2 (en) | 2013-03-13 | 2017-11-07 | Boston Scientific Scimed, Inc. | Deflectable medical devices |
US9131982B2 (en) | 2013-03-14 | 2015-09-15 | St. Jude Medical, Cardiology Division, Inc. | Mediguide-enabled renal denervation system for ensuring wall contact and mapping lesion locations |
US8876813B2 (en) | 2013-03-14 | 2014-11-04 | St. Jude Medical, Inc. | Methods, systems, and apparatus for neural signal detection |
US9974477B2 (en) | 2013-03-15 | 2018-05-22 | St. Jude Medical, Cardiology Division, Inc. | Quantification of renal denervation via alterations in renal blood flow pre/post ablation |
JP6139772B2 (en) | 2013-03-15 | 2017-05-31 | ボストン サイエンティフィック サイムド,インコーポレイテッドBoston Scientific Scimed,Inc. | Control unit for use with electrode pads and method for estimating leakage |
WO2014150432A1 (en) | 2013-03-15 | 2014-09-25 | St. Jude Medical, Cardiology Division, Inc. | Ablation system, methods, and controllers |
US10265122B2 (en) | 2013-03-15 | 2019-04-23 | Boston Scientific Scimed, Inc. | Nerve ablation devices and related methods of use |
US9713490B2 (en) | 2013-03-15 | 2017-07-25 | St. Jude Medical, Cardiology Division, Inc. | Ablation system, methods, and controllers |
JP6220044B2 (en) | 2013-03-15 | 2017-10-25 | ボストン サイエンティフィック サイムド,インコーポレイテッドBoston Scientific Scimed,Inc. | Medical device for renal nerve ablation |
US9179973B2 (en) | 2013-03-15 | 2015-11-10 | St. Jude Medical, Cardiology Division, Inc. | Feedback systems and methods for renal denervation utilizing balloon catheter |
US9186212B2 (en) | 2013-03-15 | 2015-11-17 | St. Jude Medical, Cardiology Division, Inc. | Feedback systems and methods utilizing two or more sites along denervation catheter |
WO2014176205A1 (en) | 2013-04-25 | 2014-10-30 | St. Jude Medical, Cardiology Division, Inc. | Electrode assembly for catheter system |
CN105473091B (en) | 2013-06-21 | 2020-01-21 | 波士顿科学国际有限公司 | Renal denervation balloon catheter with co-movable electrode supports |
WO2014205399A1 (en) | 2013-06-21 | 2014-12-24 | Boston Scientific Scimed, Inc. | Medical devices for renal nerve ablation having rotatable shafts |
US9707036B2 (en) | 2013-06-25 | 2017-07-18 | Boston Scientific Scimed, Inc. | Devices and methods for nerve modulation using localized indifferent electrodes |
US9872728B2 (en) | 2013-06-28 | 2018-01-23 | St. Jude Medical, Cardiology Division, Inc. | Apparatuses and methods for affixing electrodes to an intravascular balloon |
JP6204579B2 (en) | 2013-07-01 | 2017-09-27 | ボストン サイエンティフィック サイムド,インコーポレイテッドBoston Scientific Scimed,Inc. | Renal nerve ablation medical device |
US20150011991A1 (en) | 2013-07-03 | 2015-01-08 | St. Jude Medical, Cardiology Division, Inc. | Electrode Assembly For Catheter System |
EP3019106A1 (en) | 2013-07-11 | 2016-05-18 | Boston Scientific Scimed, Inc. | Medical device with stretchable electrode assemblies |
CN105377169B (en) | 2013-07-11 | 2019-04-19 | 波士顿科学国际有限公司 | Device and method for neuromodulation |
WO2015010074A1 (en) | 2013-07-19 | 2015-01-22 | Boston Scientific Scimed, Inc. | Spiral bipolar electrode renal denervation balloon |
CN105392435B (en) | 2013-07-22 | 2018-11-09 | 波士顿科学国际有限公司 | Renal nerve ablation catheter with twisting sacculus |
US10342609B2 (en) | 2013-07-22 | 2019-07-09 | Boston Scientific Scimed, Inc. | Medical devices for renal nerve ablation |
US10213248B2 (en) | 2013-08-21 | 2019-02-26 | Biosense Webster (Israel) Ltd. | Adaptive electrode for bi-polar ablation |
CN105473093B (en) | 2013-08-22 | 2019-02-05 | 波士顿科学国际有限公司 | Flexible circuit with the improved adhesion strength to renal nerve modulation sacculus |
CN105555218B (en) | 2013-09-04 | 2019-01-15 | 波士顿科学国际有限公司 | With radio frequency (RF) foley's tube rinsed with cooling capacity |
EP3043733A1 (en) | 2013-09-13 | 2016-07-20 | Boston Scientific Scimed, Inc. | Ablation balloon with vapor deposited cover layer |
AU2014327045B2 (en) | 2013-09-24 | 2019-08-08 | Adagio Medical, Inc. | Endovascular near critical fluid based cryoablation catheter and related methods |
US10631914B2 (en) | 2013-09-30 | 2020-04-28 | Covidien Lp | Bipolar electrosurgical instrument with movable electrode and related systems and methods |
WO2015057521A1 (en) | 2013-10-14 | 2015-04-23 | Boston Scientific Scimed, Inc. | High resolution cardiac mapping electrode array catheter |
US11246654B2 (en) | 2013-10-14 | 2022-02-15 | Boston Scientific Scimed, Inc. | Flexible renal nerve ablation devices and related methods of use and manufacture |
US9770606B2 (en) | 2013-10-15 | 2017-09-26 | Boston Scientific Scimed, Inc. | Ultrasound ablation catheter with cooling infusion and centering basket |
JP6259098B2 (en) | 2013-10-15 | 2018-01-10 | ボストン サイエンティフィック サイムド,インコーポレイテッドBoston Scientific Scimed,Inc. | Medical device and method for manufacturing the medical device |
EP3057521B1 (en) | 2013-10-18 | 2020-03-25 | Boston Scientific Scimed, Inc. | Balloon catheters with flexible conducting wires |
US10856936B2 (en) | 2013-10-23 | 2020-12-08 | St. Jude Medical, Cardiology Division, Inc. | Electrode assembly for catheter system including thermoplastic-based struts |
USD747491S1 (en) | 2013-10-23 | 2016-01-12 | St. Jude Medical, Cardiology Division, Inc. | Ablation generator |
USD914883S1 (en) | 2013-10-23 | 2021-03-30 | St. Jude Medical, Cardiology Division, Inc. | Ablation generator |
USD774043S1 (en) | 2013-10-23 | 2016-12-13 | St. Jude Medical, Cardiology Division, Inc. | Display screen with graphical user interface for ablation generator |
US9999748B2 (en) | 2013-10-24 | 2018-06-19 | St. Jude Medical, Cardiology Division, Inc. | Flexible catheter shaft and method of manufacture |
US9913961B2 (en) | 2013-10-24 | 2018-03-13 | St. Jude Medical, Cardiology Division, Inc. | Flexible catheter shaft and method of manufacture |
US10034705B2 (en) | 2013-10-24 | 2018-07-31 | St. Jude Medical, Cardiology Division, Inc. | High strength electrode assembly for catheter system including novel electrode |
WO2015061457A1 (en) | 2013-10-25 | 2015-04-30 | Boston Scientific Scimed, Inc. | Embedded thermocouple in denervation flex circuit |
EP3062722B1 (en) | 2013-10-28 | 2019-03-20 | St. Jude Medical, Cardiology Division, Inc. | Electrode assembly for catheter system including interlinked struts |
CA2934643A1 (en) * | 2013-11-04 | 2015-05-07 | Northwestern University | System and method for determining electrogram morphology recurrence patterns and rates during atrial fibrillation |
US9861433B2 (en) | 2013-11-05 | 2018-01-09 | St. Jude Medical, Cardiology Division, Inc. | Helical-shaped ablation catheter and methods of use |
US10314647B2 (en) | 2013-12-23 | 2019-06-11 | Medtronic Advanced Energy Llc | Electrosurgical cutting instrument |
CN105899157B (en) | 2014-01-06 | 2019-08-09 | 波士顿科学国际有限公司 | Tear-proof flexible circuit assembly |
US9730701B2 (en) | 2014-01-16 | 2017-08-15 | Boston Scientific Scimed, Inc. | Retrieval wire centering device |
WO2015119890A1 (en) | 2014-02-04 | 2015-08-13 | Boston Scientific Scimed, Inc. | Alternative placement of thermal sensors on bipolar electrode |
US11000679B2 (en) | 2014-02-04 | 2021-05-11 | Boston Scientific Scimed, Inc. | Balloon protection and rewrapping devices and related methods of use |
US10813686B2 (en) | 2014-02-26 | 2020-10-27 | Medtronic Advanced Energy Llc | Electrosurgical cutting instrument |
US10492842B2 (en) | 2014-03-07 | 2019-12-03 | Medtronic Ardian Luxembourg S.A.R.L. | Monitoring and controlling internally administered cryotherapy |
US10617459B2 (en) * | 2014-04-17 | 2020-04-14 | Adagio Medical, Inc. | Endovascular near critical fluid based cryoablation catheter having plurality of preformed treatment shapes |
US10398501B2 (en) | 2014-04-24 | 2019-09-03 | St. Jude Medical, Cardiology Division, Inc. | Ablation systems including pulse rate detector and feedback mechanism and methods of use |
EP3137007A4 (en) * | 2014-04-28 | 2017-09-27 | Cardiofocus, Inc. | System and method for visualizing tissue with an icg dye composition during ablation procedures |
US10709490B2 (en) | 2014-05-07 | 2020-07-14 | Medtronic Ardian Luxembourg S.A.R.L. | Catheter assemblies comprising a direct heating element for renal neuromodulation and associated systems and methods |
US9468407B2 (en) | 2014-05-30 | 2016-10-18 | Biosense Webster (Israel) Ltd. | Catheter with distal section having side-by-side loops |
US10194978B2 (en) * | 2014-06-13 | 2019-02-05 | Medtronic Cryocath Lp | Supporting catheter for use for phrenic nerve pacing |
US9974599B2 (en) | 2014-08-15 | 2018-05-22 | Medtronic Ps Medical, Inc. | Multipurpose electrosurgical device |
US10070882B2 (en) | 2014-08-20 | 2018-09-11 | Gyrus Acmi, Inc. | Apparatus and method for cutting tissue |
RU2017114607A (en) | 2014-09-28 | 2018-10-29 | Кардиокинетикс, Инк. | DEVICES FOR THERAPY OF HEART FUNCTIONAL DISORDERS |
US9956029B2 (en) | 2014-10-31 | 2018-05-01 | Medtronic Advanced Energy Llc | Telescoping device with saline irrigation line |
BR112017009586B1 (en) | 2014-11-13 | 2022-09-20 | Adagio Medical, Inc. | CRYOABLATION SYSTEM |
US10154888B2 (en) | 2014-12-03 | 2018-12-18 | Cardiofocus, Inc. | System and method for visual confirmation of pulmonary vein isolation during abalation procedures |
US20160213237A1 (en) | 2015-01-23 | 2016-07-28 | Boston Scientific Scimed, Inc. | Balloon catheter visualization systems, methods, and devices having pledgets |
WO2016134156A1 (en) | 2015-02-18 | 2016-08-25 | Medtronic Xomed, Inc. | Rf energy enabled tissue debridement device |
US10376302B2 (en) | 2015-02-18 | 2019-08-13 | Medtronic Xomed, Inc. | Rotating electrical connector for RF energy enabled tissue debridement device |
US10188456B2 (en) | 2015-02-18 | 2019-01-29 | Medtronic Xomed, Inc. | Electrode assembly for RF energy enabled tissue debridement device |
US10206706B2 (en) | 2015-05-29 | 2019-02-19 | Medtronic Xomed, Inc. | Inner tubular member for angled rotary surgical instrument |
US20180303535A1 (en) | 2015-06-03 | 2018-10-25 | Adagio Medical, Inc. | Cryoablation catheter having an elliptical-shaped treatment section |
CN107613894A (en) * | 2015-07-16 | 2018-01-19 | 奥林巴斯株式会社 | Treatment apparatus |
US11389227B2 (en) | 2015-08-20 | 2022-07-19 | Medtronic Advanced Energy Llc | Electrosurgical device with multivariate control |
US11051875B2 (en) | 2015-08-24 | 2021-07-06 | Medtronic Advanced Energy Llc | Multipurpose electrosurgical device |
EP3349676A4 (en) | 2015-09-18 | 2019-05-15 | Adagio Medical, Inc. | Tissue contact verification system |
US10357309B2 (en) * | 2015-09-21 | 2019-07-23 | Biosense Webster (Israel) Ltd. | Ablation current measurement |
US10549128B2 (en) | 2015-11-04 | 2020-02-04 | Vytronus, Inc. | Systems and methods for imaging and ablating tissue |
US10667896B2 (en) | 2015-11-13 | 2020-06-02 | Cardiac Pacemakers, Inc. | Bioabsorbable left atrial appendage closure with endothelialization promoting surface |
US10864031B2 (en) | 2015-11-30 | 2020-12-15 | Adagio Medical, Inc. | Ablation method for creating elongate continuous lesions enclosing multiple vessel entries |
US10716612B2 (en) | 2015-12-18 | 2020-07-21 | Medtronic Advanced Energy Llc | Electrosurgical device with multiple monopolar electrode assembly |
US10512759B2 (en) | 2016-04-19 | 2019-12-24 | Boston Scientific Scimed, Inc | Weeping balloon devices |
US11439460B2 (en) | 2016-06-23 | 2022-09-13 | St. Jude Medical, Cardiology Division, Inc. | Catheter system and electrode assembly for intraprocedural evaluation of renal denervation |
EP3515327B1 (en) | 2016-09-23 | 2024-02-14 | AtriCure, Inc. | Devices for left atrial appendage closure |
CN110559049B (en) * | 2016-10-27 | 2022-11-08 | 深圳市赛诺思医疗科技有限公司 | Chemical ablation device for treating arrhythmia |
JP6946444B2 (en) * | 2017-02-10 | 2021-10-06 | セント・ジュード・メディカル,カーディオロジー・ディヴィジョン,インコーポレイテッド | Equipment and methods for cryoablation |
US10987128B2 (en) | 2017-03-22 | 2021-04-27 | Covidien Lp | Cannula assembly |
DE102018107407A1 (en) | 2017-03-28 | 2018-10-04 | Edwards Lifesciences Corporation | POSITIONING, INSERTING AND RETRIEVING IMPLANTABLE DEVICES |
US11432809B2 (en) | 2017-04-27 | 2022-09-06 | Boston Scientific Scimed, Inc. | Occlusive medical device with fabric retention barb |
CN111225626B (en) | 2017-09-05 | 2023-11-14 | 艾达吉欧医疗公司 | Ablation catheter with shape memory probe |
EP3459469A1 (en) | 2017-09-23 | 2019-03-27 | Universität Zürich | Medical occluder device |
US10631853B2 (en) | 2017-10-06 | 2020-04-28 | Lsi Solutions, Inc. | Suture securing tube and assembly thereof |
WO2019092031A1 (en) * | 2017-11-09 | 2019-05-16 | Medical Instruments S.P.A. | Instrument for cutting heart valves |
JP7013591B2 (en) | 2017-12-18 | 2022-01-31 | ボストン サイエンティフィック サイムド,インコーポレイテッド | Closure device with expandable members |
KR101921980B1 (en) * | 2017-12-28 | 2018-11-27 | 메디퓨처스 주식회사 | Device and method for manufacturing medical 3d thread using ultrasonic wave |
WO2019139917A1 (en) | 2018-01-10 | 2019-07-18 | Adagio Medical, Inc. | Cryoablation element with conductive liner |
EP3740139A1 (en) | 2018-01-19 | 2020-11-25 | Boston Scientific Scimed Inc. | Occlusive medical device with delivery system |
WO2019191316A1 (en) | 2018-03-27 | 2019-10-03 | Sentreheart, Inc. | Devices and methods for left atrial appendage closure |
US11331104B2 (en) | 2018-05-02 | 2022-05-17 | Boston Scientific Scimed, Inc. | Occlusive sealing sensor system |
US11331144B2 (en) | 2018-05-04 | 2022-05-17 | Covidien Lp | Light energy surgical system, apparatus, and method |
JP7241095B2 (en) | 2018-05-15 | 2023-03-16 | ボストン サイエンティフィック サイムド,インコーポレイテッド | Occlusive medical device with charged polymer coating |
EP3801301A1 (en) | 2018-06-08 | 2021-04-14 | Boston Scientific Scimed Inc. | Occlusive device with actuatable fixation members |
US11672541B2 (en) | 2018-06-08 | 2023-06-13 | Boston Scientific Scimed, Inc. | Medical device with occlusive member |
US11382635B2 (en) | 2018-07-06 | 2022-07-12 | Boston Scientific Scimed, Inc. | Occlusive medical device |
CN112714632A (en) | 2018-08-21 | 2021-04-27 | 波士顿科学医学有限公司 | Barbed protruding member for cardiovascular devices |
WO2020056221A1 (en) | 2018-09-14 | 2020-03-19 | Atricure, Inc. | Cryoprobe |
EP3784153B1 (en) | 2019-01-10 | 2023-12-13 | AtriCure, Inc. | Surgical clamp |
US10610280B1 (en) | 2019-02-02 | 2020-04-07 | Ayad K. M. Agha | Surgical method and apparatus for destruction and removal of intraperitoneal, visceral, and subcutaneous fat |
US11154312B2 (en) | 2019-04-05 | 2021-10-26 | Traverse Vascular, Inc. | Reentry catheter for crossing a vascular occlusion |
WO2021011694A1 (en) | 2019-07-17 | 2021-01-21 | Boston Scientific Scimed, Inc. | Left atrial appendage implant with continuous covering |
CN114340516A (en) | 2019-08-30 | 2022-04-12 | 波士顿科学医学有限公司 | Left atrial appendage implant with sealing disk |
JP1652078S (en) * | 2019-08-30 | 2020-02-03 | ||
JP2022549717A (en) | 2019-09-26 | 2022-11-28 | ウニベルシタット チューリッヒ | left atrial appendage closure device |
JP1661152S (en) * | 2019-12-10 | 2020-06-08 | ||
US11141191B2 (en) | 2020-01-15 | 2021-10-12 | Covidien Lp | Surgical access assembly |
WO2021195085A1 (en) | 2020-03-24 | 2021-09-30 | Boston Scientific Scimed, Inc. | Medical system for treating a left atrial appendage |
US11622790B2 (en) * | 2020-05-21 | 2023-04-11 | Covidien Lp | Obturators for surgical access assemblies and methods of assembly thereof |
US11173028B1 (en) * | 2020-09-09 | 2021-11-16 | Cardiac Implants Llc | Positioning a medical device in the right atrium or right ventricle using a non-flexible catheter |
US20230181230A1 (en) * | 2021-12-15 | 2023-06-15 | Metrum Cryoflex Sp. z. o. o., Sp. k. | Cryosurgical probe and method of manufacturing thereof |
Family Cites Families (395)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US984756A (en) | 1909-09-08 | 1911-02-21 | Paul Frisch | Surgical forceps. |
US1659112A (en) * | 1927-05-12 | 1928-02-14 | Dana M Littlejohn | Toggle-squeeze hemostat forceps |
FR1366631A (en) | 1963-08-27 | 1964-07-10 | Transformatorenwerk Karl Liebn | Bleeding device for intermediate compressor stages |
US3369550A (en) | 1967-02-17 | 1968-02-20 | Thomas A. Armao | Cryogenic clamps |
FR1605386A (en) * | 1968-02-09 | 1975-02-28 | Constant temp. application appts. for neurosurgery - uses high pressure nitrogen expanded for cooling or heated by resistance | |
DE1915597A1 (en) | 1968-03-29 | 1969-10-30 | Spembly Technical Procucts Ltd | Cryogenic, bottle-like container |
US3823575A (en) * | 1971-06-07 | 1974-07-16 | Univ Melbourne | Cryogenic apparatus |
US3736936A (en) * | 1971-12-13 | 1973-06-05 | Hughes Aircraft Co | Cryogenic heat transfer device |
GB1438759A (en) * | 1972-06-02 | 1976-06-09 | Spembly Ltd | Cryo-surgical apparatus |
US3886945A (en) * | 1972-06-14 | 1975-06-03 | Frigitronics Of Conn Inc | Cryosurgical apparatus |
US3807403A (en) * | 1972-06-14 | 1974-04-30 | Frigitronics Of Conn Inc | Cryosurgical apparatus |
US3830239A (en) * | 1972-09-12 | 1974-08-20 | Frigitronics Of Conn Inc | Cryosurgical device |
US3823718A (en) * | 1972-09-15 | 1974-07-16 | T Tromovitch | Portable cryosurgical apparatus |
US3827436A (en) * | 1972-11-10 | 1974-08-06 | Frigitronics Of Conn Inc | Multipurpose cryosurgical probe |
US3924628A (en) * | 1972-12-01 | 1975-12-09 | William Droegemueller | Cyrogenic bladder for necrosing tissue cells |
NL176833C (en) * | 1973-04-26 | 1985-06-17 | Draegerwerk Ag | HEAT-INSULATING FLEXIBLE PIPE. |
US3859986A (en) * | 1973-06-20 | 1975-01-14 | Jiro Okada | Surgical device |
US3907339A (en) * | 1973-07-23 | 1975-09-23 | Frigitronics Of Conn Inc | Cryogenic delivery line |
US3862627A (en) | 1973-08-16 | 1975-01-28 | Sr Wendel J Hans | Suction electrode |
US4022215A (en) * | 1973-12-10 | 1977-05-10 | Benson Jerrel W | Cryosurgical system |
GB1513565A (en) * | 1975-04-22 | 1978-06-07 | Spembly Ltd | Cryosurgical instruments |
DE2525982C3 (en) | 1975-06-11 | 1978-03-09 | Richard Wolf Gmbh, 7134 Knittlingen | Cutting electrode for resectoscopes |
US4018227A (en) * | 1975-10-09 | 1977-04-19 | Cryomedics, Inc. | Cryosurgical instrument |
US4072152A (en) * | 1976-02-23 | 1978-02-07 | Linehan John H | Orthopedic cryosurgical apparatus |
GB1534162A (en) * | 1976-07-21 | 1978-11-29 | Lloyd J | Cyosurgical probe |
US4061135A (en) * | 1976-09-27 | 1977-12-06 | Jerrold Widran | Binocular endoscope |
US4275734A (en) * | 1977-08-12 | 1981-06-30 | Valleylab, Inc. | Cryosurgical apparatus and method |
US4207874A (en) | 1978-03-27 | 1980-06-17 | Choy Daniel S J | Laser tunnelling device |
DE2831199C3 (en) * | 1978-07-15 | 1981-01-08 | Erbe Elektromedizin Gmbh & Co Kg, 7400 Tuebingen | Cryosurgical device |
US4248224A (en) * | 1978-08-01 | 1981-02-03 | Jones James W | Double venous cannula |
US4375818A (en) | 1979-03-12 | 1983-03-08 | Olympus Optical Company Ltd. | Ultrasonic diagnosis system assembled into endoscope |
CA1129015A (en) * | 1980-06-11 | 1982-08-03 | Timofei S. Gudkin | Thermoelectric cryoprobe |
US4353371A (en) * | 1980-09-24 | 1982-10-12 | Cosman Eric R | Longitudinally, side-biting, bipolar coagulating, surgical instrument |
US4377168A (en) * | 1981-02-27 | 1983-03-22 | Wallach Surgical Instruments, Inc. | Cryosurgical instrument |
GB2094636A (en) | 1981-03-12 | 1982-09-22 | Spembly Ltd | A cryosurgical probe |
GB2100987A (en) | 1981-06-12 | 1983-01-12 | William Balfour Bald | Cryosurgical probe |
US5370675A (en) | 1992-08-12 | 1994-12-06 | Vidamed, Inc. | Medical probe device and method |
US4598698A (en) * | 1983-01-20 | 1986-07-08 | Warner-Lambert Technologies, Inc. | Diagnostic device |
US4601290A (en) * | 1983-10-11 | 1986-07-22 | Cabot Medical Corporation | Surgical instrument for cutting body tissue from a body area having a restricted space |
US5143073A (en) | 1983-12-14 | 1992-09-01 | Edap International, S.A. | Wave apparatus system |
US4664110A (en) * | 1985-03-18 | 1987-05-12 | University Of Southern California | Controlled rate freezing for cryorefractive surgery |
SE8502048D0 (en) | 1985-04-26 | 1985-04-26 | Astra Tech Ab | VACUUM FIXED HALLS FOR MEDICAL USE |
US4655216A (en) | 1985-07-23 | 1987-04-07 | Alfred Tischer | Combination instrument for laparoscopical tube sterilization |
US4917095A (en) | 1985-11-18 | 1990-04-17 | Indianapolis Center For Advanced Research, Inc. | Ultrasound location and therapy method and apparatus for calculi in the body |
US5000185A (en) | 1986-02-28 | 1991-03-19 | Cardiovascular Imaging Systems, Inc. | Method for intravascular two-dimensional ultrasonography and recanalization |
US4872346A (en) | 1986-07-18 | 1989-10-10 | Indianapolis Center For Advanced Research | Multiple frequencies from single crystal |
US5231995A (en) | 1986-11-14 | 1993-08-03 | Desai Jawahar M | Method for catheter mapping and ablation |
US5044165A (en) * | 1986-12-03 | 1991-09-03 | Board Of Regents, The University Of Texas | Cryo-slammer |
US4786155A (en) | 1986-12-16 | 1988-11-22 | Fantone Stephen D | Operating microscope providing an image of an obscured object |
DE8701218U1 (en) | 1987-01-26 | 1988-05-26 | Siemens Ag, 1000 Berlin Und 8000 Muenchen, De | |
US4779611A (en) * | 1987-02-24 | 1988-10-25 | Grooters Ronald K | Disposable surgical scope guide |
US4802475A (en) * | 1987-06-22 | 1989-02-07 | Weshahy Ahmed H A G | Methods and apparatus of applying intra-lesional cryotherapy |
US4815470A (en) | 1987-11-13 | 1989-03-28 | Advanced Diagnostic Medical Systems, Inc. | Inflatable sheath for ultrasound probe |
US4957099A (en) | 1988-02-10 | 1990-09-18 | Siemens Aktiengesellschaft | Shock wave source for extracorporeal lithotripsy |
US5588432A (en) | 1988-03-21 | 1996-12-31 | Boston Scientific Corporation | Catheters for imaging, sensing electrical potentials, and ablating tissue |
US5029574A (en) * | 1988-04-14 | 1991-07-09 | Okamoto Industries, Inc. | Endoscopic balloon with a protective film thereon |
US4924863A (en) | 1988-05-04 | 1990-05-15 | Mmtc, Inc. | Angioplastic method for removing plaque from a vas |
US4889137A (en) | 1988-05-05 | 1989-12-26 | The United States Of America As Reprsented By The Department Of Health And Human Services | Method for improved use of heart/lung machine |
US5147355A (en) * | 1988-09-23 | 1992-09-15 | Brigham And Womens Hospital | Cryoablation catheter and method of performing cryoablation |
US5108390A (en) * | 1988-11-14 | 1992-04-28 | Frigitronics, Inc. | Flexible cryoprobe |
GB2226497B (en) * | 1988-12-01 | 1992-07-01 | Spembly Medical Ltd | Cryosurgical probe |
GB8829525D0 (en) * | 1988-12-17 | 1989-02-01 | Spembly Medical Ltd | Cryosurgical apparatus |
AU4945490A (en) | 1989-01-06 | 1990-08-01 | Angioplasty Systems Inc. | Electrosurgical catheter for resolving atherosclerotic plaque |
US4976711A (en) | 1989-04-13 | 1990-12-11 | Everest Medical Corporation | Ablation catheter with selectively deployable electrodes |
US4936281A (en) | 1989-04-13 | 1990-06-26 | Everest Medical Corporation | Ultrasonically enhanced RF ablation catheter |
US4946460A (en) * | 1989-04-26 | 1990-08-07 | Cryo Instruments, Inc. | Apparatus for cryosurgery |
US4916922A (en) * | 1989-05-09 | 1990-04-17 | Mullens Patrick L | Rapid freezing apparatus |
DE3917328A1 (en) * | 1989-05-27 | 1990-11-29 | Wolf Gmbh Richard | BIPOLAR COAGULATION INSTRUMENT |
US5516505A (en) * | 1989-07-18 | 1996-05-14 | Mcdow; Ronald A. | Method for using cryogenic agents for treating skin lesions |
US5100388A (en) * | 1989-09-15 | 1992-03-31 | Interventional Thermodynamics, Inc. | Method and device for thermal ablation of hollow body organs |
GB9004427D0 (en) * | 1990-02-28 | 1990-04-25 | Nat Res Dev | Cryogenic cooling apparatus |
US5013312A (en) * | 1990-03-19 | 1991-05-07 | Everest Medical Corporation | Bipolar scalpel for harvesting internal mammary artery |
US5109830A (en) | 1990-04-10 | 1992-05-05 | Candela Laser Corporation | Apparatus for navigation of body cavities |
US5080660A (en) * | 1990-05-11 | 1992-01-14 | Applied Urology, Inc. | Electrosurgical electrode |
ZA917281B (en) * | 1990-09-26 | 1992-08-26 | Cryomedical Sciences Inc | Cryosurgical instrument and system and method of cryosurgery |
US5190541A (en) | 1990-10-17 | 1993-03-02 | Boston Scientific Corporation | Surgical instrument and method |
US5269291A (en) | 1990-12-10 | 1993-12-14 | Coraje, Inc. | Miniature ultrasonic transducer for plaque ablation |
US5139496A (en) | 1990-12-20 | 1992-08-18 | Hed Aharon Z | Ultrasonic freeze ablation catheters and probes |
US5324255A (en) | 1991-01-11 | 1994-06-28 | Baxter International Inc. | Angioplasty and ablative devices having onboard ultrasound components and devices and methods for utilizing ultrasound to treat or prevent vasopasm |
US5156151A (en) | 1991-02-15 | 1992-10-20 | Cardiac Pathways Corporation | Endocardial mapping and ablation system and catheter probe |
US5465717A (en) | 1991-02-15 | 1995-11-14 | Cardiac Pathways Corporation | Apparatus and Method for ventricular mapping and ablation |
US5316000A (en) * | 1991-03-05 | 1994-05-31 | Technomed International (Societe Anonyme) | Use of at least one composite piezoelectric transducer in the manufacture of an ultrasonic therapy apparatus for applying therapy, in a body zone, in particular to concretions, to tissue, or to bones, of a living being and method of ultrasonic therapy |
US5178133A (en) * | 1991-03-26 | 1993-01-12 | Pena Louis T | Laparoscopic retractor and sheath |
US5133724A (en) * | 1991-04-04 | 1992-07-28 | Pilling Co. | Abdominal aortic clamp |
US5207674A (en) * | 1991-05-13 | 1993-05-04 | Hamilton Archie C | Electronic cryogenic surgical probe apparatus and method |
WO1992020290A1 (en) * | 1991-05-17 | 1992-11-26 | Innerdyne Medical, Inc. | Method and device for thermal ablation |
WO1992020291A1 (en) | 1991-05-24 | 1992-11-26 | Applied Medical Resources, Inc. | Articulating tissue cutter assembly |
US5361752A (en) * | 1991-05-29 | 1994-11-08 | Origin Medsystems, Inc. | Retraction apparatus and methods for endoscopic surgery |
US5370134A (en) * | 1991-05-29 | 1994-12-06 | Orgin Medsystems, Inc. | Method and apparatus for body structure manipulation and dissection |
ATE168545T1 (en) * | 1991-05-29 | 1998-08-15 | Origin Medsystems Inc | RETRACTOR DEVICE FOR ENDOSCOPIC SURGERY |
US5232516A (en) * | 1991-06-04 | 1993-08-03 | Implemed, Inc. | Thermoelectric device with recuperative heat exchangers |
US5217860A (en) * | 1991-07-08 | 1993-06-08 | The American National Red Cross | Method for preserving organs for transplantation by vitrification |
US5558644A (en) | 1991-07-16 | 1996-09-24 | Heartport, Inc. | Retrograde delivery catheter and method for inducing cardioplegic arrest |
US5571215A (en) | 1993-02-22 | 1996-11-05 | Heartport, Inc. | Devices and methods for intracardiac procedures |
US5584803A (en) | 1991-07-16 | 1996-12-17 | Heartport, Inc. | System for cardiac procedures |
US5452733A (en) | 1993-02-22 | 1995-09-26 | Stanford Surgical Technologies, Inc. | Methods for performing thoracoscopic coronary artery bypass |
US5735290A (en) | 1993-02-22 | 1998-04-07 | Heartport, Inc. | Methods and systems for performing thoracoscopic coronary bypass and other procedures |
US5254116A (en) * | 1991-09-06 | 1993-10-19 | Cryomedical Sciences, Inc. | Cryosurgical instrument with vent holes and method using same |
US5520682A (en) * | 1991-09-06 | 1996-05-28 | Cryomedical Sciences, Inc. | Cryosurgical instrument with vent means and method using same |
US5197964A (en) * | 1991-11-12 | 1993-03-30 | Everest Medical Corporation | Bipolar instrument utilizing one stationary electrode and one movable electrode |
US5217001A (en) * | 1991-12-09 | 1993-06-08 | Nakao Naomi L | Endoscope sheath and related method |
DE69229495T2 (en) * | 1991-12-11 | 1999-12-16 | Sony Corp | Disk cartridge loading mechanism for use in disk recording and / or reproducing apparatus |
US5228923A (en) * | 1991-12-13 | 1993-07-20 | Implemed, Inc. | Cylindrical thermoelectric cells |
FR2685872A1 (en) | 1992-01-07 | 1993-07-09 | Edap Int | APPARATUS OF EXTRACORPOREAL ULTRASONIC HYPERTHERMIA WITH VERY HIGH POWER AND ITS OPERATING METHOD. |
US5366443A (en) | 1992-01-07 | 1994-11-22 | Thapliyal And Eggers Partners | Method and apparatus for advancing catheters through occluded body lumens |
US5400770A (en) * | 1992-01-15 | 1995-03-28 | Nakao; Naomi L. | Device utilizable with endoscope and related method |
US5484435A (en) | 1992-01-15 | 1996-01-16 | Conmed Corporation | Bipolar electrosurgical instrument for use in minimally invasive internal surgical procedures |
US5626599A (en) * | 1992-01-22 | 1997-05-06 | C. R. Bard | Method for the percutaneous transluminal front-end loading delivery of a prosthetic occluder |
US5222501A (en) | 1992-01-31 | 1993-06-29 | Duke University | Methods for the diagnosis and ablation treatment of ventricular tachycardia |
US5327905A (en) | 1992-02-14 | 1994-07-12 | Boaz Avitall | Biplanar deflectable catheter for arrhythmogenic tissue ablation |
US5263493A (en) | 1992-02-24 | 1993-11-23 | Boaz Avitall | Deflectable loop electrode array mapping and ablation catheter for cardiac chambers |
US5555883A (en) | 1992-02-24 | 1996-09-17 | Avitall; Boaz | Loop electrode array mapping and ablation catheter for cardiac chambers |
WO1993019705A1 (en) | 1992-03-31 | 1993-10-14 | Massachusetts Institute Of Technology | Apparatus and method for acoustic heat generation and hyperthermia |
US5540681A (en) | 1992-04-10 | 1996-07-30 | Medtronic Cardiorhythm | Method and system for radiofrequency ablation of tissue |
WO1993020768A1 (en) | 1992-04-13 | 1993-10-28 | Ep Technologies, Inc. | Steerable microwave antenna systems for cardiac ablation |
US5281215A (en) * | 1992-04-16 | 1994-01-25 | Implemed, Inc. | Cryogenic catheter |
US5281213A (en) * | 1992-04-16 | 1994-01-25 | Implemed, Inc. | Catheter for ice mapping and ablation |
US5423807A (en) * | 1992-04-16 | 1995-06-13 | Implemed, Inc. | Cryogenic mapping and ablation catheter |
US5443463A (en) * | 1992-05-01 | 1995-08-22 | Vesta Medical, Inc. | Coagulating forceps |
US5443470A (en) | 1992-05-01 | 1995-08-22 | Vesta Medical, Inc. | Method and apparatus for endometrial ablation |
US5277201A (en) | 1992-05-01 | 1994-01-11 | Vesta Medical, Inc. | Endometrial ablation apparatus and method |
US5562720A (en) | 1992-05-01 | 1996-10-08 | Vesta Medical, Inc. | Bipolar/monopolar endometrial ablation device and method |
US5295484A (en) * | 1992-05-19 | 1994-03-22 | Arizona Board Of Regents For And On Behalf Of The University Of Arizona | Apparatus and method for intra-cardiac ablation of arrhythmias |
US5324284A (en) | 1992-06-05 | 1994-06-28 | Cardiac Pathways, Inc. | Endocardial mapping and ablation system utilizing a separately controlled ablation catheter and method |
US5341807A (en) | 1992-06-30 | 1994-08-30 | American Cardiac Ablation Co., Inc. | Ablation catheter positioning system |
US5275595A (en) * | 1992-07-06 | 1994-01-04 | Dobak Iii John D | Cryosurgical instrument |
WO1994002077A2 (en) | 1992-07-15 | 1994-02-03 | Angelase, Inc. | Ablation catheter system |
US5435308A (en) * | 1992-07-16 | 1995-07-25 | Abbott Laboratories | Multi-purpose multi-parameter cardiac catheter |
GB2269107B (en) * | 1992-07-31 | 1996-05-08 | Spembly Medical Ltd | Cryosurgical ablation |
US5383886A (en) * | 1992-10-13 | 1995-01-24 | Kensey Nash Corporation | Methods and instruments for performing medical procedures percutaneously without a trocar |
WO1994007446A1 (en) | 1992-10-05 | 1994-04-14 | Boston Scientific Corporation | Device and method for heating tissue |
US5687737A (en) | 1992-10-09 | 1997-11-18 | Washington University | Computerized three-dimensional cardiac mapping with interactive visual displays |
US5322520A (en) * | 1992-11-12 | 1994-06-21 | Implemed, Inc. | Iontophoretic structure for medical devices |
US5334193A (en) * | 1992-11-13 | 1994-08-02 | American Cardiac Ablation Co., Inc. | Fluid cooled ablation catheter |
US5676693A (en) | 1992-11-13 | 1997-10-14 | Scimed Life Systems, Inc. | Electrophysiology device |
US5348554A (en) | 1992-12-01 | 1994-09-20 | Cardiac Pathways Corporation | Catheter for RF ablation with cooled electrode |
CA2109980A1 (en) * | 1992-12-01 | 1994-06-02 | Mir A. Imran | Steerable catheter with adjustable bend location and/or radius and method |
US5469853A (en) | 1992-12-11 | 1995-11-28 | Tetrad Corporation | Bendable ultrasonic probe and sheath for use therewith |
US5558671A (en) * | 1993-07-22 | 1996-09-24 | Yates; David C. | Impedance feedback monitor for electrosurgical instrument |
US5403312A (en) * | 1993-07-22 | 1995-04-04 | Ethicon, Inc. | Electrosurgical hemostatic device |
US5324286A (en) * | 1993-01-21 | 1994-06-28 | Arthur A. Fowle, Inc. | Entrained cryogenic droplet transfer method and cryosurgical instrument |
US5409483A (en) * | 1993-01-22 | 1995-04-25 | Jeffrey H. Reese | Direct visualization surgical probe |
IL104506A (en) * | 1993-01-25 | 1997-11-20 | Israel State | Fast changing heating- cooling device and method, particularly for cryogenic and/or surgical use |
US5645082A (en) | 1993-01-29 | 1997-07-08 | Cardima, Inc. | Intravascular method and system for treating arrhythmia |
DE4303882C2 (en) * | 1993-02-10 | 1995-02-09 | Kernforschungsz Karlsruhe | Combination instrument for separation and coagulation for minimally invasive surgery |
US7213601B2 (en) | 1993-02-22 | 2007-05-08 | Heartport, Inc | Minimally-invasive devices and methods for treatment of congestive heart failure |
US6161543A (en) | 1993-02-22 | 2000-12-19 | Epicor, Inc. | Methods of epicardial ablation for creating a lesion around the pulmonary veins |
US5425705A (en) * | 1993-02-22 | 1995-06-20 | Stanford Surgical Technologies, Inc. | Thoracoscopic devices and methods for arresting the heart |
US5797960A (en) | 1993-02-22 | 1998-08-25 | Stevens; John H. | Method and apparatus for thoracoscopic intracardiac procedures |
US5476495A (en) | 1993-03-16 | 1995-12-19 | Ep Technologies, Inc. | Cardiac mapping and ablation systems |
US5403311A (en) * | 1993-03-29 | 1995-04-04 | Boston Scientific Corporation | Electro-coagulation and ablation and other electrotherapeutic treatments of body tissue |
WO1994023793A1 (en) | 1993-04-15 | 1994-10-27 | Siemens Aktiengesellschaft | Therapeutic appliance for the treatment of conditions of the heart and of blood vessels in the vicinity of the heart |
US5860974A (en) | 1993-07-01 | 1999-01-19 | Boston Scientific Corporation | Heart ablation catheter with expandable electrode and method of coupling energy to an electrode on a catheter shaft |
US5630837A (en) | 1993-07-01 | 1997-05-20 | Boston Scientific Corporation | Acoustic ablation |
DE69432148T2 (en) | 1993-07-01 | 2003-10-16 | Boston Scient Ltd | CATHETER FOR IMAGE DISPLAY, DISPLAY OF ELECTRICAL SIGNALS AND ABLATION |
US5571088A (en) | 1993-07-01 | 1996-11-05 | Boston Scientific Corporation | Ablation catheters |
US5487757A (en) * | 1993-07-20 | 1996-01-30 | Medtronic Cardiorhythm | Multicurve deflectable catheter |
US5545200A (en) * | 1993-07-20 | 1996-08-13 | Medtronic Cardiorhythm | Steerable electrophysiology catheter |
US5921982A (en) | 1993-07-30 | 1999-07-13 | Lesh; Michael D. | Systems and methods for ablating body tissue |
US5928191A (en) | 1993-07-30 | 1999-07-27 | E.P. Technologies, Inc. | Variable curve electrophysiology catheter |
US5385148A (en) | 1993-07-30 | 1995-01-31 | The Regents Of The University Of California | Cardiac imaging and ablation catheter |
WO1995005212A2 (en) * | 1993-08-11 | 1995-02-23 | Electro-Catheter Corporation | Improved ablation electrode |
US5405376A (en) * | 1993-08-27 | 1995-04-11 | Medtronic, Inc. | Method and apparatus for ablation |
US5431649A (en) | 1993-08-27 | 1995-07-11 | Medtronic, Inc. | Method and apparatus for R-F ablation |
US5437651A (en) | 1993-09-01 | 1995-08-01 | Research Medical, Inc. | Medical suction apparatus |
US5396887A (en) | 1993-09-23 | 1995-03-14 | Cardiac Pathways Corporation | Apparatus and method for detecting contact pressure |
US5607462A (en) | 1993-09-24 | 1997-03-04 | Cardiac Pathways Corporation | Catheter assembly, catheter and multi-catheter introducer for use therewith |
US5496312A (en) | 1993-10-07 | 1996-03-05 | Valleylab Inc. | Impedance and temperature generator control |
US5400783A (en) | 1993-10-12 | 1995-03-28 | Cardiac Pathways Corporation | Endocardial mapping apparatus with rotatable arm and method |
US5673695A (en) * | 1995-08-02 | 1997-10-07 | Ep Technologies, Inc. | Methods for locating and ablating accessory pathways in the heart |
US5582609A (en) | 1993-10-14 | 1996-12-10 | Ep Technologies, Inc. | Systems and methods for forming large lesions in body tissue using curvilinear electrode elements |
WO1995010322A1 (en) | 1993-10-15 | 1995-04-20 | Ep Technologies, Inc. | Creating complex lesion patterns in body tissue |
WO1995010225A1 (en) | 1993-10-15 | 1995-04-20 | Ep Technologies, Inc. | Multiple electrode element for mapping and ablating |
US6146379A (en) | 1993-10-15 | 2000-11-14 | Ep Technologies, Inc. | Systems and methods for creating curvilinear lesions in body tissue |
US5545193A (en) | 1993-10-15 | 1996-08-13 | Ep Technologies, Inc. | Helically wound radio-frequency emitting electrodes for creating lesions in body tissue |
US5575810A (en) * | 1993-10-15 | 1996-11-19 | Ep Technologies, Inc. | Composite structures and methods for ablating tissue to form complex lesion patterns in the treatment of cardiac conditions and the like |
US5656028A (en) | 1993-11-03 | 1997-08-12 | Daig Corporation | Process for the nonsurgical mapping and/or treatment of ectopic atrial tachycardia using a guiding introducer |
US5628316A (en) | 1993-11-03 | 1997-05-13 | Swartz; John F. | Guiding introducer system for use in the right atrium |
US5564440A (en) | 1993-11-03 | 1996-10-15 | Daig Corporation | Method for mopping and/or ablation of anomalous conduction pathways |
US5427119A (en) | 1993-11-03 | 1995-06-27 | Daig Corporation | Guiding introducer for right atrium |
US5640955A (en) | 1995-02-14 | 1997-06-24 | Daig Corporation | Guiding introducers for use in the treatment of accessory pathways around the mitral valve using a retrograde approach |
US5575766A (en) * | 1993-11-03 | 1996-11-19 | Daig Corporation | Process for the nonsurgical mapping and treatment of atrial arrhythmia using catheters guided by shaped guiding introducers |
US5722400A (en) | 1995-02-16 | 1998-03-03 | Daig Corporation | Guiding introducers for use in the treatment of left ventricular tachycardia |
US5497774A (en) | 1993-11-03 | 1996-03-12 | Daig Corporation | Guiding introducer for left atrium |
US5536267A (en) | 1993-11-08 | 1996-07-16 | Zomed International | Multiple electrode ablation apparatus |
GB2283678B (en) | 1993-11-09 | 1998-06-03 | Spembly Medical Ltd | Cryosurgical catheter probe |
US5921924A (en) | 1993-12-03 | 1999-07-13 | Avitall; Boaz | Mapping and ablation catheter system utilizing multiple control elements |
US5487385A (en) * | 1993-12-03 | 1996-01-30 | Avitall; Boaz | Atrial mapping and ablation catheter system |
US5730127A (en) * | 1993-12-03 | 1998-03-24 | Avitall; Boaz | Mapping and ablation catheter system |
US5462521A (en) * | 1993-12-21 | 1995-10-31 | Angeion Corporation | Fluid cooled and perfused tip for a catheter |
ES2129803T3 (en) | 1993-12-22 | 1999-06-16 | Sulzer Osypka Gmbh | ULTRASONICALLY MARKED CARDIAC ABLATION CATHETER. |
US5437664A (en) | 1994-01-18 | 1995-08-01 | Endovascular, Inc. | Apparatus and method for venous ligation |
US5462545A (en) | 1994-01-31 | 1995-10-31 | New England Medical Center Hospitals, Inc. | Catheter electrodes |
US5501698A (en) | 1994-02-14 | 1996-03-26 | Heartport, Inc. | Endoscopic microsurgical instruments and methods |
EP0671221B1 (en) | 1994-03-11 | 2000-04-26 | Intravascular Research Limited | Ultrasonic transducer array and method of manufacturing the same |
US5807308A (en) | 1996-02-23 | 1998-09-15 | Somnus Medical Technologies, Inc. | Method and apparatus for treatment of air way obstructions |
GB2289414B (en) | 1994-05-10 | 1998-05-13 | Spembly Medical Ltd | Cryosurgical instrument |
GB2289413A (en) * | 1994-05-10 | 1995-11-22 | Spembly Medical Ltd | Cryosurgical instrument |
GB2289510A (en) | 1994-05-10 | 1995-11-22 | Spembly Medical Ltd | Connector |
GB2289412B (en) | 1994-05-10 | 1998-09-16 | Spembly Medical Ltd | Cryosurgical instrument |
US5478309A (en) * | 1994-05-27 | 1995-12-26 | William P. Sweezer, Jr. | Catheter system and method for providing cardiopulmonary bypass pump support during heart surgery |
US5560362A (en) | 1994-06-13 | 1996-10-01 | Acuson Corporation | Active thermal control of ultrasound transducers |
US5617854A (en) | 1994-06-22 | 1997-04-08 | Munsif; Anand | Shaped catheter device and method |
US5681278A (en) * | 1994-06-23 | 1997-10-28 | Cormedics Corp. | Coronary vasculature treatment method |
US5823197A (en) | 1994-06-24 | 1998-10-20 | Somnus Medical Technologies, Inc. | Method for internal ablation of turbinates |
US5575788A (en) | 1994-06-24 | 1996-11-19 | Stuart D. Edwards | Thin layer ablation apparatus |
US5800429A (en) | 1994-06-24 | 1998-09-01 | Somnus Medical Technologies, Inc. | Noninvasive apparatus for ablating turbinates |
US5505730A (en) | 1994-06-24 | 1996-04-09 | Stuart D. Edwards | Thin layer ablation apparatus |
US5681308A (en) | 1994-06-24 | 1997-10-28 | Stuart D. Edwards | Ablation apparatus for cardiac chambers |
US5452582A (en) * | 1994-07-06 | 1995-09-26 | Apd Cryogenics, Inc. | Cryo-probe |
US5680860A (en) * | 1994-07-07 | 1997-10-28 | Cardiac Pathways Corporation | Mapping and/or ablation catheter with coilable distal extremity and method for using same |
US5690611A (en) * | 1994-07-08 | 1997-11-25 | Daig Corporation | Process for the treatment of atrial arrhythima using a catheter guided by shaped giding introducers |
JPH0845246A (en) * | 1994-07-29 | 1996-02-16 | Sony Corp | Recording medium, reproducing method, recording device and reproducing device |
US5545195A (en) | 1994-08-01 | 1996-08-13 | Boston Scientific Corporation | Interstitial heating of tissue |
US5810802A (en) | 1994-08-08 | 1998-09-22 | E.P. Technologies, Inc. | Systems and methods for controlling tissue ablation using multiple temperature sensing elements |
US6558375B1 (en) | 2000-07-14 | 2003-05-06 | Cardiofocus, Inc. | Cardiac ablation instrument |
US6071274A (en) | 1996-12-19 | 2000-06-06 | Ep Technologies, Inc. | Loop structures for supporting multiple electrode elements |
US6152920A (en) | 1997-10-10 | 2000-11-28 | Ep Technologies, Inc. | Surgical method and apparatus for positioning a diagnostic or therapeutic element within the body |
US6464700B1 (en) | 1994-10-07 | 2002-10-15 | Scimed Life Systems, Inc. | Loop structures for positioning a diagnostic or therapeutic element on the epicardium or other organ surface |
US5836947A (en) | 1994-10-07 | 1998-11-17 | Ep Technologies, Inc. | Flexible structures having movable splines for supporting electrode elements |
US6142994A (en) | 1994-10-07 | 2000-11-07 | Ep Technologies, Inc. | Surgical method and apparatus for positioning a diagnostic a therapeutic element within the body |
US5885278A (en) | 1994-10-07 | 1999-03-23 | E.P. Technologies, Inc. | Structures for deploying movable electrode elements |
US5722402A (en) | 1994-10-11 | 1998-03-03 | Ep Technologies, Inc. | Systems and methods for guiding movable electrode elements within multiple-electrode structures |
US5830214A (en) | 1994-11-08 | 1998-11-03 | Heartport, Inc. | Fluid-evacuating electrosurgical device |
US5573532A (en) * | 1995-01-13 | 1996-11-12 | Cryomedical Sciences, Inc. | Cryogenic surgical instrument and method of manufacturing the same |
US5595183A (en) | 1995-02-17 | 1997-01-21 | Ep Technologies, Inc. | Systems and methods for examining heart tissue employing multiple electrode structures and roving electrodes |
US5676662A (en) * | 1995-03-17 | 1997-10-14 | Daig Corporation | Ablation catheter |
US5626607A (en) * | 1995-04-03 | 1997-05-06 | Heartport, Inc. | Clamp assembly and method of use |
WO1996034646A1 (en) | 1995-05-01 | 1996-11-07 | Medtronic Cardiorhythm | Dual curve ablation catheter and method |
US5688267A (en) | 1995-05-01 | 1997-11-18 | Ep Technologies, Inc. | Systems and methods for sensing multiple temperature conditions during tissue ablation |
US5735280A (en) | 1995-05-02 | 1998-04-07 | Heart Rhythm Technologies, Inc. | Ultrasound energy delivery system and method |
EP0957792A4 (en) | 1995-05-02 | 2000-09-20 | Heart Rhythm Tech Inc | System for controlling the energy delivered to a patient for ablation |
US5697949A (en) | 1995-05-18 | 1997-12-16 | Symbiosis Corporation | Small diameter endoscopic instruments |
US6022346A (en) | 1995-06-07 | 2000-02-08 | Ep Technologies, Inc. | Tissue heating and ablation systems and methods using self-heated electrodes |
US6293943B1 (en) | 1995-06-07 | 2001-09-25 | Ep Technologies, Inc. | Tissue heating and ablation systems and methods which predict maximum tissue temperature |
US5827216A (en) | 1995-06-07 | 1998-10-27 | Cormedics Corp. | Method and apparatus for accessing the pericardial space |
US5718241A (en) | 1995-06-07 | 1998-02-17 | Biosense, Inc. | Apparatus and method for treating cardiac arrhythmias with no discrete target |
US6113592A (en) | 1995-06-09 | 2000-09-05 | Engineering & Research Associates, Inc. | Apparatus and method for controlling ablation depth |
US5697925A (en) | 1995-06-09 | 1997-12-16 | Engineering & Research Associates, Inc. | Apparatus and method for thermal ablation |
US6023638A (en) | 1995-07-28 | 2000-02-08 | Scimed Life Systems, Inc. | System and method for conducting electrophysiological testing using high-voltage energy pulses to stun tissue |
US5678550A (en) * | 1995-08-11 | 1997-10-21 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Apparatus and method for in situ detection of areas of cardiac electrical activity |
US5800484A (en) | 1995-08-15 | 1998-09-01 | Rita Medical Systems, Inc. | Multiple antenna ablation apparatus with expanded electrodes |
US5836311A (en) | 1995-09-20 | 1998-11-17 | Medtronic, Inc. | Method and apparatus for temporarily immobilizing a local area of tissue |
US5590657A (en) | 1995-11-06 | 1997-01-07 | The Regents Of The University Of Michigan | Phased array ultrasound system and method for cardiac ablation |
US5716389A (en) * | 1995-11-13 | 1998-02-10 | Walinsky; Paul | Cardiac ablation catheter arrangement with movable guidewire |
US5733280A (en) * | 1995-11-15 | 1998-03-31 | Avitall; Boaz | Cryogenic epicardial mapping and ablation |
US5707355A (en) | 1995-11-15 | 1998-01-13 | Zimmon Science Corporation | Apparatus and method for the treatment of esophageal varices and mucosal neoplasms |
US5906606A (en) | 1995-12-04 | 1999-05-25 | Target Therapuetics, Inc. | Braided body balloon catheter |
US5827281A (en) | 1996-01-05 | 1998-10-27 | Levin; John M. | Insulated surgical scissors |
US5671747A (en) | 1996-01-24 | 1997-09-30 | Hewlett-Packard Company | Ultrasound probe having interchangeable accessories |
US5904711A (en) | 1996-02-08 | 1999-05-18 | Heartport, Inc. | Expandable thoracoscopic defibrillation catheter system and method |
US5810721A (en) | 1996-03-04 | 1998-09-22 | Heartport, Inc. | Soft tissue retractor and method for providing surgical access |
US5800482A (en) | 1996-03-06 | 1998-09-01 | Cardiac Pathways Corporation | Apparatus and method for linear lesion ablation |
US5895417A (en) | 1996-03-06 | 1999-04-20 | Cardiac Pathways Corporation | Deflectable loop design for a linear lesion ablation apparatus |
US6015407A (en) | 1996-03-06 | 2000-01-18 | Cardiac Pathways Corporation | Combination linear ablation and cooled tip RF catheters |
US5755760A (en) * | 1996-03-11 | 1998-05-26 | Medtronic, Inc. | Deflectable catheter |
US5676692A (en) | 1996-03-28 | 1997-10-14 | Indianapolis Center For Advanced Research, Inc. | Focussed ultrasound tissue treatment method |
US6302880B1 (en) | 1996-04-08 | 2001-10-16 | Cardima, Inc. | Linear ablation assembly |
US5863291A (en) | 1996-04-08 | 1999-01-26 | Cardima, Inc. | Linear ablation assembly |
US5800428A (en) | 1996-05-16 | 1998-09-01 | Angeion Corporation | Linear catheter ablation system |
US5730074A (en) | 1996-06-07 | 1998-03-24 | Farmer Fabrications, Inc. | Liquid dispenser for seed planter |
US5861021A (en) | 1996-06-17 | 1999-01-19 | Urologix Inc | Microwave thermal therapy of cardiac tissue |
US5776176A (en) | 1996-06-17 | 1998-07-07 | Urologix Inc. | Microwave antenna for arterial for arterial microwave applicator |
US5882346A (en) | 1996-07-15 | 1999-03-16 | Cardiac Pathways Corporation | Shapable catheter using exchangeable core and method of use |
US5720775A (en) * | 1996-07-31 | 1998-02-24 | Cordis Corporation | Percutaneous atrial line ablation catheter |
US5993447A (en) | 1996-08-16 | 1999-11-30 | United States Surgical | Apparatus for thermal treatment of tissue |
US5846218A (en) | 1996-09-05 | 1998-12-08 | Pharmasonics, Inc. | Balloon catheters having ultrasonically driven interface surfaces and methods for their use |
US5846187A (en) | 1996-09-13 | 1998-12-08 | Genzyme Corporation | Redo sternotomy retractor |
US5697928A (en) * | 1996-09-23 | 1997-12-16 | Uab Research Foundation | Cardic electrode catheter |
US5891134A (en) | 1996-09-24 | 1999-04-06 | Goble; Colin | System and method for applying thermal energy to tissue |
US6237605B1 (en) | 1996-10-22 | 2001-05-29 | Epicor, Inc. | Methods of epicardial ablation |
US6311692B1 (en) | 1996-10-22 | 2001-11-06 | Epicor, Inc. | Apparatus and method for diagnosis and therapy of electrophysiological disease |
US7052493B2 (en) | 1996-10-22 | 2006-05-30 | Epicor Medical, Inc. | Methods and devices for ablation |
US6719755B2 (en) | 1996-10-22 | 2004-04-13 | Epicor Medical, Inc. | Methods and devices for ablation |
US6840936B2 (en) | 1996-10-22 | 2005-01-11 | Epicor Medical, Inc. | Methods and devices for ablation |
US6805128B1 (en) | 1996-10-22 | 2004-10-19 | Epicor Medical, Inc. | Apparatus and method for ablating tissue |
US20040260278A1 (en) | 1996-10-22 | 2004-12-23 | Anderson Scott C. | Apparatus and method for ablating tissue |
US5893848A (en) | 1996-10-24 | 1999-04-13 | Plc Medical Systems, Inc. | Gauging system for monitoring channel depth in percutaneous endocardial revascularization |
US5785706A (en) | 1996-11-18 | 1998-07-28 | Daig Corporation | Nonsurgical mapping and treatment of cardiac arrhythmia using a catheter contained within a guiding introducer containing openings |
US5910150A (en) | 1996-12-02 | 1999-06-08 | Angiotrax, Inc. | Apparatus for performing surgery |
US5931810A (en) | 1996-12-05 | 1999-08-03 | Comedicus Incorporated | Method for accessing the pericardial space |
US5782828A (en) | 1996-12-11 | 1998-07-21 | Irvine Biomedical, Inc. | Ablation catheter with multiple flexible curves |
US6071279A (en) | 1996-12-19 | 2000-06-06 | Ep Technologies, Inc. | Branched structures for supporting multiple electrode elements |
US6048329A (en) | 1996-12-19 | 2000-04-11 | Ep Technologies, Inc. | Catheter distal assembly with pull wires |
US6332880B1 (en) | 1996-12-19 | 2001-12-25 | Ep Technologies, Inc. | Loop structures for supporting multiple electrode elements |
US5895386A (en) * | 1996-12-20 | 1999-04-20 | Electroscope, Inc. | Bipolar coagulation apparatus and method for arthroscopy |
US5919188A (en) | 1997-02-04 | 1999-07-06 | Medtronic, Inc. | Linear ablation catheter |
US5916213A (en) | 1997-02-04 | 1999-06-29 | Medtronic, Inc. | Systems and methods for tissue mapping and ablation |
US5844349A (en) | 1997-02-11 | 1998-12-01 | Tetrad Corporation | Composite autoclavable ultrasonic transducers and methods of making |
US5788636A (en) | 1997-02-25 | 1998-08-04 | Acuson Corporation | Method and system for forming an ultrasound image of a tissue while simultaneously ablating the tissue |
US5899898A (en) | 1997-02-27 | 1999-05-04 | Cryocath Technologies Inc. | Cryosurgical linear ablation |
US5897554A (en) | 1997-03-01 | 1999-04-27 | Irvine Biomedical, Inc. | Steerable catheter having a loop electrode |
US5873845A (en) | 1997-03-17 | 1999-02-23 | General Electric Company | Ultrasound transducer with focused ultrasound refraction plate |
US6214754B1 (en) | 1997-03-21 | 2001-04-10 | Electro-Science Laboratories, Inc. | Silicon nitride coating compositions |
US5954661A (en) | 1997-03-31 | 1999-09-21 | Thomas Jefferson University | Tissue characterization and treatment using pacing |
US5879295A (en) | 1997-04-02 | 1999-03-09 | Medtronic, Inc. | Enhanced contact steerable bowing electrode catheter assembly |
US5906580A (en) | 1997-05-05 | 1999-05-25 | Creare Inc. | Ultrasound system and method of administering ultrasound including a plurality of multi-layer transducer elements |
US5971983A (en) | 1997-05-09 | 1999-10-26 | The Regents Of The University Of California | Tissue ablation device and method of use |
US6012457A (en) | 1997-07-08 | 2000-01-11 | The Regents Of The University Of California | Device and method for forming a circumferential conduction block in a pulmonary vein |
US5921983A (en) * | 1997-05-13 | 1999-07-13 | Shannon, Jr.; Malcolm L. | Electrosurgical device for uvulopalatoplasty |
US5792140A (en) | 1997-05-15 | 1998-08-11 | Irvine Biomedical, Inc. | Catheter having cooled multiple-needle electrode |
US5849028A (en) | 1997-05-16 | 1998-12-15 | Irvine Biomedical, Inc. | Catheter and method for radiofrequency ablation of cardiac tissue |
US6217576B1 (en) | 1997-05-19 | 2001-04-17 | Irvine Biomedical Inc. | Catheter probe for treating focal atrial fibrillation in pulmonary veins |
US5876399A (en) | 1997-05-28 | 1999-03-02 | Irvine Biomedical, Inc. | Catheter system and methods thereof |
WO1998056324A1 (en) | 1997-06-13 | 1998-12-17 | Arthrocare Corporation | Electrosurgical systems and methods for recanalization of occluded body lumens |
US6514249B1 (en) | 1997-07-08 | 2003-02-04 | Atrionix, Inc. | Positioning system and method for orienting an ablation element within a pulmonary vein ostium |
US6164283A (en) | 1997-07-08 | 2000-12-26 | The Regents Of The University Of California | Device and method for forming a circumferential conduction block in a pulmonary vein |
US6117101A (en) | 1997-07-08 | 2000-09-12 | The Regents Of The University Of California | Circumferential ablation device assembly |
US6245064B1 (en) | 1997-07-08 | 2001-06-12 | Atrionix, Inc. | Circumferential ablation device assembly |
US6096037A (en) * | 1997-07-29 | 2000-08-01 | Medtronic, Inc. | Tissue sealing electrosurgery device and methods of sealing tissue |
AU732188B2 (en) | 1997-08-13 | 2001-04-12 | Surx, Inc. | Noninvasive devices, methods, and systems for shrinking of tissues |
US5908029A (en) | 1997-08-15 | 1999-06-01 | Heartstent Corporation | Coronary artery bypass with reverse flow |
US6139563A (en) * | 1997-09-25 | 2000-10-31 | Allegiance Corporation | Surgical device with malleable shaft |
US6120496A (en) | 1998-05-05 | 2000-09-19 | Scimed Life Systems, Inc. | Surgical method and apparatus for positioning a diagnostic or therapeutic element within the body and coupling device for use with same |
US6610055B1 (en) | 1997-10-10 | 2003-08-26 | Scimed Life Systems, Inc. | Surgical method for positioning a diagnostic or therapeutic element on the epicardium or other organ surface |
US8709007B2 (en) | 1997-10-15 | 2014-04-29 | St. Jude Medical, Atrial Fibrillation Division, Inc. | Devices and methods for ablating cardiac tissue |
US6007499A (en) | 1997-10-31 | 1999-12-28 | University Of Washington | Method and apparatus for medical procedures using high-intensity focused ultrasound |
US6120500A (en) | 1997-11-12 | 2000-09-19 | Daig Corporation | Rail catheter ablation and mapping system |
US6917834B2 (en) | 1997-12-03 | 2005-07-12 | Boston Scientific Scimed, Inc. | Devices and methods for creating lesions in endocardial and surrounding tissue to isolate focal arrhythmia substrates |
US6270471B1 (en) | 1997-12-23 | 2001-08-07 | Misonix Incorporated | Ultrasonic probe with isolated outer cannula |
PT931775E (en) * | 1998-01-26 | 2001-10-31 | Luigi Riva | METHOD FOR AIR COOLING IN EXISTING CEILING SPACES IN BUILDINGS |
US6325798B1 (en) | 1998-02-19 | 2001-12-04 | Curon Medical, Inc. | Vacuum-assisted systems and methods for treating sphincters and adjoining tissue regions |
US6142993A (en) | 1998-02-27 | 2000-11-07 | Ep Technologies, Inc. | Collapsible spline structure using a balloon as an expanding actuator |
US6042580A (en) | 1998-05-05 | 2000-03-28 | Cardiac Pacemakers, Inc. | Electrode having composition-matched, common-lead thermocouple wire for providing multiple temperature-sensitive junctions |
US6527767B2 (en) | 1998-05-20 | 2003-03-04 | New England Medical Center | Cardiac ablation system and method for treatment of cardiac arrhythmias and transmyocardial revascularization |
US6186951B1 (en) | 1998-05-26 | 2001-02-13 | Riverside Research Institute | Ultrasonic systems and methods for fluid perfusion and flow rate measurement |
US6231518B1 (en) | 1998-05-26 | 2001-05-15 | Comedicus Incorporated | Intrapericardial electrophysiological procedures |
US6241727B1 (en) | 1998-05-27 | 2001-06-05 | Irvine Biomedical, Inc. | Ablation catheter system having circular lesion capabilities |
US6241722B1 (en) | 1998-06-17 | 2001-06-05 | Cryogen, Inc. | Cryogenic device, system and method of using same |
US6238393B1 (en) | 1998-07-07 | 2001-05-29 | Medtronic, Inc. | Method and apparatus for creating a bi-polar virtual electrode used for the ablation of tissue |
US6016811A (en) | 1998-09-01 | 2000-01-25 | Fidus Medical Technology Corporation | Method of using a microwave ablation catheter with a loop configuration |
US6251128B1 (en) | 1998-09-01 | 2001-06-26 | Fidus Medical Technology Corporation | Microwave ablation catheter with loop configuration |
US6042556A (en) | 1998-09-04 | 2000-03-28 | University Of Washington | Method for determining phase advancement of transducer elements in high intensity focused ultrasound |
US6245065B1 (en) | 1998-09-10 | 2001-06-12 | Scimed Life Systems, Inc. | Systems and methods for controlling power in an electrosurgical probe |
US6385472B1 (en) | 1999-09-10 | 2002-05-07 | Stereotaxis, Inc. | Magnetically navigable telescoping catheter and method of navigating telescoping catheter |
US6425867B1 (en) | 1998-09-18 | 2002-07-30 | University Of Washington | Noise-free real time ultrasonic imaging of a treatment site undergoing high intensity focused ultrasound therapy |
US6245062B1 (en) | 1998-10-23 | 2001-06-12 | Afx, Inc. | Directional reflector shield assembly for a microwave ablation instrument |
US6296619B1 (en) | 1998-12-30 | 2001-10-02 | Pharmasonics, Inc. | Therapeutic ultrasonic catheter for delivering a uniform energy dose |
US6206831B1 (en) | 1999-01-06 | 2001-03-27 | Scimed Life Systems, Inc. | Ultrasound-guided ablation catheter and methods of use |
CA2368707C (en) | 1999-02-02 | 2006-06-06 | Transurgical, Inc. | Intrabody hifu applicator |
US6217528B1 (en) | 1999-02-11 | 2001-04-17 | Scimed Life Systems, Inc. | Loop structure having improved tissue contact capability |
US6508774B1 (en) | 1999-03-09 | 2003-01-21 | Transurgical, Inc. | Hifu applications with feedback control |
US6325797B1 (en) | 1999-04-05 | 2001-12-04 | Medtronic, Inc. | Ablation catheter and method for isolating a pulmonary vein |
US20010007070A1 (en) | 1999-04-05 | 2001-07-05 | Medtronic, Inc. | Ablation catheter assembly and method for isolating a pulmonary vein |
US6270476B1 (en) * | 1999-04-23 | 2001-08-07 | Cryocath Technologies, Inc. | Catheter |
US6398792B1 (en) | 1999-06-21 | 2002-06-04 | O'connor Lawrence | Angioplasty catheter with transducer using balloon for focusing of ultrasonic energy and method for use |
US6235024B1 (en) | 1999-06-21 | 2001-05-22 | Hosheng Tu | Catheters system having dual ablation capability |
US6461356B1 (en) | 1999-07-01 | 2002-10-08 | C.R. Bard, Inc. | Medical device having an incrementally displaceable electrode |
US6290699B1 (en) | 1999-07-07 | 2001-09-18 | Uab Research Foundation | Ablation tool for forming lesions in body tissue |
US20070282324A1 (en) | 1999-07-19 | 2007-12-06 | Matthias Vaska | Apparatus and method for diagnosis and therapy of electrophysiological disease |
WO2001005306A1 (en) | 1999-07-19 | 2001-01-25 | Epicor, Inc. | Apparatus and method for ablating tissue |
US6287261B1 (en) | 1999-07-21 | 2001-09-11 | Scimed Life Systems, Inc. | Focused ultrasound transducers and systems |
US6371955B1 (en) | 1999-08-10 | 2002-04-16 | Biosense Webster, Inc. | Atrial branding iron catheter and a method for treating atrial fibrillation |
US6332881B1 (en) | 1999-09-01 | 2001-12-25 | Cardima, Inc. | Surgical ablation tool |
US6607520B2 (en) | 1999-09-15 | 2003-08-19 | The General Hospital Corporation | Coiled ablation catheter system |
US6368275B1 (en) | 1999-10-07 | 2002-04-09 | Acuson Corporation | Method and apparatus for diagnostic medical information gathering, hyperthermia treatment, or directed gene therapy |
WO2001028623A2 (en) | 1999-10-18 | 2001-04-26 | Focus Surgery, Inc. | Split beam transducer |
US6745080B2 (en) | 1999-11-22 | 2004-06-01 | Scimed Life Systems, Inc. | Helical and pre-oriented loop structures for supporting diagnostic and therapeutic elements in contact with body tissue |
US6645199B1 (en) | 1999-11-22 | 2003-11-11 | Scimed Life Systems, Inc. | Loop structures for supporting diagnostic and therapeutic elements contact with body tissue and expandable push devices for use with same |
EP1241994A4 (en) | 1999-12-23 | 2005-12-14 | Therus Corp | Ultrasound transducers for imaging and therapy |
US6409720B1 (en) | 2000-01-19 | 2002-06-25 | Medtronic Xomed, Inc. | Methods of tongue reduction using high intensity focused ultrasound to form an ablated tissue area containing a plurality of lesions |
US6692450B1 (en) | 2000-01-19 | 2004-02-17 | Medtronic Xomed, Inc. | Focused ultrasound ablation devices having selectively actuatable ultrasound emitting elements and methods of using the same |
US6413254B1 (en) | 2000-01-19 | 2002-07-02 | Medtronic Xomed, Inc. | Method of tongue reduction by thermal ablation using high intensity focused ultrasound |
US6361531B1 (en) | 2000-01-21 | 2002-03-26 | Medtronic Xomed, Inc. | Focused ultrasound ablation devices having malleable handle shafts and methods of using the same |
US6663622B1 (en) | 2000-02-11 | 2003-12-16 | Iotek, Inc. | Surgical devices and methods for use in tissue ablation procedures |
WO2001070112A1 (en) | 2000-03-20 | 2001-09-27 | Pharmasonics, Inc. | High output therapeutic ultrasound transducer |
US6605084B2 (en) | 2000-03-24 | 2003-08-12 | Transurgical, Inc. | Apparatus and methods for intrabody thermal treatment |
DE60114164D1 (en) | 2000-03-24 | 2005-11-24 | Boston Scient Ltd | HANGING TO POSITION A DIAGNOSTIC OR THERAPEUTIC DEVICE ON THE EPICARD OR ANY OTHER ORGAN SURFACE |
US6419648B1 (en) | 2000-04-21 | 2002-07-16 | Insightec-Txsonics Ltd. | Systems and methods for reducing secondary hot spots in a phased array focused ultrasound system |
US20020107514A1 (en) * | 2000-04-27 | 2002-08-08 | Hooven Michael D. | Transmural ablation device with parallel jaws |
US6546935B2 (en) | 2000-04-27 | 2003-04-15 | Atricure, Inc. | Method for transmural ablation |
WO2001082778A2 (en) | 2000-04-28 | 2001-11-08 | Focus Surgery, Inc. | Ablation system with visualization |
EP1289439B1 (en) | 2000-06-13 | 2005-03-16 | Atrionix, Inc. | Surgical ablation probe for forming a circumferential lesion |
US6477396B1 (en) | 2000-07-07 | 2002-11-05 | Biosense Webster, Inc. | Mapping and ablation catheter |
US20020068885A1 (en) | 2000-07-13 | 2002-06-06 | Harhen Edward Paul | Energy application with inflatable annular lens |
WO2002005868A2 (en) | 2000-07-13 | 2002-01-24 | Transurgical, Inc. | Thermal treatment methods and apparatus with focused energy application |
US6811562B1 (en) | 2000-07-31 | 2004-11-02 | Epicor, Inc. | Procedures for photodynamic cardiac ablation therapy and devices for those procedures |
US6669692B1 (en) | 2000-08-21 | 2003-12-30 | Biosense Webster, Inc. | Ablation catheter with cooled linear electrode |
US6942661B2 (en) | 2000-08-30 | 2005-09-13 | Boston Scientific Scimed, Inc. | Fluid cooled apparatus for supporting diagnostic and therapeutic elements in contact with tissue |
US6436059B1 (en) | 2000-09-12 | 2002-08-20 | Claudio I. Zanelli | Detection of imd contact and alignment based on changes in frequency response characteristics |
JP2002093160A (en) * | 2000-09-18 | 2002-03-29 | Mitsubishi Electric Corp | Semiconductor memory |
US6641579B1 (en) | 2000-09-29 | 2003-11-04 | Spectrasonics Imaging, Inc. | Apparatus and method for ablating cardiac tissue |
US6926669B1 (en) | 2000-10-10 | 2005-08-09 | Medtronic, Inc. | Heart wall ablation/mapping catheter and method |
US20020087151A1 (en) | 2000-12-29 | 2002-07-04 | Afx, Inc. | Tissue ablation apparatus with a sliding ablation instrument and method |
US6575921B2 (en) | 2001-02-09 | 2003-06-10 | Acorn Cardiovascular, Inc. | Device for heart measurement |
US6743225B2 (en) | 2001-03-27 | 2004-06-01 | Uab Research Foundation | Electrophysiologic measure of endpoints for ablation lesions created in fibrillating substrates |
US6771996B2 (en) | 2001-05-24 | 2004-08-03 | Cardiac Pacemakers, Inc. | Ablation and high-resolution mapping catheter system for pulmonary vein foci elimination |
US6740080B2 (en) | 2001-08-31 | 2004-05-25 | Cardiac Pacemakers, Inc. | Ablation system with selectable current path means |
US6767346B2 (en) * | 2001-09-20 | 2004-07-27 | Endocare, Inc. | Cryosurgical probe with bellows shaft |
US6942662B2 (en) | 2001-12-27 | 2005-09-13 | Gyrus Group Plc | Surgical Instrument |
US20070293855A1 (en) | 2002-02-15 | 2007-12-20 | Sliwa John W Jr | Methods and devices for ablation |
US7044946B2 (en) * | 2003-06-10 | 2006-05-16 | Cryocath Technologies Inc. | Surgical clamp having treatment elements |
US7819860B2 (en) * | 2003-06-10 | 2010-10-26 | Medtronic Cryocath Lp | Surgical clamp having trasmurality assessment capabilities |
US7699845B2 (en) | 2006-06-23 | 2010-04-20 | St. Jude Medical, Atrial Fibrillation Division, Inc. | Ablation device and method with connector |
US20090192602A1 (en) | 2008-01-25 | 2009-07-30 | Medtronic, Inc. | Deformable Sizer and Holder Devices for Minimally Invasive Cardiac Surgery |
-
1997
- 1997-10-15 US US08/943,683 patent/US6161543A/en not_active Expired - Lifetime
- 1997-10-22 EP EP07018968A patent/EP1864619B1/en not_active Expired - Lifetime
- 1997-10-22 WO PCT/US1997/019552 patent/WO1998017187A1/en active IP Right Grant
- 1997-10-22 AU AU50031/97A patent/AU5003197A/en not_active Abandoned
- 1997-10-22 EP EP97912974A patent/EP0991362B1/en not_active Expired - Lifetime
-
2001
- 2001-09-12 US US09/954,393 patent/US20020017306A1/en not_active Abandoned
- 2001-12-21 US US10/032,303 patent/US20020068970A1/en not_active Abandoned
-
2002
- 2002-06-12 US US10/171,390 patent/US20030024537A1/en not_active Abandoned
- 2002-06-12 US US10/171,411 patent/US7387126B2/en not_active Expired - Fee Related
- 2002-06-14 US US10/172,732 patent/US20030029462A1/en not_active Abandoned
-
2007
- 2007-04-17 US US11/785,392 patent/US8002771B2/en not_active Expired - Fee Related
- 2007-11-06 US US11/935,582 patent/US7517345B2/en not_active Expired - Fee Related
-
2008
- 2008-04-14 US US12/102,592 patent/US20080183168A1/en not_active Abandoned
-
2009
- 2009-03-12 US US12/403,123 patent/US8177780B2/en not_active Expired - Fee Related
-
2012
- 2012-05-14 US US13/470,886 patent/US8535301B2/en not_active Expired - Fee Related
Cited By (96)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030036754A1 (en) * | 1998-10-23 | 2003-02-20 | Lyndall Erb | Vacuum-assisted securing apparatus for a microwave ablation instrument |
US20020128642A1 (en) * | 1998-10-23 | 2002-09-12 | Afx, Inc. | Directional microwave ablation instrument with marking device |
US9724105B2 (en) | 1999-05-20 | 2017-08-08 | Sentreheart, Inc. | Methods and apparatus for transpericardial left atrial appendage closure |
US8974473B2 (en) | 1999-05-20 | 2015-03-10 | Sentreheart, Inc. | Methods and apparatus for transpericardial left atrial appendage closure |
US8721663B2 (en) | 1999-05-20 | 2014-05-13 | Sentreheart, Inc. | Methods and apparatus for transpericardial left atrial appendage closure |
US20080125795A1 (en) * | 1999-05-20 | 2008-05-29 | Aaron V. Kaplan | Methods and apparatus for transpericardial left atrial appendage closure |
US20060206107A1 (en) * | 1999-05-28 | 2006-09-14 | Afx, Inc. | Monopole tip for ablation catheter and methods for using same |
US20060116673A1 (en) * | 2000-01-18 | 2006-06-01 | Jules Gauthier | Ablation instrument and method |
US20050251129A1 (en) * | 2000-04-12 | 2005-11-10 | Dany Berube | Electrode arrangement for use in a medical instrument |
US20040138652A1 (en) * | 2000-04-12 | 2004-07-15 | Afx, Inc. | Electrode arrangement for use in a medical instrument |
US20030236505A1 (en) * | 2000-07-21 | 2003-12-25 | Frank Bonadio | Cannula |
US20030050631A1 (en) * | 2000-12-29 | 2003-03-13 | Afx, Inc. | Tissue ablation apparatus with a sliding ablation instrument and method |
US20020087151A1 (en) * | 2000-12-29 | 2002-07-04 | Afx, Inc. | Tissue ablation apparatus with a sliding ablation instrument and method |
US20030109868A1 (en) * | 2000-12-29 | 2003-06-12 | Afx, Inc. | Medical instrument positioning tool and method |
US20040243118A1 (en) * | 2001-06-01 | 2004-12-02 | Ayers Gregory M. | Device and method for positioning a catheter tip for creating a cryogenic lesion |
US7099717B2 (en) * | 2002-01-03 | 2006-08-29 | Afx Inc. | Catheter having improved steering |
US20050075629A1 (en) * | 2002-02-19 | 2005-04-07 | Afx, Inc. | Apparatus and method for assessing tissue ablation transmurality |
US20030220639A1 (en) * | 2002-02-19 | 2003-11-27 | Afx, Inc. | Apparatus and method for assessing transmuarlity of a tissue ablation |
US7195625B2 (en) | 2002-12-11 | 2007-03-27 | Cryocor, Inc. | Catheter system for performing a single step cryoablation |
US20040243117A1 (en) * | 2002-12-11 | 2004-12-02 | Lentz David J. | Catheter system for performing a single step cryoablation |
US7914524B2 (en) | 2003-06-10 | 2011-03-29 | Medtronic Cryocath Lp | Surgical clamp having trasmurality assessment capabilities |
US20040254606A1 (en) * | 2003-06-10 | 2004-12-16 | Dan Wittenberger | Surgical clamp having trasmurality assessment capabilities |
US7819860B2 (en) | 2003-06-10 | 2010-10-26 | Medtronic Cryocath Lp | Surgical clamp having trasmurality assessment capabilities |
US7938823B2 (en) | 2003-06-10 | 2011-05-10 | Medtronic Cryocath Lp | Surgical clamp having transmurality assessment capabilities |
US7955325B2 (en) | 2003-06-10 | 2011-06-07 | Medtronic Cryocath Lp | Surgical clamp having transmurality assessment capabilities |
US20070149960A1 (en) * | 2003-06-10 | 2007-06-28 | Cryocath Technologies Inc. | Surgical clamp having transmurality assessment capabilities |
US20070149962A1 (en) * | 2003-06-10 | 2007-06-28 | Dan Wittenberger | Surgical clamp having trasmurality assessment capabilities |
US20070149969A1 (en) * | 2003-06-10 | 2007-06-28 | Cryocath Technologies Inc. | Surgical clamp having transmurality assessment capabilities |
US7981110B2 (en) | 2003-06-10 | 2011-07-19 | Medtronic Cryocath Lp | Surgical clamp having trasmurality assessment capabilities |
US8398632B1 (en) | 2003-06-10 | 2013-03-19 | Medtronic Cryocath Lp | Surgical clamp having treatment elements |
US20040254607A1 (en) * | 2003-06-10 | 2004-12-16 | Cryocath Technologies Inc. | Minimally invasive surgical clamp having treatment elements |
US7347856B2 (en) | 2003-06-10 | 2008-03-25 | Cryocath Technologies Inc. | Minimally invasive surgical clamp having treatment elements |
US20070073313A1 (en) * | 2003-10-09 | 2007-03-29 | Sentreheart, Inc. | Apparatus and method for the ligation of tissue |
US20080221593A1 (en) * | 2003-10-09 | 2008-09-11 | Sentreheart, Inc. | Apparatus and method for the ligation of tissue |
US9271819B2 (en) | 2003-10-09 | 2016-03-01 | Sentreheart, Inc. | Apparatus and method for the ligation of tissue |
US7846168B2 (en) | 2003-10-09 | 2010-12-07 | Sentreheart, Inc. | Apparatus and method for the ligation of tissue |
US8795297B2 (en) | 2003-10-09 | 2014-08-05 | Sentreheart, Inc. | Apparatus and method for the ligation of tissue |
US20050154404A1 (en) * | 2003-10-09 | 2005-07-14 | Liddicoat John R. | Apparatus and method for the ligation of tissue |
US7828810B2 (en) | 2003-10-09 | 2010-11-09 | Sentreheart, Inc. | Apparatus and method for the ligation of tissue |
US10327780B2 (en) | 2003-10-09 | 2019-06-25 | Sentreheart, Inc. | Apparatus and method for the ligation of tissue |
US10806460B2 (en) | 2003-10-09 | 2020-10-20 | Sentreheart Llc | Apparatus and method for the ligation of tissue |
US11350944B2 (en) | 2003-10-09 | 2022-06-07 | Sentreheart Llc | Apparatus and method for the ligation of tissue |
WO2005110246A3 (en) * | 2004-05-07 | 2007-05-03 | Cryocath Technologies Inc | Surgical clamp having trasmurality assessment capabilities |
US20050283146A1 (en) * | 2004-06-17 | 2005-12-22 | Lentz David J | Thermally extended spiral cryotip for a cryoablation catheter |
US20060063121A1 (en) * | 2004-09-22 | 2006-03-23 | Barry David L | Containment apparatus for multi-pass ovens |
US20070208329A1 (en) * | 2004-12-10 | 2007-09-06 | Jim Ward | Ablative treatment of atrial fibrillation via the coronary sinus |
US7731715B2 (en) * | 2004-12-10 | 2010-06-08 | Edwards Lifesciences Corporation | Ablative treatment of atrial fibrillation via the coronary sinus |
US20060178662A1 (en) * | 2005-02-04 | 2006-08-10 | Ripley Kenneth L | Warming gradient control for a cryoablation applicator |
US7918865B2 (en) | 2005-04-07 | 2011-04-05 | Sentreheart, Inc. | Apparatus and method for the ligation of tissue |
US20110144660A1 (en) * | 2005-04-07 | 2011-06-16 | Liddicoat John R | Apparatus and method for the ligation of tissue |
US9522006B2 (en) | 2005-04-07 | 2016-12-20 | Sentreheart, Inc. | Apparatus and method for the ligation of tissue |
US8932208B2 (en) | 2005-05-26 | 2015-01-13 | Maquet Cardiovascular Llc | Apparatus and methods for performing minimally-invasive surgical procedures |
US20070129719A1 (en) * | 2005-05-26 | 2007-06-07 | Amar Kendale | Apparatus and methods for performing minimally-invasive surgical procedures |
US20070185479A1 (en) * | 2006-02-06 | 2007-08-09 | Liming Lau | Methods and devices for performing ablation and assessing efficacy thereof |
US20070225697A1 (en) * | 2006-03-23 | 2007-09-27 | Ketan Shroff | Apparatus and methods for cardiac ablation |
US20080039879A1 (en) * | 2006-08-09 | 2008-02-14 | Chin Albert K | Devices and methods for atrial appendage exclusion |
US20110024614A1 (en) * | 2006-10-19 | 2011-02-03 | Syft Technologies Limited | Sift-ms instrument |
US9498223B2 (en) | 2007-03-30 | 2016-11-22 | Sentreheart, Inc. | Devices for closing the left atrial appendage |
US20090157118A1 (en) * | 2007-03-30 | 2009-06-18 | Sentreheart, Inc. | Devices, systems, and methods for closing the left atrial appendage |
US8771297B2 (en) | 2007-03-30 | 2014-07-08 | Sentreheart, Inc. | Devices, systems, and methods for closing the left atrial appendage |
US20090143791A1 (en) * | 2007-03-30 | 2009-06-04 | Sentreheart, Inc. | Devices, systems, and methods for closing the left atrial appendage |
US11020122B2 (en) | 2007-03-30 | 2021-06-01 | Sentreheart Llc | Methods for closing the left atrial appendage |
US11826050B2 (en) | 2007-03-30 | 2023-11-28 | Atricure, Inc. | Devices, systems, and methods for closing the left atrial appendage |
US8986325B2 (en) | 2007-03-30 | 2015-03-24 | Sentreheart, Inc. | Devices, systems, and methods for closing the left atrial appendage |
US10966725B2 (en) | 2007-03-30 | 2021-04-06 | Sentreheart Llc | Devices and systems for closing the left atrial appendage |
US20090082797A1 (en) * | 2007-09-20 | 2009-03-26 | Fung Gregory W | Devices and methods for remote suture management |
US8469983B2 (en) | 2007-09-20 | 2013-06-25 | Sentreheart, Inc. | Devices and methods for remote suture management |
US10993766B2 (en) | 2007-10-05 | 2021-05-04 | Maquet Cardiovascular Llc | Devices and methods for minimally-invasive surgical procedures |
US10058380B2 (en) | 2007-10-05 | 2018-08-28 | Maquet Cordiovascular Llc | Devices and methods for minimally-invasive surgical procedures |
US20090093809A1 (en) * | 2007-10-05 | 2009-04-09 | Anderson Evan R | Devices and methods for minimally-invasive surgical procedures |
US20090209986A1 (en) * | 2008-02-15 | 2009-08-20 | Stewart Michael C | Devices, Tools and Methods for Atrial Appendage Exclusion |
US20100179527A1 (en) * | 2009-01-15 | 2010-07-15 | Boston Scientific Scimed, Inc. | Controlling Depth of Cryoablation |
US8480664B2 (en) | 2009-01-15 | 2013-07-09 | Boston Scientific Scimed, Inc. | Controlling depth of cryoablation |
US20100199077A1 (en) * | 2009-01-30 | 2010-08-05 | Freescale Semiconductor, Inc. | Authenticated debug access for field returns |
US20100241113A1 (en) * | 2009-03-20 | 2010-09-23 | Boston Scientific Scimed, Inc. | Protecting the phrenic nerve while ablating cardiac tissue |
US11950784B2 (en) | 2009-04-01 | 2024-04-09 | Atricure, Inc. | Tissue ligation devices and controls therefor |
US20110087247A1 (en) * | 2009-04-01 | 2011-04-14 | Fung Gregory W | Tissue ligation devices and controls therefor |
US10799241B2 (en) | 2009-04-01 | 2020-10-13 | Sentreheart Llc | Tissue ligation devices and controls therefor |
US9198664B2 (en) | 2009-04-01 | 2015-12-01 | Sentreheart, Inc. | Tissue ligation devices and controls therefor |
US8795310B2 (en) * | 2010-04-13 | 2014-08-05 | Sentreheart, Inc. | Methods and devices for accessing and delivering devices to a heart |
US20110276075A1 (en) * | 2010-04-13 | 2011-11-10 | Sentreheart, Inc. | Methods and devices for accessing and delivering devices to a heart |
US10405919B2 (en) | 2010-04-13 | 2019-09-10 | Sentreheart, Inc. | Methods and devices for treating atrial fibrillation |
US9486281B2 (en) | 2010-04-13 | 2016-11-08 | Sentreheart, Inc. | Methods and devices for accessing and delivering devices to a heart |
US11026690B2 (en) | 2011-06-08 | 2021-06-08 | Sentreheart Llc | Tissue ligation devices and tensioning devices therefor |
US9498206B2 (en) | 2011-06-08 | 2016-11-22 | Sentreheart, Inc. | Tissue ligation devices and tensioning devices therefor |
US10251650B2 (en) | 2013-03-12 | 2019-04-09 | Sentreheart, Inc. | Tissue litigation devices and methods therefor |
US11207073B2 (en) | 2013-03-12 | 2021-12-28 | Sentreheart Llc | Tissue ligation devices and methods therefor |
US9408608B2 (en) | 2013-03-12 | 2016-08-09 | Sentreheart, Inc. | Tissue ligation devices and methods therefor |
US11844566B2 (en) | 2013-10-31 | 2023-12-19 | Atricure, Inc. | Devices and methods for left atrial appendage closure |
US10799288B2 (en) | 2013-10-31 | 2020-10-13 | Sentreheart Llc | Devices and methods for left atrial appendage closure |
US10258408B2 (en) | 2013-10-31 | 2019-04-16 | Sentreheart, Inc. | Devices and methods for left atrial appendage closure |
US10130369B2 (en) | 2015-03-24 | 2018-11-20 | Sentreheart, Inc. | Tissue ligation devices and methods therefor |
US10959734B2 (en) | 2015-03-24 | 2021-03-30 | Sentreheart Llc | Tissue ligation devices and methods therefor |
US9936956B2 (en) | 2015-03-24 | 2018-04-10 | Sentreheart, Inc. | Devices and methods for left atrial appendage closure |
US11389167B2 (en) | 2016-02-26 | 2022-07-19 | Atricure, Inc. | Devices and methods for left atrial appendage closure |
US10292710B2 (en) | 2016-02-26 | 2019-05-21 | Sentreheart, Inc. | Devices and methods for left atrial appendage closure |
Also Published As
Publication number | Publication date |
---|---|
AU5003197A (en) | 1998-05-15 |
US8535301B2 (en) | 2013-09-17 |
US20040106918A1 (en) | 2004-06-03 |
US6161543A (en) | 2000-12-19 |
US20090171335A1 (en) | 2009-07-02 |
EP0991362B1 (en) | 2007-12-12 |
US7387126B2 (en) | 2008-06-17 |
WO1998017187A1 (en) | 1998-04-30 |
US8177780B2 (en) | 2012-05-15 |
EP1864619A2 (en) | 2007-12-12 |
EP0991362A1 (en) | 2000-04-12 |
US20080045935A1 (en) | 2008-02-21 |
US20020017306A1 (en) | 2002-02-14 |
EP1864619A3 (en) | 2008-08-13 |
US8002771B2 (en) | 2011-08-23 |
US20020068970A1 (en) | 2002-06-06 |
US20080183168A1 (en) | 2008-07-31 |
EP0991362A4 (en) | 2004-10-06 |
US7517345B2 (en) | 2009-04-14 |
US20120226269A1 (en) | 2012-09-06 |
EP1864619B1 (en) | 2010-07-21 |
US20030029462A1 (en) | 2003-02-13 |
US20070191714A1 (en) | 2007-08-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7387126B2 (en) | Surgical system and procedure for treatment of medically refractory atrial fibrillation | |
CA2222326C (en) | Devices and methods for port-access multivessel coronary artery bypass surgery | |
US7001415B2 (en) | Transmural ablation device | |
US6613069B2 (en) | Tunneling instrument for port access multivessel coronary artery bypass surgery | |
US6494211B1 (en) | Device and methods for port-access multivessel coronary artery bypass surgery | |
US6905498B2 (en) | Transmural ablation device with EKG sensor and pacing electrode | |
US20020023653A1 (en) | Methods and systems for performing thoracoscopic cardiac bypass and other procedures | |
DE69738378T2 (en) | DEVICE FOR TREATING MEDICAL-REFRACTORY FORWARD FIBRILLATIONS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: EPICOR MEDICAL, INC., CALIFORNIA Free format text: CHANGE OF NAME;ASSIGNOR:EPICOR, INC.;REEL/FRAME:015329/0571 Effective date: 20030316 |